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Abstract
Regardless of all the major achievements in the field of genomics and in depth studies
of the protein-coding genes, our knowledge about non-coding regions and their con-
tribution in diseases remains incomplete. Large scale projects such as the ENCODE
have produced a wealth of sequencing data which can be utilised to study epigenetic
features associated with gene regulation. These studies have comprehensively identified
regulatory elements such as enhancers in the human genome, but numerous questions
still remain on their effect on gene function and disease causation.
The aim of this thesis is to identify enhancer regulatory networks in the mouse
genome and investigate their effect on mouse models of human diseases. In order
to study enhancer regulation, I have taken two approaches. First, I have produced a
catalogue of well-defined multiple enhancer types in a diverse range of mouse tissues
and cell-types. By systematically comparing different enhancer types, I found that
super- and typical-enhancers have different effect on gene expression, but both are
preferentially associated with relevant tissue-type phenotypes. Also genes associated
with super- and typical-enhancers exhibit no difference in phenotype effect size or
pleiotropy. Second, by utilising publicly available regulatory annotations, my enhancer
catalogue and omics data, I have investigated regulatory mechanisms associated with
metabolic and circadian mouse models. Here I identified novel regulatory networks or
enhancers or transcription factor binding sites pertaining to the mutant mice.
In conclusion, my research has shown the usefulness of integrating enhancer anno-
tations with an array of molecular data and has for the first time shown how different
enhancer architectures influence gene function in the mouse genome. This study pro-
vides a valuable dataset to further characterise the mechanisms of gene regulation by
enhancers in the mouse genome.

I would like to dedicate this thesis to my loving parents, my sisters, and my dear friend
Paras Pathak who sadly is no longer with us.

Acknowledgements
This thesis has been a challenging journey and would not have been possible without
the help and feedback of many people. First and foremost, I would like to thank my
supervisors Dr Ann-Marie Mallon and Dr Michelle Simon for guiding throughout
my DPhil. They supported me throughout this journey, helped me at every stage and
challenged my limits to bring out the best in me. They always believed in my skills
and provided me with great opportunities, for which I am truly grateful. Special thanks
goes to Michelle; she was very patient while working with me and was always willing
to help.
I would also like to to thank all members of the Mallon lab particularly Simon,
John, Hugh, Luis and Henrik. A big thanks to Simon, who helped me with statistical
problems, troubleshooting errors and writing more efficient algorithms. He was always
there to install any computational packages I required on our server and modify the grid
cluster according to my needs. John has been a great colleague and a friend. Thank
you John for your help and support, and for teaching me the fundamentals of machine
learning. Thanks to Hugh, Luis and Henrik who always provided me with critical
feedback and were immensely helpful in my analysis of the IMPC data. I would also
like to thank Ivan and Ilya from the Makeev lab, who guided me through the motif
analysis of ChIP-seq data. Others I would like to thank include Prof Roger Cox and Dr
Patrick Nolan for their fruitful collaborations and providing me the opportunity to be a
part of their research.
I would like thank all my friends in Oxford and London, especially Jin, who was
always there to help me with all my life problems. A big thanks to Miriam for being
there during the last two years of my DPhil; you always brightened up my day after
those long working hours, thank you. I would also like to thank Amy for proofreading
my thesis; your corrections were really helpful.
Finally, I would like to thank my family for their unconditional love. Without their
love and support, I would have not achieved anything in my life. A big thanks to my
sisters for being the rock of my life.

Table of contents
List of figures xiii
List of tables xvii
Nomenclature xix
1 Background 1
1.1 Overview of mammalian transcriptional regulation . . . . . . . . . . 1
1.1.1 Transcription . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.1.2 Translation . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.1.3 Non-coding DNA . . . . . . . . . . . . . . . . . . . . . . . . 4
1.1.4 Cis-regulatory elements . . . . . . . . . . . . . . . . . . . . 5
1.1.5 Transcription factors . . . . . . . . . . . . . . . . . . . . . . 7
1.1.6 Chromatin - a gatekeeper of regulatory regions . . . . . . . . 9
1.2 Enhancers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.2.1 History . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.2.2 Enhancer function . . . . . . . . . . . . . . . . . . . . . . . 11
1.2.3 Enhancer states and their associated chromatin marks . . . . . 12
1.2.4 Enhancer-promoter interaction . . . . . . . . . . . . . . . . . 15
1.2.5 Enhancer target genes . . . . . . . . . . . . . . . . . . . . . 17
1.3 Current methods to identify enhancer regions . . . . . . . . . . . . . 19
1.3.1 Predictions using motifs and conservation . . . . . . . . . . . 19
1.3.2 Predictions using TF binding . . . . . . . . . . . . . . . . . . 20
1.3.3 Predictions using chromatin accessibility . . . . . . . . . . . 21
1.3.4 Predictions using histone modifications . . . . . . . . . . . . 22
1.3.5 Predictions using enhancer-promoter interactions . . . . . . . 23
1.4 Super-enhancers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
1.4.1 Super-enhancer identification . . . . . . . . . . . . . . . . . 25
1.4.2 Properties of super-enhancers . . . . . . . . . . . . . . . . . 26
1.4.3 Controversy over super-enhancer structure and function . . . 27
Table of contents
1.5 Mis-regulation of enhancer function in disease . . . . . . . . . . . . . 29
1.5.1 Early examples of enhancer malfunction in disease . . . . . . 29
1.5.2 Enhancers in cancer and other diseases . . . . . . . . . . . . 29
1.5.3 Super-enhancers in human diseases . . . . . . . . . . . . . . 33
1.6 The Mouse as a model organism . . . . . . . . . . . . . . . . . . . . 37
1.6.1 Mammalian phenotypes . . . . . . . . . . . . . . . . . . . . 37
1.6.2 Large scale phenotyping projects . . . . . . . . . . . . . . . . 38
1.6.3 Functional testing of enhancers in the mouse . . . . . . . . . 39
1.6.4 MRC Harwell Institute . . . . . . . . . . . . . . . . . . . . . 40
1.7 Aims of the thesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
2 Klf14 transcriptional networks in human and mouse 43
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
2.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
2.2.1 Transcriptional targets of Klf14 in the mouse genome . . . . . 47
2.2.2 De novo motif discovery from Klf14 transcriptional targets . . 51
2.2.3 Epigenetic profiling of the KLF14 locus . . . . . . . . . . . . 54
2.2.4 Phylogenetic Module Complexity Analysis . . . . . . . . . . 58
2.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
2.3.1 Datasets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
2.3.2 RNA-seq data analysis . . . . . . . . . . . . . . . . . . . . . 61
2.3.3 De novo motif discovery . . . . . . . . . . . . . . . . . . . . 62
2.3.4 Identifying known transcription factor binding sites . . . . . . 62
2.3.5 Phylogenetic Module Complexity Analysis . . . . . . . . . . 63
2.3.6 Positional bias algorithm . . . . . . . . . . . . . . . . . . . . 65
2.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
3 Identification of regulatory elements in the mouse genome 71
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
3.2.1 Chromatin state segmentation across 22 mouse tissues . . . . 74
3.2.2 Open chromatin and TF binding activity . . . . . . . . . . . . 78
3.2.3 Identification of tissue-specific regulatory elements . . . . . . 83
3.2.4 Detection of super-enhancers in the mouse genome . . . . . . 88
3.2.5 Evolutionary conservation of mouse enhancers . . . . . . . . 88
3.2.6 Disease-associated SNPs in mouse enhancers . . . . . . . . . 92
3.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
3.3.1 Learning Chromatin states in the mouse genome . . . . . . . 96
x
Table of contents
3.3.2 Comparing regulatory elements with DHSs and TFBSs . . . . 96
3.3.3 Clustering of promoters and enhancers across 22 tissues . . . 97
3.3.4 Tissue-specificity index of regulatory elements . . . . . . . . 97
3.3.5 Correlating TSREs with DHSs . . . . . . . . . . . . . . . . . 98
3.3.6 Identifying SEs in the mouse genome . . . . . . . . . . . . . 98
3.3.7 Sequence conservation of mouse enhancers . . . . . . . . . . 99
3.3.8 Enrichment of DA-SNPs in the mouse enhancers . . . . . . . 100
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
4 Impact of enhancer architecture on gene function and mouse phenotypes 105
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
4.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
4.2.1 Associating regulatory elements to potential target genes . . . 109
4.2.2 Profiling genome-wide enhancer activity and target gene ex-
pression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
4.2.3 Influence of enhancer architecture on phenotypes . . . . . . . 117
4.2.4 Protein-protein interactions amongst enhancer associated genes 127
4.2.5 Transcription factor binding in SEs and TEs . . . . . . . . . . 129
4.2.6 Combinatorial learning approach for phenotype prediction . . 131
4.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
4.3.1 Datasets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
4.3.2 Associating TSREs to potential target genes . . . . . . . . . . 140
4.3.3 Expression analysis of enhancer associated genes . . . . . . . 140
4.3.4 GO, mammalian phenotype and disease enrichment analysis . 141
4.3.5 Protein-protein interaction maps . . . . . . . . . . . . . . . . 142
4.3.6 Cistrome data . . . . . . . . . . . . . . . . . . . . . . . . . . 143
4.3.7 Enrichment of TFBSs in SEs and TEs . . . . . . . . . . . . . 143
4.3.8 TFBS density analysis . . . . . . . . . . . . . . . . . . . . . 144
4.3.9 Predicting gene-phenotype associations . . . . . . . . . . . . 145
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
5 Assessing the role of Zfhx3 as a circadian regulator in the SCN 151
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151
5.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155
5.2.1 Effect of Zfhx3Sci mutation on gene expression . . . . . . . . 155
5.2.2 Dissecting functionally distinct modules in Zfhx3Sci/+ network 157
5.2.3 Investigating the Zfhx3 regulome in the SCN . . . . . . . . . 161
5.2.4 Differential Zfhx3 binding between ZT3 and ZT15 . . . . . . 164
xi
Table of contents
5.2.5 Identifying Zfhx3 binding motif in the SCN . . . . . . . . . . 165
5.2.6 Comparing Zfhx3 binding with Zfhx3Sci/+ transcriptional targets 172
5.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 174
5.3.1 Analysis of RNA-seq data . . . . . . . . . . . . . . . . . . . 174
5.3.2 PPI and GO enrichment analysis of RNA-seq data . . . . . . 174
5.3.3 Analysis of AT and other circadian related motifs . . . . . . . 175
5.3.4 Processing of Zfhx3 ChIP-seq data . . . . . . . . . . . . . . . 175
5.3.5 Motif analysis of Zfhx3 ChIP-seq peaks . . . . . . . . . . . . 176
5.3.6 Assessing the recognition quality of the enriched motifs . . . 177
5.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 178
6 Summary and future directions 181
List of publications 187
References 189
Appendix A Supplementary figures 225
Appendix B Supplementary tables 237
xii
List of figures
1.1 Schematic of eukaryotic gene expression . . . . . . . . . . . . . . . . 3
1.2 Various types of cis-regulatory elements . . . . . . . . . . . . . . . . 6
1.3 Computational modelling of TF binding specificity . . . . . . . . . . 8
1.4 Chromatin accessibility and pioneer factors . . . . . . . . . . . . . . 10
1.5 Enhancer function . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.6 Cell-type specific activity of histone modification signatures . . . . . 14
1.7 Various enhancer states . . . . . . . . . . . . . . . . . . . . . . . . . 15
1.8 Mechanisms of enhancer-promoter communication . . . . . . . . . . 16
1.9 Identification of transcription factor binding in vivo . . . . . . . . . . 20
1.10 Identification of genome-wide open chromatin regions . . . . . . . . 22
1.11 Identification of genome-wide chromatin marks . . . . . . . . . . . . 23
1.12 Identification of enhancer-promoter interactions . . . . . . . . . . . . 24
1.13 Identification of super-enhancers . . . . . . . . . . . . . . . . . . . . 26
1.14 Timeline of SNPs discovered by GWASs . . . . . . . . . . . . . . . . 31
2.1 Association of KLF14 variants with metabolic traits . . . . . . . . . . 45
2.2 Clinical chemistry analysis of the Klf14 knockout mice . . . . . . . . 47
2.3 Differentially expressed genes between Klf14tm1(KOMP)Vlcg PAT and
MAT mice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
2.4 GO enrichment analysis of Klf14 transcriptional targets . . . . . . . . 49
2.5 Protein-protein interaction map amongst Klf14 transcriptional targets in
the mouse and the human trans-network genes . . . . . . . . . . . . . 50
2.6 Comparison of Klf14 binding motif in human and mouse . . . . . . . 53
2.7 Direct transcriptional targets of Klf14 in the mouse . . . . . . . . . . 53
2.8 Comparison of KLF14 epigenomic landscape between human and
mouse genomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
2.9 Genomic view of the potential motif matches in the human KLF14
associated enhancer . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
2.10 Identification of cis-regulatory variants in the KLF14 locus . . . . . . 59
2.11 TF binding positional bias with respect to the T2D SNPS in the KLF14
locus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
xiii
List of figures
2.12 Workflow demonstrating the de novo motif discovery strategy applied
to the Klf14 transcriptional targets . . . . . . . . . . . . . . . . . . . 63
3.1 Chromatin state segmentation and characterisation across 22 mouse
tissues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
3.2 Genomic view of chromatin state segmentation output . . . . . . . . . 76
3.3 Number of predicted regulatory elements in the mouse genome from
three different studies . . . . . . . . . . . . . . . . . . . . . . . . . . 77
3.4 Comparison of chromatin states across the tissues . . . . . . . . . . . 79
3.5 Correlation between predicted regulatory elements and DHSs . . . . . 80
3.6 Enrichment of TFBSs within regulatory elements . . . . . . . . . . . 82
3.7 Clustering of strong enhancers and active promoters across 22 mouse
tissues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
3.8 Distribution of tissue-specific regulatory elements . . . . . . . . . . . 86
3.9 Tissue-specific regulatory elements in 22 mouse tissues . . . . . . . . 87
3.10 Detection of SEs in the mouse genome . . . . . . . . . . . . . . . . . 89
3.11 Sequence conservation of mouse enhancers across 20 mammalian species 91
3.12 Non-coding DA-SNPs associated with 26 phenotypic traits and diseases 92
3.13 Enrichment of disease-associated genetic variants in the human and
mouse enhancers . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
4.1 Research aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
4.2 Region-gene associations of regulatory elements . . . . . . . . . . . . 110
4.3 Enhancer activity and its influence on gene expression . . . . . . . . 112
4.4 Impact of constituent enhancer density on target gene expression . . . 114
4.5 Distinct enhancer tissue-types associated with genes . . . . . . . . . . 116
4.6 Mammalian phenotype and human disease annotations enriched in the
SEC and TEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
4.7 Enrichment of enhancer-associated genes in mammalian phenotypes . 120
4.8 Enrichment of enhancer-associated genes in IMPC phenotypic traits . 121
4.9 Epigenomic landscape and phenotype associations of Adcy1 . . . . . 122
4.10 Epigenomic landscape and phenotype associations of Ikzf3 . . . . . . 124
4.11 Phenotype severity of SE and TE associated gene knockouts . . . . . 126
4.12 Breadth of phenotypes associated with SE and TE gene knockouts in
the mouse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
4.13 PPI maps of enhancer associated genes . . . . . . . . . . . . . . . . . 128
4.14 Master regulators enriched in SEs and TEs . . . . . . . . . . . . . . . 130
4.15 Transcription factor binding within SE and TE constituents . . . . . . 131
4.16 Evaluation of classifiers to predict gene-phenotype associations in the
mouse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
xiv
List of figures
4.17 Predicting genes associated with nervous system phenotype . . . . . . 135
4.18 PPI map of novel nervous system phenotype predictions with AD
associated genes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
4.19 Evaluation of the top scoring false-positives from random forest classifiers138
4.20 Top scoring novel gene predictions . . . . . . . . . . . . . . . . . . . 139
5.1 A schematic illustration of the mammalian core circadian clock (from
Lowrey and Takahashi (2004)) . . . . . . . . . . . . . . . . . . . . . 153
5.2 Overview of the short circuit (Sci) phenotype (from Parsons et al. (2015))154
5.3 SCN genes differentially expressed between Zfhx3Sci/+ and Zfhx3+/+ . 156
5.4 Motif enrichment in differentially expressed genes associated with
Zfhx3Sci/+ mutation . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
5.5 PPI map of differentially expressed genes in Zfhx3Sci/+ mice . . . . . 158
5.6 GO enrichment analysis of functional modules in the Zfhx3Sci/+ network 159
5.7 Genomic view of Zfhx3 ChIP-seq peaks in the SCN . . . . . . . . . . 162
5.8 Overview of Zfhx3 binding profile in the SCN . . . . . . . . . . . . . 163
5.9 GO enrichment analysis of genes associated with Zfhx3 ChIP-seq peaks 164
5.10 Differential binding analysis of Zfhx3 activity between ZT3 and ZT15 165
5.11 Comparison of ZBTB33 motif with previously known Zfhx3 binding
motif models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
5.12 Distribution of motif sites with respect to Zfhx3 binding peak summits 168
5.13 Analysing co-binding between motifs enriched in Zfhx3 binding peaks 169
5.14 Computational validation assessing the recognition quality of enriched
motifs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171
5.15 Expression of Zfhx3 ChIP-seq peaks associated genes in the SCN . . . 172
5.16 Comparison of Zfhx3 ChIP-seq associated genes with Zfhx3Sci/+ tran-
scriptional targets . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173
5.17 Overview of the RNA-seq pipeline . . . . . . . . . . . . . . . . . . . 174
A.1 ChromHMM models with different number of chromatin states . . . . 225
A.2 SEs and TEs identified in 22 mouse tissues . . . . . . . . . . . . . . . 226
A.3 H3K27ac enrichment within SEs and TEs in 22 mouse tissues . . . . 227
A.4 Comparison of H3K4me1, H3K27ac and DNaseI signal across stitched
cohesive units . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 228
A.5 Chromatin activity within SE and TE constituent enhancers . . . . . . 229
A.6 Enrichment of DA-SNPs from GWASs in SE and TE domains of human
and mouse genomes . . . . . . . . . . . . . . . . . . . . . . . . . . . 230
A.7 Effect of enhancer activity on target gene expression . . . . . . . . . 231
A.8 PPI maps of enhancer associated genes . . . . . . . . . . . . . . . . . 232
A.9 PPI network simulations . . . . . . . . . . . . . . . . . . . . . . . . 233
xv
List of figures
A.10 Feature importance of random forest classifiers used to predict gene-
phenotype associations . . . . . . . . . . . . . . . . . . . . . . . . . 234
A.11 Experimental data related to the Zfhx3Sci mutation . . . . . . . . . . . 235
xvi
List of tables
1.1 Histone tail modifications and their presumed biological associations . 13
1.2 Examples of 3C based studies and their observations . . . . . . . . . 18
1.3 Summary of previous studies which involved identification of super-
enhancers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
1.4 Examples of enhancers linked to human disease . . . . . . . . . . . . 32
1.5 Super-enhancers in cancer . . . . . . . . . . . . . . . . . . . . . . . 34
1.6 Therapeutic targeting of super-enhancers in cancer . . . . . . . . . . 36
2.1 Over-represented motifs identified in promoter regions . . . . . . . . 52
2.2 Over-represented motifs identified in upstream DHSs . . . . . . . . . 52
2.3 Potential TF PWM matches (q < 0.01) in the human KLF14 associated
enhancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
2.4 Classification of T2D associated variants in the KLF14 locus using the
PMCA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
3.1 List of TFs analysed and the source of their ChIP-seq data . . . . . . 81
3.2 Comparison of DA-SNPs enrichment in human and mouse enhancer
regions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
4.1 Summary of the gene features used in the random forest classifier to
predict gene-phenotype associations . . . . . . . . . . . . . . . . . . 132
4.2 GO enrichment analysis of 11 novel nervous system phenotype predic-
tions identified to be densely connected with AD associated genes . . 138
5.1 Motif analysis of Zfhx3 binding peaks in the SCN . . . . . . . . . . . 167
B.1 GO enrichment analysis of SE associated genes . . . . . . . . . . . . 238
B.2 GO enrichment analysis of TE associated genes . . . . . . . . . . . . 239
B.3 Mammalian phenotype and human disease annotations enriched in
enhancer classes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 240
B.4 Mammalian phenotype and human disease annotations enriched in the
WEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 241
B.5 Disease annotation terms enriched amongst genes associated with ner-
vous system phenotype in mouse . . . . . . . . . . . . . . . . . . . . 242
xvii
List of tables
B.6 GO enrichment analysis of genes in module 4 of the Zfhx3Sci/+ network 243
xviii
Nomenclature
Acronyms / Abbreviations
3C Chromosome confirmation capture
4C Circular chromosome confirmation capture
5C Chromosome confirmation capture carbon copy
AD Alzheimer’s disease
AML Acute myeloid leukaemia
ATAC-seq Assay for transposase accessible chromatin followed by sequencing
AUC Area under the curve
BAT Brown adipose tissue
BET Bromodomain and extra-terminal
Bmarrow Bone marrow
BmarrowDm Bone marrow derived marcophages
bp Base pairs
Brain_HM Brain hippocampus middle
Brain_ITL Brain inferior temporal lobe
Brain_MFL Brain mid frontal lobe
CAS9 CRISPR-associated protein 9
CDK Cyclin-dependent kinases
CH12 B-cell lymphoma cells
CHi-C Capture Hi-C
ChIP Chromatin immunoprecipitation
ChIP-seq Chromatin immunoprecipitation followed by sequencing
CKI Casein kinases
CRE Cis-regulatory element
CRISPR Clustered regularly interspaced short palindromic repeats
xix
Nomenclature
CRM Cis-regulatory module
DamID DNA adenine methyltransferase identification
DA-SNP Disease-associated SNP
DHS DNaseI hypersensitive site
DLBC Diffuse large B-cell lymphoma
DNase-seq DNaseI hypersensitive sites sequencing
ENU N-ethyl-N-nitrosourea
EPU Enhancer-promoter unit
eRNA Enhancer RNA
Esb4 Mouse embryonic stem cells
ESC Embryonic stem cell
Es-E14 Mouse embryonic stem cell line at day E14.5
ES Effect size
FAIRE-seq Formaldehyde-assisted identification of regulator elements followed by
sequencing
GO Gene ontology
GWAS Genome-wide association study
H3K27ac Histone H3 lysine27 acetylation
H3K27me3 Histone H3 lysine27 trimethylation
H3K4me1 Histone H3 lysine4 monomethylation
H3K4me2 Histone H3 lysine4 dimethylation
H3K4me3 Histone H3 lysine4 trimethylation
H3K79me3 Histone H3 lysine79 trimethylation
HDL High-density lipoprotein
Heart_LV Heart left ventricle
Heart_RA Heart right atrium
Heart_RV Heart right ventricle
hESC Human embryonic stem cell
HSMM Human skeletal muscle myoblast
HUVEC Human umbilical vein endothelial cell
IGH immunoglobulin heavy chain
xx
Nomenclature
IMPC International mouse phenotyping consortium
kb Kilobase
LCR Locus control region
LD Linkage disequilibrium
LDL Low-density lipoprotein
Mb Megabase
MEF Mouse embryonic fibroblast
MEL Leukaemia cells, K562 analogue
MGD Mouse genome database
MNase-seq Micrococcal nuclease digestion followed by sequencing
MP Mammalian phenotype
MRCHI MRC Harwell Institute
mRNA Messenger RNA
NHEK Normal human epidermal keratinocyte
NHLF Normal human lung fibroblast
OCDEM Oxford Centre for Diabetes, Endocrinology and Metabolism
OR Odds ratio
PFM Positional frequency matrix
PIC Pre-initiation complex
PMCA Phylogenetic module complexity analysis
Pol II RNA polymerase II
PPI Protein-protein interaction
PR Precision-recall
PWM Positional weight matrix
ROC Receiver operating characteristic
RORE Retinoic acid-related orphan receptor response element
ROSE Rank ordering of super-enhancers
RPKM Reads per kilobase of transcript per million mapped reads
RRE Rev-erbα/ROR-binding element
Sci Short circuit
SCLC Small cell lung cancer
xxi
Nomenclature
SCN Suprachiasmatic nucleus
SEC Super-enhancer class
SE Super-enhancer
SNP Single nucleotide polymorphism
SV40 Simian virus 40
T2D Type 2 diabetes
TAD Topologically associated domain
T-ALL T-cell acute lymphoblastic leukaemia
TEC Typical-enhancer class
TE Typical-enhancer
TFBS Transcription factor binding site
TF Transcription factor
tRNA Transfer RNA
TSRE Tissue-specific regulatory element
TSS Transcription start site
TTFL Transcriptional-translational feedback loop
Wbrain Whole brain
WEC Weak-enhancer class
ZT Zeitgeber time
xxii
Chapter 1
Background
Transcriptional regulation is a complex process which involves a complex network
of transcription factors (TFs), co-factors and chromatin regulators binding to DNA
regulatory elements like promoters and distal enhancers. Although precise control of
gene expression is achieved with the help of multiple regulatory elements, enhancers
play a central role in transcriptional regulation. Enhancers are capable of activating
transcription of their target genes and driving cell-type specific gene expression which
is important for the diversity in cell function. Genomic disruptions, either via genetic
sequence variants or somatic mutations, within enhancer regions and the TFs associated
with them, can cause mis-regulation of their target genes often leading to disease
conditions. In this thesis, I will be studying gene regulation by enhancers to understand
the disease conditions caused by their malfunction. In this chapter, I describe the
concepts related to transcriptional regulation with a main focus on enhancers. I first
provide a brief overview of how transcription is influenced by regulatory elements,
followed by a comprehensive explanation of enhancers; their properties, interactions
and chromatin regulators associated with their function. I then describe the current
approaches in genomics to identify potential enhancers, followed by the identification
of super-enhancers; dense clusters of active enhancers. Lastly, I explain how the
malfunction of these regions can contribute to human diseases and traits.
1.1 Overview of mammalian transcriptional regulation
Cells are the basic structural and functional unit of living organisms. For the survival
of an organism, the cells must respond to internal and external stimuli to perform
the necessary functions. In a cell, thousands of genes are expressed which produce
proteins and proteins control the cell function. Therefore, expression of genes in the
correct amount is critical for optimum functioning of the cell and its related biological
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processes such as cell differentiation and cell development. The synthesis of proteins
from genes involves a series of tightly regulated steps, in which the genetic information
required to synthesise the protein product flows from DNA to RNA (a process called
transcription), followed by the conversion of RNA into a protein (a process called
translation) (Crick, 1970; Crick et al., 1961). Transcription of a gene is controlled by
regulatory elements such as its core promoter and distal enhancers. The core promoter of
a gene is located just upstream of its transcription start site (TSS), while enhancers may
be situated megabases (Mbs) away from the gene they regulate. Both core promoters
and enhancers contain binding sites for TFs; proteins which recruit and interact with
other co-factors, and collectively they activate or repress the rate of transcription process.
The distal enhancers are brought into close proximity to the core promoter of a gene
by the looping of the chromosome, which allows the enhancer-bound TFs to interact
with the promoter-bound TFs and co-factors, and ultimately enhance the transcription
process. The following section provides a brief overview of the concepts and processes
associated with transcription, and how it is regulated by the regulatory elements such as
promoters, enhancers and TFs.
1.1.1 Transcription
The first and the key regulatory step in gene expression is transcription, a process in
which a segment of DNA is converted to its RNA copy by an enzyme called RNA
polymerase II (pol II) (Fig. 1.1). Transcription initiates at a region immediate upstream
of the TSS known as the core promoter. At the core promoter of a gene, a group of
factors (together known as the pre-initiation complex (PIC)) required to initiate the
transcription are assembled (Lenhard et al., 2012). The PIC comprises of pol II; general
TFs; and co-factors such as the Mediator complex which are thought to bring TFs
and co-activators close to the pol II. Once the PIC is assembled, pol II separates the
two strands of DNA and uses one of the strands as a template to produce RNA. Pol
II moves along the template DNA, reading one base at a time to produce a growing
chain of complimentary RNA molecule in 5’ to 3’ direction (Kornberg, 2007). This
process is known as elongation. Pol II generally transcribes 25-60 bases downstream
before it pauses, a state which requires binding of additional factors to release pol II
and continue its movement through the gene body. This pausing of pol II helps in
the additional control of gene expression (recently reviewed in Mayer et al. (2017)).
Once the complete gene is transcribed, the transcription is terminated by the signal
from terminator sequences such as the chain of adenine nucleotides added at the 3’
end of the RNA transcript by a process called polyadenylation (Connelly and Manley,
1988). After termination, the RNA transcript undergoes processing where the introns
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are removed and exons are joined together (a process called RNA splicing) to form a
single protein-coding sequence of mature messenger RNA (mRNA) (Wahl et al., 2009).
1.1.2 Translation
The mature mRNA produced from transcription is transported from the nucleus of the
cell into its cytoplasm, where it comes in contact with the cell’s protein production
factory called the ribosome (Green and Noller, 1997) (Fig. 1.1). The ribosomes bind
at the 5’ end of the mRNA and move towards the 3’ end. The process of translation
initiates when the ribosomal units encounter a start codon (AUG) in the mRNA sequence.
During this process, the sequence information in the mRNA is decoded into a chain of
corresponding amino acids with the help of transfer RNAs (tRNAs) (Ramakrishnan,
2002). This chain of amino acids grows until the ribosomal complex encounters one of
the stop codons (UAA, UAG, UGA) which marks the termination of translation and
releases the complete amino acid chain. Overall, the amount of protein to be produced
and its activity depends on the process of translation.
NUCLEUS
CYTOPLASM
Translation
Transcription
Splicing
Transport
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Mature transcript 
(mRNA)
Primary transcript 
(RNA)
DNA
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Fig. 1.1 Schematic of eukaryotic gene expression. The segment of DNA encoding for the
gene comprises of exons and introns. This DNA segment is transcribed into a RNA molecule
inside the nucleus, which undergoes processing such as splicing of introns and polyadenylation
to produce the mature mRNA. The mRNA is then transported into the cytoplasm where its
sequence is translated into a corresponding chain of amino acids and the protein product is
released. Figure adapted from https://www.ncbi.nlm.nih.gov/probe/docs/applexpression.
In an organism, genes are tightly regulated i.e. they are expressed only when they are
required to carry out a function in the body. In eukaryotes, transcription occurs within
the nucleus while translation occurs in the cytoplasm, which provides a cell with an
opportunity to regulate gene expression at every phase. For instance, a cell may control
its protein production by (1) regulating gene transcription; (2) regulating splicing of
RNA transcript; (3) regulating mRNA transport and localisation into cytoplasm; (4)
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regulating which mRNAs undergo translation; (5) regulating the rate of translation; and
(6) post-translational control (Darnell, 1982). However, for the majority of the cells,
the most effective method to control the production of genes is at the transcriptional
level as it decides whether a gene should be transcribed or not to produce the mRNA
(Guenther et al., 2007a). Such control over transcription is mainly achieved by non-
coding regulatory DNA sequences known as cis-regulatory elements (CREs), and
their associated proteins such as TFs. The following sections describe the non-coding
regulatory elements and TFs in detail.
1.1.3 Non-coding DNA
The non-coding DNA is the portion of the genome which does not contribute to a
gene, and hence is not translated into a protein. These regions, previously alluded to as
‘junk DNA’, are scattered throughout the genome. They make up ∼90% or more of the
genome in higher organisms. For instance, only∼2% of the human genome is estimated
to be protein-coding (approximately 20,000 - 25,000 genes) and the rest ∼98% of the
genome is considered to be non-coding. Some non-coding regions can get transcribed,
but do not undergo the process of translation and therefore, no functional protein is
made. For this reason, the non-coding regions were initially considered to have no
functional role in an organism. The term ‘junk DNA’ was first used by Susumu Ohno in
1972 to represent pseudogenes (defective DNA segments related to known genes, but
do not code for proteins) (Ohno, 1972), but soon the term used was to represent all non-
coding DNA sequences such as cis- and trans-regulatory elements, introns, non-coding
functional RNA, repeat sequences, telomeres and transposons (Comings, 1972). After
studying DNA segments across multiple species, Ohno hypothesised that the non-coding
regions may have been functional in the past, but they have lost their usefulness through
our evolution into more complex higher organisms (Ohno, 1972). This formed the
notion that non-coding DNA is not under the effect of selective pressure, and genetic
variations occurring in these regions would not disrupt any biological function.
Since non-coding DNA was considered to be functionally inactive, the majority of
the biological research was conducted on the protein-coding part of the DNA. But as
the human genome became more accessible, some researches discarded the notion that
all non-coding DNA is junk (Kuska, 1998). With the completion of human genome in
2003, and the availability of next generation sequencing technologies, the ENCODE
project (Birney et al., 2007) was the first systematic study to investigate the non-coding
portion of the human genome using various state of the art sequencing techniques.
The ENCODE pilot project inspected 1% of the human genome (or 30 million bases
collectively), and discovered that some regions within the non-coding DNA sequence
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are functional and play a critical role in controlling gene expression (Birney et al.,
2007). The next phase of the ENCODE project inspected the complete human genome,
which identified that up to 18% of the human DNA sequence is involved in controlling
the 2% protein-coding portion of the human genome (ENCODE Project Consortium,
2012). Furthermore, they reported that approximately 80% of the human genome could
be associated with some sort of biochemical function (ENCODE Project Consortium,
2012), hence scrapping the belief that the majority of the DNA is junk.
1.1.4 Cis-regulatory elements
Cis-regulatory elements (CREs) are one of the most important type of non-coding
DNA sequences which facilitate binding sites for TFs and/or other regulatory molecules
required to appropriately regulate the gene expression (Wittkopp and Kalay, 2011).
The regulation of gene expression by CREs can involve either activating, repressing or
sustaining expression levels. Gene expression is regulated by an interplay between five
main types of CREs, categorised based on their function (Fig. 1.2):
1. Promoters: This is the stretch of DNA sequence ≤1 kilobase (kb) upstream of
the TSS where the transcription initiates. The process of transcription activation
requires a set of TFs to bind the promoter region in a particular order. Once this is
achieved, pol II binds to the promoter and starts transcribing the gene downstream
(Butler and Kadonaga, 2002). Most genes have a single promoter element close to
the TSS, but some genes can contain multiple promoters to initiate transcription
under certain circumstances.
2. Enhancers: These elements are segments of DNA, usually a few hundred base
pairs (bp) long, which harbour binding sites for TFs that increase the basal level of
transcription achieved by promoters. The TFs that bind to enhancers are known as
transcription activators. Enhancers can be present upstream, downstream, within
the introns or even several Mbs away from the gene they regulate (known as the
target gene) (Kleinjan and Lettice, 2008). Their function is also independent
of their orientation with respect to the target gene. A gene can be regulated by
multiple enhancers, and likewise, one enhancer can regulate more than one gene.
3. Silencers: These elements harbour binding sites for TFs that inhibit the tran-
scription of genes. The TFs that bind to silencers are known as repressors.
The repressor proteins can either function independently or together with other
co-repressors (Sertil et al., 2003). Similar to enhancers, silencer function is inde-
pendent of its orientation and position with respect to its target gene (Ogbourne
and Antalis, 1998). A classical example of a silencer element is the AT-rich OCT1
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binding domain found in the promoter (∼140 bp upstream of TSS) of thyroid
stimulating hormone beta gene (TSHB), which has been shown to repress the
expression of TSHB (Kim et al., 1996).
4. Insulators: These elements protect genes from being inappropriately regulated
by nearby regulatory elements. Insulators when located between an enhancer
and a promoter, works as an interaction blocker between them, hence, preventing
the enhancer to activate the transcription of its nearby gene (Kellum and Schedl,
1992; West et al., 2002). Insulators can also act as barriers to prevent irrelevant
gene silencing by condensed chromatin in the surrounding regions (Sun and Elgin,
1999).
5. Locus control regions (LCRs): A LCR is composed of multiple CREs which
together influence the expression of a group of genes (Li et al., 2002). The ele-
ments within a LCR (for instance, enhancer and silencer elements) cooperatively
exert a strong enhancer activity and drive the expression of their associated genes
in a cell-type specific manner. An example of such a region is the well charac-
terised LCR associated with the β -globin locus (Grosveld et al., 1987), located
approximately 25 kb upstream of the β -globin genes. This LCR is essential for
the expression of β -globin genes in erythroid cells.
Pol2
TF
TF
Promoter
Silencer
Insulator
Gene	X
TSS
Fig. 1.2 Various types of cis-regulatory elements. A schematic showing the various types of
cis-regulatory elements in the genome. Promoters are located just upstream of TSSs, and are
composed of a core promoter (dark blue) and a proximal promoter region (light blue). Promoters
assemble the basal transcriptional machinery to initiate transcription, while enhancers interact
with promoters to increase the level of transcription. Silencers exhibit the opposite effect to
enhancers by repressing the level of transcription. Insulators act as barriers to prevent the
influence of enhancers and silencers on neighbouring genes. Figure adapted from Luizon and
Ahituv (2015).
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1.1.5 Transcription factors
The transcription of genes by pol II is facilitated by a family of regulatory proteins
called TFs, and other factors capable of controlling the chromatin structure. TFs are
the largest family of proteins in humans, forming approximately 9% of the genes
(Babu et al., 2004). Together, these proteins help assemble the basal transcriptional
machinery at the core promoter, hence playing a key role in transcription initiation.
Apart from promoters, TFs also bind at enhancer regions where they have a central role
in enhancer activation. TFs can be categorised into two types: general and sequence
specific. General TFs mostly interact with pol II to initiate transcription, while the
latter bind to specific targets to drive specific patterns of gene expression (Kadonaga,
2004). TFs perform their function by binding to the DNA either directly, or indirectly
via another protein. The TFs capable of direct binding, however, can only bind at
regions with specific sequence patterns, hence are referred to as sequence specific
TFs. This sequence specificity of TFs is believed to be a result of chemical bonds and
Van der Waals interactions between DNA binding domains of TFs and nucleotides in
the DNA (Luscombe et al., 2001). Moreover, TFs usually bind in clusters within the
enhancer regions in specific combinatorial binding patterns (Yan et al., 2013). The
TFs involved in cooperative binding often have protein-protein interactions amongst
themselves. Once the necessary TFs bind to the DNA, they can either activate or repress
the expression of the associated gene. In eukaryotic organisms, the transcriptional TF
network is complex as most of the genes require multiple TFs for their regulation, and a
single TF typically can regulate many genes.
Transcription factor binding
DNA sequences functioning as enhancers contain short sequences (usually 6-12 bp) to
which sequence-specific TFs bind. These short DNA sequences are known as motifs.
At some positions in the motif sequence, the TFs are often able to bind to more than
one nucleotide, which are referred to as ‘degenerate’ positions. Detecting motifs in the
genome can help to identify the location of the binding sites of their associated TFs,
and can also identify other co-factors binding near them, which could be involved in the
same functional pathway. However, identification of genomic sites where TFs bind is a
difficult problem and an ongoing challenge in the field of genomics. Two approaches
have been commonly used to model the sequence binding specificity of a TF.
The first approach is the consensus sequence model, in which the sequence vari-
ability in the binding sites are summarised into a consensus sequence (Fig. 1.3A-B).
The degenerate positions in the consensus sequence are represented by distinct symbols.
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However, the consensus sequence fails to measure the variability in the nucleotides at
each position.
Fig. 1.3 Computational modelling of TF binding specificity. For a set of DNA sequences
bound by a TF (A), the consensus sequence (B) summarises the variability in binding sites by
representing patterns of nucleotide occurrences with distinct symbols. PFM (C) and PWM (D)
on the other hand, more accurately quantifies the nucleotide variability at each position of the
binding site, which can be used to calculate a score (E) representing the binding energy of the
TF. The PWM of a TF can be visualised in a sequence logo (F) for easy interpretation. Figure
taken from Wasserman and Sandelin (2004).
Second and a better approach is the position weight matrix (PWM) model (Stormo,
2000), which more accurately quantifies the nucleotide variability at each position.
In this method, the number of observed nucleotides at each position of the binding
site are first counted to construct a position frequency matrix (PFM) (Fig. 1.3C), and
then normalised, converted to probabilities compared to background distribution and
transformed to log-scale (Fig. 1.3D). Using this model, a score for a DNA sequence is
calculated by summing the values in the PWM for each nucleotide (Fig. 1.3E), which
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corresponds to the binding energy of a TF (Stormo, 2000). Finally, for easy and fast
interpretation, the PWMs are visualised as sequence logos where the height of each
nucleotide is scaled according to its observed frequency (Fig. 1.3F). To date, PWM is
the preferred method to display the DNA binding preference of a TF.
1.1.6 Chromatin - a gatekeeper of regulatory regions
DNA is normally wrapped around histones which results in a compact configuration of
dense nucleosomes inside the nucleus. However, researchers in the 1970s found that
genomic locations associated with active genes are less compact compared to non-active
genes (Axel et al., 1973; Weintraub and Groudine, 1976). More recent studies have
identified TFs to bind DNA regions which are depleted of nucleosomes. For example, in
vivo binding sites of TFs have been observed to strongly correlate with nucleosome free
regions in D.melanogaster (Li et al., 2011) and mammalian genomes (John et al., 2011).
This identified a critical role of chromatin as an accessibility barrier in TF binding and
enhancer activity. It is now known that the dense nucleosome structure of the DNA
does not allow TFs to bind, hence, this state is referred to as ‘closed’ or ‘inaccessible’
chromatin. On the other hand, when the region is nucleosome free, it is ‘open’ and
accessible for TFs and other co-regulators to bind.
The conversion of a ‘closed’ chromatin state into ‘open’ chromatin, and vice-versa,
is mostly controlled by specific regulatory proteins known as pioneer factors (Fig.
1.4). These proteins have the ability to disrupt the chromatin structure, which allows
them to bind to the DNA even when it is inaccessible. By doing so, they incorporate
chromatin-remodelling complexes which reposition the nucleosomes in this region and
make it accessible to other TFs, thereby allowing the enhancer to assemble the required
TF complex for its activation. This phenomenon was first discovered in yeast (Almer
et al., 1986), where the activation of the PHO5 gene was accompanied by the removal
of nucleosomes at an upstream regulatory sequence. Soon after, the TF HNF3 was
discovered in the mouse to be essential for the activation of Alb1 enhancer in liver
(Liu et al., 1991). An example of a well studied pioneer factor is PU.1 (also known as
SPI1), which is essential for the generation of macrophages and B-cells (Scott et al.,
1994a). To date, many pioneer TFs have been discovered such as FOXA1 (Cirillo et al.,
2002), MYOD1 (Serna et al., 2005) and PAX5 (McManus et al., 2011), which play an
essential role before the regulatory networks initiate. Depending on the TF function and
requirement, a pioneer factor may bind an enhancer for a short span until the enhancer
becomes active (Hoogenkamp et al., 2009; Liber et al., 2010), or in some scenarios,
may remain enhancer-bound and drive cell-type specific lineages (Mercer et al., 2011).
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Fig. 1.4 Chromatin accessibility and pioneer factors. Chromatin acts as an accessibility
barrier between TFs and enhancer regions. DNA regions with a high density of nucleosomes
can restrict the binding of TFs. Chromatin accessibility is controlled by regulatory proteins
known as pioneer factors, which have the ability to bind nucleosome rich regions and make
them accessible to other TFs. Figure adapted from Shlyueva et al. (2014).
Although multiple regulatory elements are involved in controlling the gene ex-
pression, enhancers play one of the most important role in transcriptional regulation
because of their ability to activate and enhance the transcription, and drive cell-type
specific expression patterns. From here onwards, this chapter is focused on enhancers
and their associated mechanisms. The following sections provide greater details about
the function of enhancers, approaches to predict enhancer regions, and discuss how
disruptions in these regions can lead to diseases.
1.2 Enhancers
1.2.1 History
The first enhancer region was identified in 1981, as a 72 bp sequence segment of the
simian virus 40 (SV40) genome (Banerji et al., 1981). This sequence could increase
the transcription levels of a reporter gene (a β -globin gene) by two hundred times in
HeLa cells (a cell line derived from cervical cancer cells). Surprisingly, it was observed
that this enhancer sequence could influence the transcription of the reporter gene from
different locations in either orientation; it could increase the transcription levels of
the reporter gene when placed near the promoter, or several kbs away, upstream or
downstream of the gene (Banerji et al., 1981). Subsequent to this discovery, many
studies confirmed these observations and identified more enhancers in animal viruses
(Hansen and Sharp, 1983; Schirm et al., 1985; Spandidos and Wilkie, 1983; Villiers
et al., 1982) and metazoan genomes (Banerji et al., 1983).
One of the first enhancers in the mammalian genome was described in the im-
munoglobulin heavy chain (IGH) locus. The function of this IGH associated enhancer
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sequence was observed to be cell dependent; the enhancer was functionally active in
myeloma cells (derived from cancerous plasma cells), but not in HeLa cells (Banerji
et al., 1983; Davidson et al., 1986). A similar observation was made with enhancers
associated with β -globin gene, where enhancer function was not only cell-type specific,
but also stage-specific in the developmental process (Antoniou et al., 1988; Kollias
et al., 1987; Trudel and Costantini, 1987). Initially, enhancers were considered to be
structural elements associated with chromatin organisation, but this assumption soon
changed as evidence about cell-type specific activity of enhancers emerged. It was
hypothesised that the cell-dependent activity of enhancers was a result of the presence
or absence of cell-type specific TFs binding to the enhancers. Indeed, around end of the
1980s, further studies using in vivo and in vitro techniques characterised the binding
sites of several TFs and demonstrated that enhancer function is dependent on specific
TF binding activity (Lee et al., 1987; Maniatis et al., 1987).
It is now 37 years since the first discovery of enhancer in the SV40 genome, the core
definition of enhancers has not changed significantly (Pennacchio et al., 2013; Tippens
et al., 2018). The completion of the human genome project and the falling cost of
high-throughput sequencing technologies have facilitated the identification of enhancers
on a genome-wide scale. In the last decade, many research groups and large-scale
projects such as the ENCODE (ENCODE Project Consortium, 2012) and the Roadmap
Epigenome Project (Bernstein et al., 2010), have identified up to a million potential
enhancers in a plethora of human cell-types and tissues by employing high-throughput
sequencing technologies. Such projects have not only produced a wealth of useful
epigenetic data, but also increased the interests of researchers in epigenetics. As a result,
enhancers are currently considered as the most important class of functional elements
in the non-coding part of the genome.
1.2.2 Enhancer function
Enhancers are responsible for increasing the transcription rate of their target genes.
Moreover, most of the mechanisms that drive cell-type specific gene expression at
different stages of the developmental process are believed to be regulated by enhancers
(Zlotorynski, 2018). Enhancers achieve this by recruiting cell-type specific TFs and
co-factors. An important property of enhancers is that their function is independent of
their orientation and distance with respect to their target gene, hence they are capable
of exhibiting their effects on a gene located several hundred kbs or Mbs away through
chromosome looping (Gondor and Ohlsson, 2009) (explained later in section 1.2.4).
For successful transcription, a gene requires the PIC to be assembled at its promoter
region, which will initiate the transcription and overpower pol II pausing resulting
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in transcription elongation (Fig. 1.5). However, the level of basal transcription by
promoters is often low. The enhancers come in contact with the promoters via looping
and increase the rate of transcription by increasing the number of factors involved
in the process. Most important factors amongst these include the Mediator complex,
which is a co-activator complex binding to other TFs and pol II (Kagey et al., 2010);
cohesin, which stabilises and sometimes even drive cell-type specific enhancer-promoter
communication bridge (Kagey et al., 2010); and factors important for paused pol II
release and elongation such as BRD4 (Liu et al., 2013). Additionally, enhancers
can exhibit their effect in an additive or partially redundant manner on the overall
transcription of their target genes. This characteristic is evident from in vivo assays
(such as reporter assays) where amalgamating multiple enhancer sequences often display
transcription levels equivalent to their combined effect (Arnone and Davidson, 1997).
PIC
Pol	2
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Fig. 1.5 Enhancer function. Enhancers once bound by the required TFs become active and
up-regulate the expression of their target genes. Enhancer function involves the formation of a
DNA loop in order to bring enhancers into close proximity with the promoters of their target
genes. This DNA loop is believed to be mediated by cohesin and the Mediator complex. Figure
adapted from Heinz et al. (2015).
1.2.3 Enhancer states and their associated chromatin marks
Enhancer activation starts with binding of TFs and remodelling of the nucleosome
within the enhancer region. The binding of TFs is followed, and in some scenarios
assisted by, the binding of other co-regulators such as p300 and CREB-binding protein
(Wang et al., 2009); pol II; chromatin remodellers such as the BRG1 complex (Morris
et al., 2014); and the Mediator complex (Kagey et al., 2010). These events lead to
the modifications of histone tails (such as methylation and acetylation) present in the
immediate enhancer related nucleosome. Interestingly, it has been observed that some of
these histone modification signatures are specifically associated with enhancers (Table
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1.1). For example, enhancer sites are enriched in histone H3 lysine4 monomethylation
(H3K4me1) or histone H3 lysine4 dimethylation (H3K4me2), and lack histone H3
lysine4 trimethylation (H3K4me3), while active enhancer sites have the addition of
histone H3 lysine27 acetylation (H3K27ac) (Creyghton et al., 2010; Heintzman et al.,
2007). Additionally, enhancers marked by the repressive mark histone H3 lysine27
trimethylation (H3K27me3) are considered to be poised (Zentner et al., 2011).
Table 1.1 Histone tail modifications and their presumed biological associations.
Histone mark Functional association
H3K4me1 Enhancers and distal elements, and regions downstream of transcription start sites
H3K4me2 Cis-regulatory regions and promoters of transcriptionally active genes
H3K4me3 Promoters and transcription start sites
H3K27ac Active regulatory elements
H3K9ac Active regulatory elements with preference for promoters
H3K27me3 Elements repressed by polycomb proteins
H3K79me2 Transcription, with preference to 5’ end of genes
H3K9me3 Repressive heterochromatin and repetitive elements
H3K36me3 Actively transcribed portions of genes and chromatin regions.
As an example, the enhancer activity and epigenetic features associated with T-cell
acute lymphocytic leukaemia 1 (TAL1) in multiple human cell lines are shown in Fig. 1.6.
Enhancers B and C, representing an enhancer stretch of 19 kb downstream and 3.8 kb
upstream of TAL1 TSS respectively, activate TAL1 transcription in human umbilical
vein endothelial cells (HUVECs) (Gottgens et al., 2004), while in K562 erythroid
cells, enhancer A (51 kb downstream of TAL1 TSS) and enhancer C are responsible for
doing the same (Delabesse et al., 2005). The enrichment of H3K4me2 and H3K27ac
is consistent with the cell-type specific activity of the enhancers. Note that the cell
lines which do not express TAL1, such as human embryonic stem cells (hESCs), normal
human epidermal keratinocyte (NHEK) and normal human lung fibroblast (NHLF),
lack histone modifications associated with active enhancers, while displaying high
enrichment of the repressive mark H3K27me3.
As opposed to enhancers, active promoter regions have an enrichment of H3K4me3
and H3K27ac, and a depletion of H3K4me1 (Heintzman et al., 2007; Kim et al., 2005).
Other signatures such as enrichment of histone H3 lysine79 trimethylation (H3K79me3)
and pol II, have been associated with active enhancers which regulate the genes involved
in the developmental process (Bonn et al., 2012). It is important to note that although
not all the regions with these histone modification signatures are functionally active
enhancers, but the majority of active enhancers have been observed to have these
characteristics. For this reason, such epigenetic marks have been utilised by researchers
to annotate and differentiate between the various enhancer states (Ernst and Kellis,
2012). The enhancers have been broadly categorised into the following four states (Fig.
1.7):
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Fig. 1.6 Cell-type specific activity of histone modification signatures. Genomic view of
∼60 kb region around the TAL1 gene, displaying levels of H3K4me2, H3K27me3, H3K27ac and
DNase HS (DNaseI hypersensitive sites which represent open chromatin regions) in seven human
cell lines. hESC, human embryonic stem cell; HUVECs, human umbilical vein endothelial
cells; HSMM, human skeletal muscle myoblast; NHEK, normal human epidermal keratinocyte;
NHLF, normal human lung fibroblast. Figure taken from Heinz et al. (2015).
1. Inactive: An inactive enhancer is covered with closed or compact chromatin
which makes the region inaccessible to protein binding, hence they lack TF and
co-regulator activity (Fig. 1.7A).
2. Primed: A primed enhancer has open chromatin, and therefore, this region
may be bound by TFs. However, these TFs depend on other additional factors
such as external stimulus, other TFs and co-regulators, to activate the enhancer
function. Histones near primed enhancers may have H3K4me1 modifications, but
are depleted of H3K27ac (Fig. 1.7B).
3. Poised: A poised enhancer is essentially a primed enhancer additionally charac-
terised by repressive chromatin marks such as H3K27me3, and may have a small
open chromatin region (Fig. 1.7C).
4. Active: Active enhancers have an accessible chromatin and are bound by all the
essential TFs required for enhancer activation. These elements are marked by a
high enrichment of H3K27ac and H3K4me1(Fig. 1.7D).
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Fig. 1.7 Various enhancer states. (A) Inactive enhancers usually consists of high density of
nucleosomes which make them inaccessible to TFs. (B) Enhancers which are not yet active and
depend on other signals to get activated may be enriched with H3K4me1. (C) Poised enhancers
may be marked by H3K4me1 and repressive mark H3K27me3. (D) Active enhancers are bound
by TFs and have high enrichment of H3K4me1 and H3K27ac. Figure adapted from Shlyueva
et al. (2014).
1.2.4 Enhancer-promoter interaction
Soon after the discovery of enhancers, it was proposed that enhancers interact with
the promoters of their target genes even from hundreds of kbs away, which raised the
question of how do enhancers find and interact with promoters from such long distances.
Over the years, two major models have been proposed to explain this mechanism (Fig.
1.8). First, a facilitated-tracking model, which states that once an enhancer is bound by
activator proteins, it moves along the DNA in the direction of promoter, thus forming a
loop which increases in size until the enhancer-bound complex comes into contact with
the promoter (Blackwood and Kadonaga, 1998; Wang et al., 2005). Second, a looping
model which suggests that there occurs a more direct contact between the genomic
location of the enhancer and the promoter within the nucleus, by looping out of the DNA
(Gondor and Ohlsson, 2009). This chromosome looping is believed to be mediated by
cohesins (Hadjur et al., 2009; Hou et al., 2010) and other TFs like GATA1 (Vakoc et al.,
2005), Mediator (Kagey et al., 2010) and CTCF (Hou et al., 2010). Enhancer RNAs
(eRNAs), which are a by-product of enhancers being transcribed by pol II, are also
believed to be physically engaged in the formation of such loops (Hsieh et al., 2014).
Since there could exist large distances between enhancer and promoter elements,
it is unlikely that the chromatin structure between the two elements spanning over
such large distance is directly involved in the enhancer-promoter interaction. Hence,
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Fig. 1.8 Mechanisms of enhancer-promoter communication. The tracking model proposes
that enhancer-bound TF complex moves towards the promoter of their target gene without
leaving the enhancer sequence. The looping model proposes that the enhancer-bound TF
complex loops out of the intervening DNA sequence to interact with the promoter of its target
gene. Figure adapted from Vernimmen and Bickmore (2015).
the facilitated-tracking model is likely to be applicable for close enhancer-promoter
interactions (< 10 kb) in comparison to long-range enhancer-promoter communications,
where the chromosomal looping model is more appropriate. Indeed, the few studies
which provide evidence for a facilitated-tracking model involved a relatively small
distance between the enhancer and promoter (Hatzis and Talianidis, 2002; Wang et al.,
2005). Presently, the facilitated-tracking model is only supported by a small number of
studies and requires further testing.
In contrast to the facilitated-tracking model, the looping model has been widely
tested experimentally using fluorescence in situ hybridisation and chromosome confir-
mation capture (3C) type techniques, which have provided evidence for the long-range
enhancer-promoter interactions through chromatin looping. The 3C type techniques
includes 3C (Lieberman-Aiden et al., 2009) and its variants such as circular chromo-
some confirmation capture (4C) (Zhao et al., 2006), chromosome confirmation capture
carbon copy (5C) (Dostie et al., 2006) and Hi-C (Belton et al., 2012). These 3C based
assays are able to capture regions in the genome which are physically close to each
other, independent of their proximity on the linear DNA. For instance, the β -globin
locus was amongst the first group of genes where DNA looping interactions were
identified between β -globin promoters and a LCR situated 25 kb upstream of them
(Carter et al., 2002). Another 3C variant method called chromatin interaction analysis
with paired-end tag sequencing (ChIA-PET) (Fullwood et al., 2009) has been widely
used, which integrates the chromatin immunoprecipitation (ChIP) technique (Das et al.,
2004) with 3C based assays to capture chromosomal contacts involved with protein
factors important in transcription, such as the pol II. Such studies have shown that
gene promoters have frequent long-range interactions with multiple enhancers (which
are often cell-type specific) to form active chromatin hubs (Laat and Grosveld, 2003).
Genome-wide analysis of chromatin interactions using 3C based techniques (termed Hi-
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C) have also identified that genome is partitioned into active and inactive compartments
(Lieberman-Aiden et al., 2009). These compartments have been further sub-divided
into domains at the sub-megabase level called topologically associated domains (TADs).
TADs represent regions of the genome having high chromatin interactions and have
been found to be conserved amongst humans and mouse (Dixon et al., 2012).
1.2.5 Enhancer target genes
The enhancer-promoter interaction maps from chromosome capture studies are also
being utilised to identify potential genes regulated by enhancers. The identification
of the target gene regulated by a particular enhancer has been a challenging task in
regulatory genomics. Generally in the past, the nearest annotated gene to the enhancer
on the linear genome has been assumed to be its potential target gene. But, even the
genomic regions separated by several Mbs on the linear genome might be located
close to each other in the 3D organisation of the genome, therefore, the gene nearest
to the enhancer may not be its correct target gene in many cases. Indeed, the data
from 3C based chromosome interactions suggest that enhancers often skip their nearest
annotated gene and regulate distantly located genes. However, the results from such
studies are not consistent and report that the proportion of enhancers that regulate their
nearest gene ranges between 7% up to > 80%. Some of the 3C based studies and their
findings are shown in Table 1.2. Contrastingly, a study based on co-expression patterns
to predict regulatory interactions show that 88% of functional enhancers in Drosophila
regulate their nearest gene, with 8% of the remaining genes interacting with their second
nearest gene (Kvon et al., 2014). Additionally, they found that up to 80% of intragenic
enhancers in Drosophila regulate the gene within which they are located, which suggests
that enhancers more than often regulate the gene they overlap. Overall, the functional
relevance of the genome-wide enhancer-gene interactions obtained from 3C based
studies has been difficult to completely validate due to the limitations described below.
Firstly, the resolution of capturing the chromosome interactions is often low (5 kb
- 1 Mb) as it depends on the sequencing depth and restriction enzyme digestion sites.
Although, recent methods such as in situ Hi-C have increased the resolution up to 1 kb
by performing very deep sequencing (over 25 billion reads) (Rao et al., 2014), it is
expensive and computationally intensive to produce and analyse such large amount of
reads to achieve a high resolution. Hence, due to the low resolution in the majority of the
studies, it is possible that the chromosome confirmation is not able to reliably capture the
contacts between adjacent genomic elements (< 5 kb), where many enhancers could be
located (Yao et al., 2015). For instance, using the capture Hi-C method (CHi-C) (Mifsud
et al., 2015) which specifically involves enrichment of reads around the promoters,
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Table 1.2 Examples of 3C based studies and their observations.
Data Organism Cell line/tissue Finding Reference 
 
5C 
 
Human 
 
GM12878, 
K562, HeLa-S3 
 
7% of all interactions are with the nearest 
TSS; 27% of distal elements interact with 
their nearest gene, or 47% if only expressed 
genes are used in the analysis 
 
Sanyal et al., 
2012 
ChIA-PET Human MCF7, K562, 
HeLa, HCT116, 
NB4 
60% of enhancers interact with their nearest 
gene 
Li et al., 2012 
ChIA-PET Mouse mESCs 83% of SEs and 87% of TEs interact with 
their proximal active gene 
Dowen et al., 
2014 
CHi-C Human GM12878, 
CD43+ 
66% of all interactions are with the nearest 
promoter 
 
Mifsud et al., 
2015 
 
a higher frequency of interactions (66%) was identified to interact with the nearest
promoter (Table 1.2). Besides, many studies have shown that enhancers often do not
regulate and skip the genes not expressed in the cell-type under study (Mifsud et al.,
2015; Sanyal et al., 2012), suggesting that the interactions between enhancer and their
target genes may depend on the genomic or epigenomic circumstances.
Secondly, the 3C based methods were initially developed to capture the physical
contacts in the genome, which may not necessarily correspond to functional regulatory
interactions (reviewed in Laat and Duboule (2013)). Indeed, many studies have found
frequent inter- and intra-chromosomal interactions within genomic regions with no
chromatin activity (Lieberman-Aiden et al., 2009; Sanyal et al., 2012). For instance, a
5C study in fetal lung cells identified 1 million interactions, out of which only∼6% were
detected between an annotated promoter and a distal region (Jin et al., 2013). It is also
believed that many of these interactions which are not related to gene expression may
arise from random collision in the nucleus or within the TADs, or they may be involved
in maintaining the nuclear structure, hence are stable but not functional (Dekker et al.,
2013). It is also possible that some enhancers interact with the promoters of their target
genes by a different mechanism rather than looping. Therefore, the 3C based studies
may not provide a complete set of chromatin interactions between potential enhancers
and their target genes (Yao et al., 2015).
Although chromosome confirmation studies have provided immense insights into
the spatial organisation of the genome, the rules to infer enhancer-promoter interactions
are not yet clear and require further investigation using in vivo genetic approaches.
Since there is a paucity of chromosome confirmation data in different cell-types, many
genome-wide studies associate potential enhancers to their nearest genes, in order to
obtain enough enhancer-promoter interactions to provide them with useful biological
insights (Hnisz et al., 2013; Hnisz et al., 2015; Loven et al., 2013; Whyte et al., 2013).
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1.3 Current methods to identify enhancer regions
The identification and characterisation of enhancers has been of great interest amongst
researchers since their discovery. Especially, in the last decade, studying enhancers
have been of prime focus in the area of genomics, revealing their importance not only
in regulating cell-type and stage-specific gene expression, but also in disease causation
(discussed later in this chapter). However, identification of enhancers has been a
challenging task. One of the reasons for this is that identifying enhancers and their
activity solely from DNA sequences is unreliable. Moreover, it is difficult to identify
essential regions within enhancers and infer their functional consequence in the event
of disruption. But, with the advancement in next-generation sequencing technologies
during the last decade, it has now become possible to reliably capture enhancer related
chromatin features at a genome-wide scale. In addition, techniques to modify genomic
DNA in vivo allow researchers to experimentally investigate enhancer activity and its
functional consequences. In the following section, I describe some of the common
approaches which are used to predict enhancer regions and how they take advantage of
the known characteristics of enhancers to identify them.
1.3.1 Predictions using motifs and conservation
As described earlier, enhancers are known to contain binding sites for TFs, which
are often observed to be conserved between closely related species. Therefore, com-
putationally searching for TF binding motifs within a genomic sequence can help to
predict enhancer regions. Two approaches have been used to achieve this: (1) by
identifying genomic sequences enriched for TF binding motifs; or (2) by identifying
genomic sequences highly conserved between species. Both these methods depend
on prior knowledge of motif sequences bound by TFs. There are many computational
and experimental methods to identify the motif sequence of a TF. The computational
approaches mainly involve looking for short sequences either over-represented or with
high evolutionary sequence conservation amongst potential regulatory regions such as a
group of functionally related sequences. For instance, examining the promoter regions
upstream of co-regulated or co-expressed genes for enriched and conserved sequences
is a common technique to identify motifs (Roth et al., 1998).
However, the computational approaches described above have limitations. Since
motifs are short DNA sequences generally 6-12 bp in length, they could even match to
random genomic sequences which can produce a high rate of false-positives. In reality,
only a small fraction of these matches would be bound by the TF in vivo (Wasserman
and Sandelin, 2004). Additionally, TF binding is often tissue-specific and relies heavily
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on interactions with other co-factors and proteins (Yanez-Cuna et al., 2012), which
suggests that only a small fraction of computationally identified motif matches would
have functional relevance. Likewise, motif matches with high evolutionary sequence
conservation do not guarantee that they would be bound by the TF in the tissue of
interest, or that they would be functionally active. Previous studies have shown that
enhancers can be functional and weakly conserved between the species (Blow et al.,
2010; Meireles-Filho and Stark, 2009), therefore, methods to predict enhancers solely
based on conservation may capture only a portion of the total enhancers active genome-
wide.
1.3.2 Predictions using TF binding
Compared to computational scanning of motifs to predict transcription factor binding
sites (TFBSs), a more accurate approach is to identify the in vivo binding sites of a TF.
Many experimental approaches have been used to identify genome-wide in vivo TFBSs.
These methods include chromatin immunoprecipitation followed by sequencing (ChIP-
seq) (Johnson et al., 2007), and its variants such as ChIP-exo (Rhee and Pugh, 2011) and
DNA adenine methyltransferase identification (DamID) (Steensel and Henikoff, 2000).
Of these methods, ChIP-seq has been the most commonly used technique. ChIP-seq
involves the chemical crosslinking of TFs to their in vivo binding sites and enrichment
of these DNA-protein complexes using antibodies specific to the TFs (Fig. 1.9). This
is followed by deep sequencing of the retrieved DNA fragments and computational
analysis to identify genomic regions bound by the TF. A major limitation of ChIP
based methods is that they require a highly specific antibody for the TF of interest, and
antibodies for many TFs have not been discovered yet. An additional limitation is the
cost, since only one TF can be profiled in a single ChIP-seq experiment.
TF TF
ChIP-seq
antibody
Fig. 1.9 Identification of transcription factor binding in vivo. ChIP-seq uses antibodies
specific to the TFs to identify the location of their genome-wide DNA binding sites. Figure
adapted from Shlyueva et al. (2014).
An analysis of a single ChIP-seq experiment detects on average thousands of in
vivo binding sites, most frequently occurring within promoters, introns and intergenic
regions (Spitz and Furlong, 2012). From ChIP-seq data of hundreds of TFs, we know
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that TF binding pattern actively changes during development, indicating that TFs act in
a time and cell-type specific manner (Yanez-Cuna et al., 2012). Generally, a ChIP-seq
experiment is able to detect the majority of functional binding sites of a TF (Zeitlinger
et al., 2007). However, not all the binding sites identified by ChIP-seq are functional
and therefore, would not correlate with functional enhancers (Fisher et al., 2012). These
observations have revealed that a TF can be bound to the DNA without influencing the
expression of any gene. Although the exact reason for this is unclear, it is believed that
these non-functional binding sites may be dependent on cooperative binding and still
require binding of other TFs to activate their function. Moreover, TFs tend to have a
general affinity towards the DNA and may bind to regions with open chromatin outside
their functional network at low levels or for a very short period of time.
1.3.3 Predictions using chromatin accessibility
Since active enhancers lack nucleosomes and contain a loosely packed chromatin, iden-
tification of such regions on the DNA can help in predicting enhancers and other regula-
tory elements. Techniques such as DNaseI hypersensitive sites sequencing (DNase-seq)
(Boyle et al., 2008) and micrococcal nuclease digestion followed by sequencing (MNase-
seq) (Yuan et al., 2005) have been mostly used for this purpose. These techniques use
enzymes such as DNaseI or micrococcal nuclease respectively, which have the property
to cleave the DNA at nucleosome depleted regions (Fig. 1.10). Therefore, these tech-
niques are able to capture the complete accessible or open chromatin landscape of a
cell or tissue, and predict enhancers independent of TF information. This is particularly
important as DNase-seq or MNase-seq could be used to predict enhancers even in
those cells for which critical lineage-specific TFs are not yet discovered. In addition to
DNase-seq and MNase-seq, other techniques such as formaldehyde-assisted identifi-
cation of regulator elements followed by sequencing (FAIRE-seq) (Giresi et al., 2007)
and assay for transposase accessible chromatin followed by sequencing (ATAC-seq)
(Buenrostro et al., 2015) have been developed recently to quantify chromatin acces-
sibility. FAIRE-seq is based on the fact that formaldehyde crosslinking is stronger at
nucleosome-occupied regions, compared to nucleosome-free regions. Whereas ATAC-
seq uses a Tn5 transposase to place sequencing adapters into open chromatin regions of
the DNA (Buenrostro et al., 2015).
The TFBSs identified using ChIP-seq have been observed to be significantly corre-
lated with open chromatin regions detected using DNase-seq or FAIRE-seq (Kaplan
et al., 2011; Pique-Regi et al., 2011). Although, the majority of open chromatin regions
overlap with TFBSs which may represent enhancer regions, not all open chromatin
regions correspond to active enhancers. Other regulatory proteins such as insulators,
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Fig. 1.10 Identification of genome-wide open chromatin regions. DNase-seq uses the en-
zyme DNaseI which has the property to cleave the DNA regions depleted of nucleosomes. These
regions are referred to as DNaseI hypersensitive sites (DHSs). Figure adapted from Shlyueva
et al. (2014).
also bind at regions of open chromatin. For instance, the CCCTC-binding factor (also
know as CTCF) with enhancer-blocking insulator properties is detected within open
chromatin regions, but does not function as an enhancer (Xi et al., 2007). Moreover,
the core promoter region near the TSSs have open chromatin as TFs and co-regulators
bind there (Xi et al., 2007). Lastly, open chromatin regions may also be inactive due to
the binding of repressive TFs, a phenomenon commonly observed during development
(Gray and Levine, 1996). For such reasons, in order to predict enhancers, the open
chromatin information is often combined with other characteristics of enhancers such
as histone modifications.
1.3.4 Predictions using histone modifications
Researchers have widely used histone modifications to predict enhancer activity, taking
advantage of the fact that distinct histone tail modifications occur near enhancers
and other regulatory elements (described above in section 1.2.3). Like chromatin
accessibility, predicting enhancers using histone modifications is independent of TF
information and can be applied to any cell-type or tissue (Fig. 1.11). For this reason,
ChIP-seq of histone marks has been the most commonly used method adopted by large
international genomic projects (Bernstein et al., 2010; ENCODE Project Consortium,
2012; Ernst et al., 2011; Kharchenko et al., 2010; Shen et al., 2012) to map genome-wide
enhancers in different organisms and these predictions have shown to correlate well with
enhancer activity assays (Arnold et al., 2013; Heintzman et al., 2007). Algorithms like
ChromHMM (Ernst and Kellis, 2012) have enabled us to better annotate the different
enhancer states by combining data from multiple histone marks into easy interpretable
annotations. For example, by modelling together eight histone marks and the CTCF
binding profile, Ernst et al. (2011) were able to categorise the genome into 15 chromatin
states corresponding to active and inactive enhancers and promoters. Such systematic
genome-wide annotation of enhancers using histone modifications have even discovered
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novel enhancer states, such as enhancers enriched with both active and repressive
histone marks (H3K4me1 and H3K27me3 respectively) termed as bivalent enhancers
(Bernstein et al., 2006; Shu et al., 2011).
TF
ChIP-seq
antibody
H3K27ac
Fig. 1.11 Identification of genome-wide chromatin marks. Histones flanking enhancer re-
gions contain specific modifications such as H3K27ac. ChIP-seq using antibodies specific to
these histone marks is used to detect the genome-wide locations of histone modifications. Figure
adapted from Shlyueva et al. (2014).
Despite histone modifications being widely used to identify potential enhancers, it
is not yet known what proportion of the complete enhancer landscape can be captured
using this method. It has been observed that the predictions from known histone
modifications and their combinations may not perfectly correlate with enhancer activity
(Arnold et al., 2013; Bonn et al., 2012). For instance, a study in D.melanogaster
detected ∼40% of mesodermal enhancers lacked H3K27ac signal (Bonn et al., 2012),
however, these numbers may vary in different organisms. In addition, novel histone
acetylation marks such as H3K64ac and H3K122ac, have been recently discovered to
correlate with promoter and enhancer activity (Pradeepa et al., 2016). Though data for
these novel histone modifications is not abundant at the moment, such additional marks
may improve enhancer prediction in the near future.
1.3.5 Predictions using enhancer-promoter interactions
It has now been established that enhancers come in contact with promoters of the
gene they regulate, therefore, identification of these interactions or the characteristics
associated with them can also help in enhancer prediction. This concept has been
utilised by two methods. The first method is based on the fact that co-factors help
mediate the enhancer-promoter interactions, hence, identification of genomic binding
sites of such co-factors can predict enhancers. Although, the complete mechanism of
the 3D organisation of the genome still remains to be determined, scaffold proteins
like Mediator and cohesin are known to stabilise the chromosome looping (Kagey
et al., 2010). Therefore, ChIP-seq profiles of Mediator and cohesin have been used
to predict enhancers (Whyte et al., 2013) (Fig. 1.12). The second method is the 3C
based assays (describer earlier in section 1.2.4) which directly quantifies both intra- and
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inter-chromosomal physical contacts between enhancers and the core promoters of their
target genes (Fig. 1.12). Although, chromosome confirmation capture techniques have
been used to identify enhancers and predict their regulatory interactions with the target
genes, there are some limitations associated with this methodology which are described
earlier in section 1.2.5.
Non-target	
genesMediator
Target	gene
Cohesin
Enhancer
Pol	2
Pol	2
Mediator
Cohesin
Pol	2
ChIA-PET
ChIP-seq ChIA-PET Chromosome	confirmation	capture
Fixation	and	shearing
Fig. 1.12 Identification of enhancer-promoter interactions. Enhancers are brought into close
proximity of the promoters of their target genes through chromosome looping, which is mediated
by Mediator complex and cohesin. ChIP-seq can be used to identify the contact points between
Mediator complex and cohesin. ChIA-PET and 3C based methods involve formaldehyde
crosslinking of spatial contacts, shearing of linear DNA, fragmentation, ligation and deep
sequencing. ChIA-PET additionally involves a ChIP phase for the enrichment of contacts which
involve a particular protein such as the pol II. 3C based methods detect all the spatial and
physical contacts within a defined genomic region. Both ChIA-PET and 3C based methods
can identify pairwise interactions between the contact points (shown as lines), some of which
may correspond to regulatory interactions (solid lines) and some may not (dotted lines). Figure
adapted from Shlyueva et al. (2014).
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1.4 Super-enhancers
A single enhancer is enough to activate the transcription of its target gene. But some
genes are located in regions near a high density of enhancers. Such genes have been
often observed to be expressed in a tissue- or cell-type specific manner. A well charac-
terised example of such a region is the enhancer rich LCR associated with tissue-specific
expression of globin genes in erythroid cells (Levings and Bungert, 2002). These dense
clusters of active enhancers have been termed as super-enhancers (SEs) and recognised
as a new class of regulatory element.
The term ‘super-enhancer’ was first used in 2004, corresponding to a 30 bp enhancer
sequence which could activate the transcription of immediate-early gene (ie-1) both
in vitro and in vivo (Chen et al., 2004). More recently, genome-wide SEs have been
identified and characterised using ChIP-seq, to detect regions densely bound by key
TFs. In comparison to regular enhancers (referred to as typical-enhancers (TEs)), SEs
span relatively large genomic regions (up to tens of kb) and have significantly higher
enrichment of chromatin regulators, TFs and co-factors such as the Mediator complex,
p300, Brd4 and pol II (Hnisz et al., 2013).
1.4.1 Super-enhancer identification
SEs were first distinguished from TEs in mouse ESCs (mESCs) using Med1 binding
signal by Whyte et al. (2013). This classification was achieved in three steps: (1)
binding sites of key TFs associated with pluripotency in mESCs (such as Sox2, Oct4,
Nanog) were identified using ChIP-seq and considered as potential enhancer regions;
(2) enhancer regions within a distance of 12.5 kb were stitched together (Fig. 1.13A);
and (3) Med1 binding profile was used to identify stitched enhancers with significantly
high enrichment of Med1 signal and were defined as SEs (Fig. 1.13B). In order to
discover SEs in differentiated cells, key lineage-specific TFs have been commonly used
instead of pluripotency associated TFs. For example, the binding occupancy of the TF
PU.1 was used by Whyte et al. (2013) to identify potential enhancer regions in pro-B
cells and further categorise them into SEs. This methodology to detect SEs was later
implemented by Whyte et al. (2013) in a program called ROSE (Rank Ordering of
Super-Enhancers), which has since become the standard method to do such analysis and
has been applied to an assortment of cells and tissues (Table 1.3). However, the marks
used to identify potential enhancers and segregate SEs have been variable. Overall,
Mediator binding and H3K27ac chromatin mark has been most commonly used to
segregate SEs from TEs.
25
Background
Super-enhancers
Typical-enhancers
Bi
nd
in
g	
fa
ct
or
	si
gn
al
	(e
.g
.	M
ed
1)
Stitched	enhancers	ranked	by	binding	
factor	signal
Low High
enhancers
Stitched	enhancers
A
B
Fig. 1.13 Identification of super-enhancers. (A) The enhancer regions identified in any cell-
type or tissue within a distance of 12.5 kb are stitched together into cohesive units. (B) The
stitched enhancer units are then ranked by a binding factor enrichment signal (such as Med1 or
H3K27ac) and a threshold of its inflection point is calculated. The stitched enhancer units with
a binding factor signal higher than the estimated threshold are defined as SEs. Figure adapted
from Pott and Lieb (2015).
1.4.2 Properties of super-enhancers
SEs have been associated with their nearest genes based on the observation that enhancer-
promoter looping interactions frequently occur within 50 kb (Gondor and Ohlsson,
2009; Ong and Corces, 2011; Sanyal et al., 2012; Spitz and Furlong, 2012). Systematic
mapping of SEs across diverse tissues and cell lines in human and mouse has shown
that SEs regulate key genes that define the cell identity, and drive high expression of
their target genes compared to TEs (Adam et al., 2015; Fang et al., 2015; Hnisz et al.,
2013; Huang et al., 2016; Loven et al., 2013; Ohba et al., 2015; Pelish et al., 2015;
Shin et al., 2016; Siersbæk et al., 2014; Vahedi et al., 2015; Whyte et al., 2013). For
example, important genes involved in ESCs pluripotency such as Oct4, Sox2 and Nanog,
are found near SEs (Whyte et al., 2013). In another study, Sox2 associated SE was
identified to be essential for 90% of Sox2 expression (Li et al., 2014). Genes associated
with SEs have also been observed to be expressed in a cell-type specific manner (Loven
et al., 2013). Furthermore, compared to genes associated with TEs, SE associated
genes appear to be more sensitive to perturbations. For example, shRNA knockdown of
Med12 mostly affected the expression of SE associated genes, however, the degree of
impact on the expression levels of TE associated genes was much lower.
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Table 1.3 Summary of previous studies which involved identification of super-enhancers.
Table adapted from Niederriter et al. (2015).
Enhancer 
identification 
Factor to 
distinguish SE and 
TE 
Tissue/Cell Organism Reference 
1. Oct4, Sox2, Nanog 
2. Stitch together 
Med1 
mESC Mouse Whyte et al., 2013 
mESC Mouse Hnisz et al., 2015 
1. Med1 
2. Stitch together 
MM1.S cell line 
SCLC cells 
Glioblastoma cells 
Human Loven et al., 2013 
Multiple AML cell lines Human Dawson et al., 2014 
1. H3K4me1/DHS 
2. Stitch together Erythroid cells Mouse Hay et al., 2016 
1. PU.1 
2. Stitch together PU.1 Pro-B cells Mouse Whyte et al., 2013 
1. MyoD 
2. Stitch together MyoD Myotubes Mouse Whyte et al., 2013 
1. T-bet 
2. Stitch together T-bet T-helper cells Mouse Whyte et al., 2013 
1. C/EBPA 
2. Stitch together C/EBPA Macrophages Mouse Whyte et al., 2013 
1. EBNA2 
2. Stitch together EBNA2 
EBV-transformed 
lymphoblastic cells Human Zhou et al., 2015 
1. H3K27ac 
2. Stitch together 
H3K27ac 
86 tissues/cell lines Human Hnisz et al., 2013 Suzuki et al., 2017 
Colorectal cancer cells 
ER+ breast cancer cells Human Hnisz et al., 2015 
Jurkat cells Human Dawson et al., 2014 
MOLM-1 cells Human Groschel et al., 2014 
Neuroblastoma cells Human Chipumuro et al., 2014 
T-cells Mouse Vahedi et al., 2015 
EBV-transformed 
lymphoblastic cells Human Zhou et al., 2015 
ESCs, Pro-B cells, Th 
cells, myotubes, 
macrophages 
Mouse Suzuki et al., 2017 
Not described Striatum Mouse Achour et al., 2015 
1. BRD4 
2. Stitch together BRD4 
B cell lymphoma Human Chapuy et al., 2013 
Activated endothelial 
cells Human Brown et al., 2014 
1. STAT5/H3K27ac 
2. Stitch together Med1/H3K27ac/GR Mammary tissue Mouse Shin et al., 2016 
	
1.4.3 Controversy over super-enhancer structure and function
Since the first characterisation of SEs by Whyte et al. (2013), many studies have
identified SEs in a wide range of tissues and cells. However, for most tissues Med1
data is not available and lineage-specific TFs are often undiscovered, therefore different
co-factors (e.g. p300) and chromatin marks (e.g. H3K27ac) have been utilised for
SE characterisation (Table 1.3), hence leading to inconsistent methodologies. Many
researchers also remain sceptical over the method of SE identification, arguing that the
clustering of enhancers on the linear genome into SEs and TEs solely based on chromatin
marks enrichment is arbitrary and lacks functional relevance (Gray and Levine, 1996;
Pott and Lieb, 2015). This is because such a clustering could group together enhancers
which regulate different genes and conversely, it could group enhancers which regulate
the same gene into different clusters.
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Another aspect of SEs which has been questioned is its novelty; it is believed that SEs
show previously known characteristics of enhancers and overlap with previously defined
regulatory elements. For instance, SEs in K562 cells overlap with the well characterised
LCR of the human β -globin locus (Hnisz et al., 2013). Similar to SEs, clusters of
potential regulatory elements termed as ‘clusters of open regulatory elements’ (COREs),
have been previously described using open chromatin regions and linked to tissue-
specific TFs (Gaulton et al., 2010; Song et al., 2011). Another previously described
enhancer category similar to SE is a ‘stretch enhancer’ (Parker et al., 2013). First
characterised around the same time as SEs, stretch enhancers were defined as enhancer
regions (non-stitched) greater than or equal to 3 kb in length. However, a comparison
between stretch enhancers and SEs in the same cell-types showed that stretch enhancers
are significantly higher in number and SEs make up only a small proportion of stretch
enhancers (∼3%), suggesting SEs to be a subset of stretch enhancers (Niederriter et
al., 2015). Based on these observations, some researchers believe that SEs may be
counterparts of previously defined regulatory elements, with differences in number and
genomic position arising due to the different criteria used to define such elements.
With respect to the SE function, it is not yet clear whether individual enhancer
elements within a SE work in an additive (total contribution towards target gene ex-
pression equal to the sum of the strength of its individual elements), synergistic (total
contribution towards target gene expression greater than the sum of the strength of
its individual elements), redundant (total contribution towards target gene expression
less than the sum of the strength of its individual elements) or a more complicated
manner. Recent advances in genome editing techniques such as CRISPR-Cas9 (short
for clustered regularly interspaced short palindromic repeats and CRISPR-associated
protein 9) mediated deletions (Shalem et al., 2014), have facilitated researchers to ex-
plore the impact of individual SE elements on their target gene transcription by deleting
them. For instance, in vivo deletion of individual enhancers within the α-globin SE
showed that two out of five individual enhancers significantly contributed to α-globin
expression in an independent and additive manner (Hay et al., 2016). Whereas, a similar
study in Wap associated SE showed its expression to be partially dependent on each
of the individual SE elements, which the authors referred to as a functional hierarchy
within the SE (Shin et al., 2016). Furthermore, Moorthy et al. (2017) observed that
each individual enhancer within enhancer clusters contributes to the expression of their
associated genes (Dppa5a, Ooep) and hence, have partially redundant function.
Conversely, Hnisz et al. (2015) investigated the function of individual and combina-
tions of enhancer elements within Pou5f1 SE using reporter assays, which showed that
the individual enhancer elements within Pou5f1 SE neither have additive nor synergistic
effect when present in a single copy, instead they exhibit a complicated influence on each
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others activity. Recently, another study performed similar experiments in SEs associated
with three micro-RNAs (miR-290-295 in mESCs, miR-1 in myotubes and miR-148a in
Pro-B cells) by generating cell lines depleted of individual enhancer elements within the
SEs, which again showed a cooperative effect amongst individual SE elements, rather
than an additive or redundant effect (Suzuki et al., 2017). Interestingly, genome-wide
chromatin interaction data from ChIA-PET suggests that individual enhancer elements
within SEs have more frequent interactions compared to elements within TEs (Dowen
et al., 2014). Clearly, similar studies are required to learn and understand about the
influence of individual SE elements on each other and on their target gene expression,
especially on a genome-wide scale.
1.5 Mis-regulation of enhancer function in disease
1.5.1 Early examples of enhancer malfunction in disease
Given that the enhancers play a key role in transcriptional regulation, it is of no surprise
that apart from the changes in the protein-coding portion of the genome, any kind of
disruption either in the enhancer regions, or in TFs that directly interact with enhancers
could attribute to diseases. One of the earliest instances of the involvement of a
regulatory region in disease was identified in the blood disorder thalassaemia. A DNA
translocation disrupting the LCR associated with the β -globin locus was identified to be
responsible for β -thalassaemia (Kioussis et al., 1983). This LCR located approximately
25 kb upstream of β -globin locus, is mostly composed of enhancers, which are together
responsible for driving high expression of the β -globin genes. Later, using 3C based
methods, these enhancers were shown to have long-range interactions with the promoter
of β -globin genes (Tolhuis et al., 2002). In another example, mutations in a limb specific
enhancer, situated 1 Mb upstream of sonic hedgehog gene (SHH) leads to polydactyly
(abnormal limb development) (Lettice et al., 2002). These examples show that mutations
or other disruptions within enhancers can lead to enhancer loss of function.
1.5.2 Enhancers in cancer and other diseases
Early studies exploring disease-causing mutations were performed mostly on a single
gene, and investigated simple phenotypic traits in Mendelian diseases such as cystic
fibrosis. However, these methods could not be directly applied to diseases with a
complex genetic nature such as diabetes and obesity. But, over the past decade, powerful
statistical methods have been developed to associate genetic variants to complex diseases
and traits. Genome-wide association studies (GWASs) have been a key resource for this
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purpose analysing millions of genome-wide genetic variants (usually single nucleotide
polymorphisms (SNPs)) to test their association with both Mendelian and complex
diseases. GWASs are based on linkage disequilibrium (LD, measured as a squared
correlation r2); an event of two SNP alleles co-occurring close to each other is not
random and exists as a result of natural selection and recombinant rate (Slatkin, 2008). A
typical GWAS involves two groups of individuals; one which are affected by a particular
disease trait under study, and the other which are not affected by that trait (control set).
Both groups are then genotyped for SNPs and allelic frequencies of their SNPs are
compared between the two groups using rigorous statistical tests, which identifies SNPs
with strong association to the disease trait under investigation (typical thresholds used:
p-value= 5×10−8; r2 > 0.5).
To date, GWASs have reported causal genetic variants for hundreds of Mendelian
and complex diseases, which include both common diseases and traits that are risk
factors for diseases (Fig. 1.14). In addition to disease traits, GWASs have also identified
genetic variants associated with physical traits such as height (Cousminer et al., 2013),
hair colour and skin pigmentation (Han et al., 2008). Although, early studies focused
on characterising SNPs within protein-coding sequence of the genes, over 90% of the
disease-associated SNPs (DA-SNPs) from GWASs occur within the non-coding regions
of the genome (Hindorff et al., 2009; Manolio, 2010). This observation made it apparent
that SNPs within the non-coding regions contribute to disease causation as well. With
the availability of genome-wide regulatory maps in human, 64% of these non-coding
SNPs have been found to be within enhancers (H3K27ac enriched regions) (Hnisz et al.,
2013). Similarly, ∼76% of the non-coding SNPs from GWASs have been found to
occur within DHSs or in high linkage disequilibrium with a SNP within DHS (Maurano
et al., 2012). Furthermore, the DA-SNPs more than often occur in regulatory regions
active in the cell-types linked to the disease pathology. For instance, SNPs associated
with Alzheimer’s disease have been identified in brain-specific enhancers, while those
associated with coronary heart defects have been identified in heart-specific regulatory
regions (Hnisz et al., 2013; Maurano et al., 2012). This tendency of DA-SNPs to occur
in cell-type specific regulatory regions has explained how sequence variants, which
occur in all cells, lead to certain cell- or tissue-specific disease traits.
Although GWASs can detect genetic variants significantly associated with a disease
trait, it does not provide any functional information about the mechanism underlying this
association. Therefore, further characterisation of GWAS hits is required to understand
how these genetic variants in enhancer regions lead to gene aberrations and diseases.
Recent studies have started to functionally characterise the causal genetic variants in
regulatory regions to understand the pathways they disrupt, which could be utilised
to develop more efficient disease therapies. Generally, the non-coding variants within
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Fig. 1.14 Timeline of SNPs discovered by GWASs. For each year, the top three diseases and
traits with the highest number of SNPs are labelled. Figure taken from Visscher et al. (2017).
enhancer regions can disrupt the binding sites of sequence-specific TFs, which could
either completely remove a binding site from that location, or create a novel binding site
for other TFs, ultimately affecting the expression of their associated target gene. For
instance, intronic SNPs associated with fetal haemoglobin expression levels within the
gene BCL11A have been detected to alter the binding sites of GATA1 and TAL1, which
disrupts the binding patters of these TFs resulting in reduced expression of BCL11A
and fetal haemoglobin (Bauer et al., 2013). Similarly, many studies have now identified
and characterised SNPs in enhancers to be associated with common diseases (Farh
et al., 2015; Gjoneska et al., 2015; Hnisz et al., 2013; Maurano et al., 2012; Pasquali
et al., 2014). In addition to enhancer regions, many diseases have been associated with
mutations causing mis-regulation in TFs, co-factors and chromatin regulators, which
directly or indirectly interact with enhancers (reviewed in Herz (2016)). Altogether,
mutations in regulatory regions have been identified to contribute to several disease
areas such as cancer, neurological disorders, autoimmunity, diabetes and many more
(examples shown in Table 1.4).
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Table 1.4 Examples of enhancers linked to human disease.
Disease Implicated 
gene 
Type Reference 
Associated with enhancer 
Aniridia PAX6 Rearrangement Kleinjan et al., 2001 
X-linked deafness 
type 3 
POU3F4 Deletion, 
rearrangement 
De Kok et al., 1995,  
De Kok et al., 1996 
Van Buchem 
disease 
SOST Deletion Loots et al., 2005 
Campomelic 
dysplasia 
SOX9 Rearrangement Pfeifer et al., 1999 
Celft lip IRF6 Point mutation Rahimov et al., 2008 
Multiple cancer 
types 
MYC Point mutation Jia et al., 2009, 
Pomerantz et al., 2009, 
Ahmadiyeh et al., 2010, 
Sotelo et al., 2010 
Prostate cancer RFX6 Point mutation Huang et al., 2014 
Parkinson’s disease SNCA Point mutation Soldner et al., 2016 
Type 1 diabetes FOXP3 Point mutation Bassuny ET AL., 2003 
Associated with co-factors and chromatin-regulators 
Uterine 
leiomyomas; 
prostate cancer 
MED12 Point mutation Makinen et al., 2011, 
Barbieri et al., 2014 
Multiple cancer 
types 
ARID1A Point mutation Hargreaves and 
Crabtree, 2011 
Non-Hodgkin 
lymphoma, B-cell 
lymphoma 
EZH2 Point mutation Morin et al., 2011, 
Pasqualucci et al., 2011 
Rubinstein-Taybi 
Syndrome; multiple 
cancer types 
CBP, 
EP300 
Point mutation Roelfsema et al., 2005, 
Lawrence et al., 2014 
Type 2 diabetes PPARGC1A Point mutation Ling et al., 2008 
 
32
1.5 Mis-regulation of enhancer function in disease
1.5.3 Super-enhancers in human diseases
Super-enhancers in complex disease
SEs in human cell-types have been identified to frequently harbour DA-SNPs compared
to TEs. Furthermore, the DA-SNPs tend to occur in disease-relevant cell-types (Hnisz
et al., 2013). For instance, in an analysis of ∼5000 SNPs from GWASs, 19% (5/27) of
the SNPs associated with Alzheimer’s disease occurred in brain SEs; 19% (13/67) of the
SNPs associated with type 1 diabetes occurred in primary T-helper cell SEs; and 33%
(22/67) of the SNPs associated with systemic lupus erythematosus occurred in B-cell
SEs (Hnisz et al., 2013). In all the above mentioned diseases, the enrichment of their
associated SNPs was significantly higher in SEs compared to TEs. A similar pattern
was observed for other diseases such as multiple sclerosis and rheumatoid arthritis; and
traits like white blood cell distribution and fasting insulin level.
Many other independent studies found DA-SNPs to occur in SEs linked with disease-
relevant genes. For example, a GWAS performed on vitiligo (an autoimmune skin
disease) patients detected three DA-SNPs close to each other in a SE between HLA-
DRB1 and HLA-DQA1 genes (Cavalli et al., 2016). Likewise, inhibition of a SE region in
primary T-cells specifically associated with juvenile idiopathic arthritis (an autoimmune
disease) resulted in reduced expression of the disease-related genes (Peeters et al.,
2015). In addition to SEs, SNPs associated with type 2 diabetes (T2D) have also been
detected to overlap stretch enhancers annotated in pancreatic islet cells (Parker et al.,
2013). Moreover, impaired SE function can be caused by altered H3K27ac levels and
pol II binding, as detected in a mouse model of Huntington’s disease causing aberrant
regulation of striatal neuronal genes (Achour et al., 2015; Le Gras et al., 2017). These
examples provide evidence that genetic or epigenetic changes in SEs contribute to
complex diseases via mis-regulated transcription of their associated genes.
Super-enhancers in cancer
Soon after the discovery of SEs in 2013, SEs were characterised in multiple myeloma
tumour cells (Loven et al., 2013). Loven et al. (2013) observed that SEs are associated
with many oncogenes, including MYC, a gene which is commonly expressed at high
levels in many cancers. Similarly, Chapuy et al. (2013) observed SEs in diffuse large B-
cell lymphoma to be associated with many previously known oncogenes. Interestingly,
when the SE landscape was compared between tumour and healthy cells, it was observed
that oncogenes acquire SEs in tumour cells (Hnisz et al., 2013). These de-novo SEs are
believed to be acquired as a result of small indels, chromosomal translocation, focal
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amplification, over-expression of oncogenic TFs or somatic mutations (examples shown
in Table 1.5). Furthermore, eRNAs transcribed from SEs have also been shown to be
associated with tumorigenesis (Jiao et al., 2018; Li et al., 2013; Liang et al., 2016;
Teppo et al., 2016). Overall, SEs have been observed to be involved in the regulation of
genes which play a role in cancer progression.
Table 1.5 Super-enhancers in cancer.
Cancer type Implicated 
gene 
Mechanism/ observation Reference 
T-ALL TAL1 Small indels introduce novel binding sites 
for MYB resulting in a de novo SE 
Mansour et al., 2014 
Multiple 
myeloma 
MYC 
Translocation of 3’ IgH SEs; translocation 
of breakpoints resulting in a de novo SE 
Hnisz et al., 2013; 
Walker et al., 2014 
Lung cancer, 
SCLC 
Tandem repeats within SE of MYC; focal 
amplification of enhancers near MYC 
Hnisz et al., 2013; 
Iwakawa et al., 2013 
AML, lung 
adenocarcinoma, 
endometrial 
carcinoma 
Focal amplification of a large SE 
downstream of MYC 
Shi et al., 2013 
Zhang et al., 2016 
T-ALL Overexpression of TAL1 TF within SE 
associated with MYC 
Hnisz et al., 2013 
AML EVI1 Translocation of GATA2 SE Groschel et al., 2014 
Adenoid cystic 
carcenoma 
MYB Translocation of SEs increase expression 
of MYB 
Drier et al., 2016 
Neuroblastoma LMO1 Somatic mutation in intron causing 
differential GATA binding 
Oldridge et al., 2015 
 
T-ALL: T-cell acute lymphoblastic leukaemia; SCLC: small cell lung cancer; AML: acute myeloid
leukaemia.
Targeting super-enhancers for cancer therapeutics
A common characteristic of most cancer cells is that they have high oncogenic tran-
scriptional activity compared to healthy cells, which help them to grow at a faster rate
(Lin et al., 2012). Therefore, suppressing transcriptional activity of specific oncogenic
targets is believed to be an effective clinical therapeutic. Since SEs regulate genes
involved in tumour progression, attempts are underway to target SE activity to reduce
oncogenic transcriptional activity. In order to achieve this, researchers are utilising
small molecules to inhibit specific essential components of SEs to disrupt their influence
on oncogenes (summarised in Table 1.6).
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SEs in myeloma cells were observed to exhibit high enrichment of MED1 and BRD4
binding (Loven et al., 2013). BRD4 is a member of bromodomain and extra-terminal
(BET) family proteins, which bind to the Mediator complex and interact with pol II,
hence, are a critical element for SE associated transcription (Hnisz et al., 2013; Zeng and
Zhou, 2002). Many BET bromodomain inhibitors (such as JQ1 and iBET) are currently
under study to target BRD4 activity within SEs. The first study to show the effect of
BET inhibitor on SE activity was conducted in myeloma cells using the BET inhibitor
JQ1 (Loven et al., 2013). This study demonstrated that treating myeloma cells with JQ1
significantly reduced BRD4 binding (up to 97%) in SEs, leading to decreased MED1
binding, increased pol II pausing, and ultimately decreased expression of genes such
as the oncogene MYC. Subsequent to this finding, similar studies were performed in
other cancer types and diseases to analyse the effect of JQ1. For example, JQ1 has been
observed to reduce the expression of genes associated with juvenile idiopathic arthritis
in T-cells (Peeters et al., 2015), and slow down the tumour growth in adenoid cystic
carcinoma (Drier et al., 2016). Apart from JQ1, other BET inhibitors like iBET, have
also been found to be effective in reducing tumour growth in acute myeloid leukaemia
(Pelish et al., 2015) and neuroblastoma (Wyce et al., 2013).
In addition to BET inhibitors, researchers have also used small molecules to in-
hibit cyclin-dependent kinases (CDKs) in SEs, which control the pol II initiation and
elongation (Malumbres, 2014). For instance, the THZ1 inhibitor can effectively inhibit
CDK7 (Kwiatkowski et al., 2014), and its treatment has shown to selectively decrease
expression of MYC family and other oncogenes in neuroblastoma cells (Chipumuro
et al., 2014), small cell lung cancer cells (Christensen et al., 2014), esophageal squa-
mous cell carcinoma (Jiang et al., 2017) and T-cell leukaemia cells (Wong et al., 2017).
Moreover, techniques like CRISPR-Cas9 facilitate gene therapy strategies in diseases
associated with SEs. For instance, Mansour et al. (2014) used CRISPR-Cas9 to delete
the somatic mutations responsible for the formation of a SE, and abolish its effect on
TAL1 expression. Although safety and efficiency of such approaches require further
extensive research in animal models, they provide new opportunities to develop effective
gene therapies. Overall, these examples demonstrate that targeting SEs can be used to
selectively inhibit expression of oncogenes, and such approaches have application in
disease diagnosis and developing cancer related therapeutics.
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Table 1.6 Therapeutic targeting of super-enhancers in cancer. Table taken from Sengupta
and George (2017).
Cancer 
type 
Inhibitor Effect on SE-driven 
transcription 
Effect of SE inhibition 
on tumour biology 
Reference 
DLBCL JQ1 (BRD4) Downregulation of SE-driven 
oncogenic and lineage-specific 
transcriptional circuits. 
Decreased lymphoma 
infiltration in the bone 
marrow and improved 
overall survival 
Chapuy et al., 
2013 
AML JQ1 (BRD4) Eviction of BRD4 and Mediator 
from select SE regions causing 
decreased expression of 
associated genes that are MYB 
targets and important for 
leukemogenesis 
Impaired proliferation 
and triggering 
differentiation of 
leukemic blasts 
Bhagwat et 
al., 2016 
Oncogenic 
Nras 
expression 
in mouse 
liver 
iBET (BRD4) Reduced expression of genes 
involved in SASP that are 
driven by SEs. 
Decreased clearance of 
oncogenic senescent 
cells. 
Tasdemir et 
al., 2016 
T-ALL, 
MYCN- 
amplified 
NB, SCLC, 
TNBC 
THZ1  
(CDK7) 
Downregulation of SE-
associated and tumour addictive 
and lineage specific gene 
expression, MYCN-driven 
transcriptional amplification 
Decreased tumour 
volumes, growth and 
increased survival 
Chipumuro et 
al., 2014, 
Kwiatkowski 
et al., 2014 
AML Cortistatin A 
(CDK8/19) 
Upregulation of SE-associated 
genes linked to tumour 
suppression and lineage 
specification. 
Reduction in disease 
progression, leukemic 
burden, and tumour 
volume, improved 
overall survival. 
Pelish et al., 
2015 
T-ALL THZ531 
(CDK12/13) 
Downregulation of DNA 
damage response and SE-
associated genes 
Apoptosis Zhang.T et al., 
2016 
Ewing 
sarcoma 
LEE011 
(CDK4/6) 
Downregulation of SE-
associated ES dependency 
genes CyclinD1/CDK4 
Cytostasis and delayed 
growth 
Kennedy et 
al., 2015 
 
DLBCL: diffuse large B-cell lymphoma; AML: acute myeloid leukaemia; SASP: senescence-etory
phenotype; T-ALL: T-cell acute lymphoblastic leukaemia; NB: neuroblastoma; SCLC: small cell lung
cancer; ES: Ewing sarcoma.
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1.6 The Mouse as a model organism
For many decades, genes associated with disease traits in human have been investigated
in model organisms such as the mouse. Studying human diseases in model organisms
has been vital for understanding the biological function of genes. For this purpose,
animal models have either been generated by disrupting genes orthologous or equivalent
to disease-causing genes in human, or that display phenotypic features similar to the
disease condition in humans. Such models have proven to be successful in enhancing
our knowledge of Mendelian disorders and penetrant mutations. Animal studies are
particularly useful as they: (1) allow to take repeated phenotypic measurements within
an environmentally and genetically controlled background; (2) could be used for tissues
not accessible from human patients; and (3) could be used for developing and testing
new drugs. Of all the animal models, the mouse has been the prime mammalian model
to study human diseases because of their high genetic and physiological similarities
to humans (Nguyen and Xu, 2008). Mouse models of human diseases have provided
novel critical insights into disease mechanisms, as these models display very similar
phenotypic characteristics to the pathological condition in humans (Schofield et al.,
2012). The following sections describe how mouse models have helped in the func-
tional annotation of mammalian genes, and in validating and characterising enhancer
sequences.
1.6.1 Mammalian phenotypes
The pathological or disease characteristics in mouse models are commonly described
as phenotypes, which could be defined as an observable trait showing deviation from
normal morphology, physiology or behaviour. In order to avoid ambiguity amongst
these phenotype terms and to allow their efficient computational analysis, they are
organised into a formal hierarchal structure of controlled vocabulary called ontologies.
For example, Gene Ontology (GO) (Ashburner et al., 2000) describes the biological
processes, molecular functions and cellular locations of the gene products. Similarly,
the most widely used ontology for mouse phenotypes is the Mammalian Phenotype
(MP) Ontology (Smith et al., 2005). The MP terms describe abnormal phenotypes and
other phenotypic measures in an animal, which are deviant from the control population.
It is important to note that the MP terms are not equivalent to any specific disease, but a
group of MP terms may describe the characteristic features of a disease. The hierarchy
based structure of the MP ontology allows mouse phenotype databases to be queried
for mutations and alleles associated with a specific phenotype, and also enables the
researchers to identify clusters of genes related to similar phenotype terms, which may
represent genes in the same functional pathway.
37
Background
1.6.2 Large scale phenotyping projects
Mouse models have been most commonly generated by: (1) N-ethyl-N-nitrosourea
(ENU) induced mutations, which involves using the chemical mutagen ENU to induce
random point mutations; (2) targeted mutations to alter the gene function (also known
as knockins); or (3) targeted mutations to completely eliminate the gene function (also
known as knockouts or null mutation). The ENU mutagenesis projects are based on
the phenotype-driven approach where the transgenic mice carrying the ENU-induced
mutations are first phenotypically screened to identify a clinical phenotype of interest,
and then other strategies such as positional mapping or genome sequencing are em-
ployed to identify the gene harbouring the causal ENU mutation. Large scale ENU
mutagenesis projects in the past have generated novel mouse models for human diseases
across several phenotype areas (Brown and Nolan, 1998; Hrabe de Angelis et al., 2000;
Masuya et al., 2005; Nolan et al., 2000; Potter et al., 2016; Thaung et al., 2002), which
have played a key role in discovering disease-associated genes. On the other hand,
targeted mutations are based on the genotype-driven approach where a researcher with
some prior knowledge about a gene, alters its gene structure via targeted mutations,
and investigates its role in the phenotype of interest. While previous studies involving
targeted mutations have been helpful to understand the gene function, they have mainly
focused on screening mouse models for a specific phenotype domain of interest. How-
ever, a gene may be responsible for performing different functions depending on where
it is expressed in the body, or its time of expression during the life span of an organism.
This phenomenon is commonly known as pleiotropy.
To identify such pleiotropic functions of genes, many large scale gene knockout
projects such as the EUMODIC (The European Mouse Disease Clinic) (Ayadi et al.,
2012), the SANGER-MGP (The Wellcome Trust Sanger Institute Mouse Genetics
Project) (Ayadi et al., 2012) and the IMPC (International Mouse Phenotype Consortium)
(Brown and Moore, 2012a), have been established in the last decade to extensively
phenotype mouse knockout lines in order to discover gene-phenotype associations which
have been previously undetected. EUMODIC and SANGER-MGP initiated in the late
2000s together have phenotyped approximately 800 mutant mouse lines (Ayadi et al.,
2012). The IMPC project started in September 2011, with the aim to produce extensive
phenotyping data for a knockout of every protein-coding gene in the mouse genome
(∼20,000 genes) (Brown and Moore, 2012b). The IMPC project involves generating a
knockout mouse line for each protein-coding gene and then screening them through a
systematic pipeline of phenotype tests to capture all the phenotypes associated with the
gene in study. The pipeline of phenotype tests includes standardised protocols covering
a wide range of biological systems tracked via the database IMPReSS (International
Mouse Phenotyping Resource of Standardised Screens; http://www.mousephenotype.
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org/impress). Phenotypic measurements are compared between the mutant mouse
lines and controls, and statistically significant phenotypes associated with a gene are
identified and are annotated using the MP ontology (Angelis et al., 2015). To date, IMPC
have phenotyped over 6,000 knockout mouse lines and over 5,000 genes, producing
∼58,000 phenotype annotations (data release 9.2). The ultimate goal of IMPC is
to build an encyclopaedia of gene function for all the protein-coding genes in the
mammalian genome, and make both the mice and the data publicly available to the
research community which would provide a platform for further investigation.
1.6.3 Functional testing of enhancers in the mouse
The majority of the mouse models in the past involved studying protein-coding genes,
but recently, mouse models have also been used to understand how enhancer sequences
function in vivo. Previously, reporter gene constructs have been used to characterise the
activity of endogenous elements such as promoters, that can drive expression (Kothary
et al., 1989). These constructs when microinjected into fertilised mouse eggs, merge
with the genome and the transgenic mice can then be screened for the activity of the
element. A similar approach has been used for testing the activity of enhancers, with
reporter gene constructs containing the candidate enhancer sequence (to be tested)
upstream of the minimal promoter. The enhancer if active, drives the expression
of the reporter gene which corresponds to the endogenous enhancer activity. Such
enhancer assays in mouse have been fundamental to identify and validate enhancers,
and to understand their functional properties. Large-scale enhancer screens have been
performed to characterise the activity of candidate enhancers in whole mouse embryos
(at E-11.5 days) by whole mount staining, and the results of such studies to date are
stored in the VISTA enhancer browser (Visel et al., 2007). This database containing
whole mount images of enhancer activity has helped researchers to identify cell-type
specific markers, and select functional enhancers for further characterisation (Gordon
et al., 2014; Sanchez-Castro et al., 2013).
Many enhancers are dependent on their genomic or chromatin context (Arnold et al.,
2013; Kvon et al., 2014) because of which some enhancer sequences with endogenous
activity may show no/weak activity in transgenic assays, due to the enhancer being
outside of their native chromatin context. It has also been shown that some enhancers
selectively work with only specific types of core promoters (Butler and Kadonaga, 2001;
Zabidi et al., 2015). These limitations associated with the traditional enhancer-reporter
assays can be overcome by using transgenes based on large bacterial (BACs), yeast
(YACs) or P1-derived artificial chromosomes (PACs) (Giraldo and Montoliu, 2001), as
they drive gene and reporter expression from native promoters, hence closely recapitu-
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lating endogenous gene expression. BACs have been most commonly used for model
organisms like mice. Collectively, enhancer assay studies in mouse have shown that
enhancers are capable of driving highly specific and dynamic gene expression profiles,
which are critical for the mammalian development. Furthermore, these studies have
demonstrated that conserved non-coding DNA sequences often display enhancer activity
in vivo (Pennacchio et al., 2006), and that enhancers involved in the developmental
process (particularly the ones active in forebrain) are highly conserved across species
(Nord et al., 2013).
In the last decade, the enhancer assays in mouse have also been utilised to func-
tionally validate enhancer predictions from massively parallel sequencing technologies
such as ChIP-seq and DNase-seq (Cotney et al., 2012; Nord et al., 2013; Visel et al.,
2009). Even enhancer sequences from the human genome have been tested in mouse
enhancer assays. For instance, 66% of the enhancers identified in the human heart tissue
successfully drove reporter gene expression when integrated with the mouse genome
(May et al., 2011). Another advantage of in vivo assays is that they allow the testing
of enhancer activity in the relevant disease-associated tissues, whereas in vitro models
may fail to detect the relevant enhancer activity. This has been useful to investigate
the effects of disease-associated genetic variants. One recent example includes the
obesity associated variants identified within an enhancer in the FTO gene, which were
demonstrated to be connected with IRX3 expression in mouse white adipose tissue
(Smemo et al., 2014). Furthermore, mouse models generated using genome editing
techniques have been extremely insightful to understand the phenotypic effects of en-
hancer deletions in their native chromatin context. Several studies have used transgenic
mice with targeted deletion of enhancers or their components, to investigate its effect
on gene expression at the whole organism level (Canver et al., 2015; Cunningham
et al., 2018; Dickel et al., 2018a; Hay et al., 2016; Shin et al., 2016; Sur et al., 2012).
Overall, such studies in transgenic mice have been critical to understand that the impact
and contributions of individual enhancer elements on gene expression is complex and
difficult to predict at the whole organism level.
1.6.4 MRC Harwell Institute
The MRC Harwell Institute (MRCHI) specialises in the use of mouse models to study
the relationships between genes and diseases. The MRCHI conducts large scale phe-
notyping screens namely, the IMPC, and an ENU ageing mutagenesis screen to study
the genetics of ageing. The research programs at the MRCHI focuses on different
areas which can be broadly divided into lifetime studies, translational studies, data
analysis and dissemination. Although these research programs have traditionally con-
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centrated on investigating functional consequences of coding-variants in mouse models,
recently there has been more emphasis on studying regulatory elements in mutant mice.
The above research and mutagenesis programs are supported by the data analysis and
dissemination groups: statistical genomics and biocomputing, which also carry out
independent research in their respective fields. My DPhil was within the biocomputing
group and I also worked closely with the neurobehavioral and metabolic genetic groups
at the MRCHI during my DPhil.
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1.7 Aims of the thesis
Since the completion of the human genome sequence, protein-coding genes have
been extensively studied to understand their function and involvement in diseases.
However, less is known about the function of non-coding regions in the genome and
their functional implication in diseases. The ENCODE project has begun to address
this gap and has shown that a large portion of the genome is involved in the regulation
of genes, directly or indirectly, and predicted up to a million potential enhancer regions
in humans (Thurman et al., 2012). Other studies have found DA-SNPs to frequently
occur within the enhancer regions of disease-relevant tissues and cell-types (Hnisz
et al., 2013). Therefore, it important to understand how transcription is controlled
by regulatory elements, especially enhancers and thus, is one of the main emerging
challenges in genomics today.
The overall aim of this thesis is to investigate the effect of regulatory regions,
especially enhancers, on mouse models of human diseases. To address this, my goal is
to:
1. Systematically identify potential active enhancers and promoters in the mouse
genome using publicly available data and compare their activity across multiple
tissues to identify tissue-specific regulatory elements.
2. Identify super-enhancers in the mouse genome and explore their functional char-
acteristics compared to typical-enhancers.
3. Investigate how different enhancer architectures influence gene expression and
tissue-specificity of their associated target genes.
4. Characterise the functional association of different enhancers in disease aetiology
by analysing mouse phenotypes and diseases linked with the enhancer-associated
genes.
5. Develop novel methods to integrate publicly available omics data with functional
data at the MRCHI, in order to study transcriptional regulatory mechanisms in
mouse models currently under investigation at the MRCHI.
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Chapter 2
Klf14 transcriptional networks in
human and mouse
In this chapter, I describe the investigation of Klf14 associated regulatory pathways
in the human and mouse genomes. This work was carried out in collaboration with
the McCarthy lab at the Oxford Centre for Diabetes, Endocrinology and Metabolism
(OCDEM), the Small lab at King’s College London and the Cox lab at the MRCHI.
Some results described in this chapter (section 2.2.1 and 2.2.2) have been published in
the following article:
Small, K. S., M. Todorcˇevic´, M. Civelek, J. S. El-Sayed Moustafa, X. Wang, M. S.
Simon, J. Fernandez-Tajes, A. Mahajan, M. Horikoshi, A. Hugill, C.A. Glastonbury, L.
Quaye, M. J. Neville, S. Sethi, et al. (2018). “Regulatory variants at KLF14 influence
type 2 diabetes risk via a female-specific effect on adipocyte size and body composition".
In: Nature Genetics 50.4, pp. 572-580. ISSN: 1546-1718. DOI: 10.1038/s41588-018-
0088-x.
2.1 Introduction
A primary objective of human genetics is to identify genetic variants which cause
diseases and phenotypic traits in the human population, and functionally understand
how these variants lead to a disease state. During the last decade, GWAS has proven to
be an important tool of human genetics and has produced a wealth of genomic regions
which show strong statistical association with a wide range of human diseases and
phenotypic traits (Visscher et al., 2017). Amongst these human diseases, metabolic
traits have been widely analysed in GWASs especially type 2 diabetes (T2D). T2D is
a condition where the pancreatic beta cells fail to produce the right amount of insulin
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which results in increased glucose levels in the body (Taylor, 2013). The worldwide
prevalence of diabetes has almost doubled in the last three decades (from∼4% in 1980 to
∼8% in 2014) (NCD-Risk-Factor-Collaboration, 2016), with∼90% of people estimated
to have T2D. Both genetic (with an estimation of 25%-69% heritability) (Almgren et al.,
2011; Poulsen et al., 1999; Willemsen et al., 2015) and environmental factors such as
sedentary lifestyle, high calorific foods and gut flora (Friedman, 2009; Moreno-Indias
et al., 2014), are believed to be the cause of T2D. This expanding prevalence has
revealed a requirement for a deeper understanding of the T2D mechanisms, a better
understanding about its aetiology, leading to better treatment or possible prevention in
the future.
Despite a pool of genetic variants potentially associated with T2D risk, the under-
lying mode of action by which these variants cause or increase the disease risk is still
obscure. Moreover, these variants collectively explain a minority (< 10%) of the total
estimated genetic heritability of T2D (Voight et al., 2010). Some of this unexplained
heritability has been attributed to the inefficiency of the current GWAS analysis to
capture variants which exert small effects (Manolio et al., 2009). In order to increase
the power to detect common genetic variants with modest effect, Voight et al. (2010)
increased the sample size by performing a meta-analysis on eight T2D genome-wide
association datasets, which discovered twelve novel risk loci for T2D. Amongst these
newly identified loci, the genetic variants near the gene KLF14 (Kruppel-like factor
14) displayed the most significant correlation with KLF14 expression in adipose tis-
sue (Voight et al., 2010), making it a strong candidate for further investigation. Not
long after that, KLF14 was also linked to high-density lipoprotein (HDL) cholesterol
(Teslovich et al., 2010) and also believed to control the metabolic syndrome ‘orchestra’
(Civelek and Lusis, 2011).
KLF14, an imprinted gene (genes whose expression is dependent on the parent-
of-origin) known to be expressed maternally, encodes for a transcription factor (TF)
which acts as a master regulator of gene expression in adipose tissue (Small et al.,
2011). Though KLF family genes are known to be involved in cell proliferation and
differentiation (Dang et al., 2000), little is known about the function of KLF14. The
GWASs have identified a set of non-coding SNPs in high linkage disequilibrium (LD),
located upstream of KLF14 (ranging between ∼4 kb to ∼48 kb upstream of its TSS) to
be associated with T2D and HDL cholesterol (Small et al., 2011), collectively referred
to as ‘KLF14 locus’ here (Fig. 2.1A). Interestingly, one of the SNPs in the KLF14 locus
(rs4731702, located 14 kb upstream of KLF14) was found to imitate the imprinting
pattern of KLF14 by correlating with the reduced expression of KLF14 in the adipose
tissue only when acquired maternally (Kong et al., 2009). This indicates KLF14 to be
the most likely gene influenced by the SNPs in the KLF14 locus. These non-coding
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SNPs in the KLF14 locus potentially alter the KLF14 expression by disrupting one
or more KLF14 associated regulatory elements such as enhancers, however SNPs in
this locus which do so are not yet known. Furthermore, as KLF14 is a TF regulating
gene expression of other genes in adipose tissue, the SNPs affecting KLF14 expression
consequently have a trans effect on KLF14 transcriptional targets, thus producing an
assortment of metabolic defects (Small et al., 2011).
Fig. 2.1 Association of KLF14 variants with metabolic traits. (A) The plots show the signifi-
cance of the variants (as −log10 p) plotted against their genomic positions. Circles represent
SNPs coloured according to their LD r2 values with respect to the index SNP rs4731702. Figure
taken from Small et al. (2011). (B) A schematic displaying the effect of T2D risk associated
SNPs in the KLF14 locus.
Although GWASs have identified that genetic variants in the KLF14 locus are
linked to T2D risk and HDL, it does not provide a biological explanation of how these
SNPs exert the phenotypic effects, therefore, the mechanism by which the SNPs in
the KLF14 locus produce metabolic traits is not yet know. In order to gain insights
into these mechanisms, the McCarthy and the Small lab investigated the functional
network affected by the SNPs in the KLF14 locus. They performed a meta-analysis
by combining multiple genome-wide association traits which expanded the range of
KLF14 trait associations to low-density lipoprotein (LDL) cholesterol, triglycerides,
waist-hip ratio and fasting insulin (Dupuis et al., 2010; Small et al., 2018). Furthermore,
using expression data in adipose tissue from the TwinsUK cohort (Buil et al., 2015),
they identified a trans-network of 385 genes affected by rs4731702 T2D risk allele in
the KLF14 locus (Fig. 2.1B). In order to identify if these affected genes are directly
regulated by KLF14, they inspected the KLF14 binding amongst them. Since the
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binding sequence recognised and bound by KLF14 has been previously identified using
ChIP-seq (Jolma et al., 2013), the McCarthy lab scanned the upstream regions of genes
in the KLF14 trans-network (up to 20 kb) for the enrichment of known KLF14 binding
site, and identified 177 (out of 385) genes to potentially harbour the KLF14 binding site.
This indicates that KLF14 may directly regulate these 177 genes in the trans-network,
while other genes may have a KLF14 binding site further away from 20 kb or may be
altered via an indirect effect (Small et al., 2018). Additionally, SREBF1, a trans-gene
itself, was identified to regulate 18 other trans-genes in the network, 11 of which are not
directly regulated by KLF14. SREBF1 is an important TF in cholesterol homeostasis
and appears to regulate a sub-network of genes involved in cholesterol biosynthesis and
lipid metabolism (Small et al., 2018).
In a joint effort with the McCarthy lab, the Cox lab explored the metabolic effects
of Klf14 in the mouse genome. For this purpose, a mouse line featuring a complete
loss of functional Klf14 (Klf14tm1(KOMP)Vlcg) was characterised by the Cox lab at the
MRCHI. Mice were bred to form two cohorts: (1) heterozygotes with the deleted allele
inherited maternally (MAT, equivalent to risk allele in human); and (2) heterozygotes
with the deleted allele inherited paternally (PAT, equivalent to non-risk allele in human).
Screening these mice through metabolic phenotyping tests revealed reduced HDL
cholesterol in MAT males (Fig. 2.2A,E), along with a modest reduction in glucose
homeostasis (Fig. 2.2B-D). Total and LDL cholesterol were also found to be relatively
lower in MAT males (Fig. 2.2F-G), while no phenotypes were observed in the female
mice (data not shown). However, no significant T2D traits were observed in these mice.
In collaboration with the Cox lab at the MRCHI, we hypothesised that the KLF14
associated traits in humans may correlate better with the mouse at the molecular level, as
opposed to the phenotypic level. Therefore, we sequenced the RNA from MAT and PAT
mice with the aim to compare the Klf14 associated transcriptional targets in mice with
the KLF14 trans-network in humans. Here, using this RNA sequencing data, I describe
the Klf14 associated transcriptional network and phenotypes in the mouse. Since
the T2D risk associated non-coding SNPs exert their effect via damaging regulatory
elements, I performed a comparative epigenetic profiling of the human and mouse
KLF14 locus, with the goal to evaluate the relationship of active regulatory elements
in this locus with T2D related pathways. I further analysed the human KLF14 locus
for phylogenetically conserved transcription factor binding sites (TFBSs) to identify
potential cis-regulatory T2D risk variants which may affect KLF14 expression. Finally, I
investigated TF families for their preferential binding close to the T2D associated SNPs
in the human locus. Overall, this study identifies potential enhancers, cis-regulatory
variants and TFs associated with T2D risk in the KLF14 locus, and provides insights
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into the conserved and specific regulatory pathways associated with KLF14 related
phenotypes between the human and mouse genomes.
Fig. 2.2 Clinical chemistry analysis of the Klf14 knockout mice. Plots display the clinical
chemistry parameters measured between male Klf14 knockout mice and their wild-type controls.
All values are displayed as mean± SD. For E-G, measurements were taken from blood sample
of 33 week old mice. Grey: wild-type MAT; black: wild-type PAT; red: knockout MAT; blue:
knockout PAT. Figure taken from Small et al. (2018).
2.2 Results
2.2.1 Transcriptional targets of Klf14 in the mouse genome
To identify the genes regulated by Klf14 in the mouse, we sequenced the RNA of
subcutaneous fat taken from the Klf14tm1(KOMP)Vlcg MAT (n = 3) and PAT (n = 3) male
mice. RNA-seq analysis comparing the global expression between MAT and PAT
identified 285 differentially expressed genes at FDR < 0.05 (or 1599 genes at p < 0.05).
Of these, 127 genes were up-regulated and 158 were down-regulated in the MAT mice,
suggesting Klf14 to act as both a repressor and an activator - a pattern also observed in the
human KLF14 trans-network. The top differentially expressed genes with a FDR < 0.05
and fold change >±2 (n = 60), along with their expression (in RPKM; reads per kilobase
of transcript per million mapped reads) across all replicates are illustrated in Fig. 2.3. A
Gene Ontology (GO) enrichment analysis shows that the genes influenced by the Klf14
deletion (FDR < 0.05) are involved in biological processes relevant to the cholesterol
phenotype observed in the knockout mice, such as response to lipid (q < 7.6×10−5),
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Fig. 2.3 Differentially expressed genes between Klf14tm1(KOMP)Vlcg PAT and MAT mice.
Heatmap demonstrating the expression of significantly differentially expressed genes
(FDR < 0.05, fold change >±2, n = 60) across all biological replicates of PAT and MAT samples.
The rows and columns of the heatmap represent genes and replicates respectively, while shading
shows the level of gene expression in log RPKM. The rows of the heatmap are clustered using
hierarchical clustering.
response to fatty acid (q < 7.38×10−3), regulation of metabolic processes (q < 8.2×
10−4), response to steroid hormone (q < 7.5×10−3) and regulation of cell proliferation
(q < 1.4×10−3) (Fig. 2.4). Furthermore, Klf14 deletion also alters the expression of
genes involved in the inflammatory response (q < 2.2×10−4), regulation of immune
system process (q < 9.7×10−4) and leukocyte migration (q < 1.2×10−3), which agrees
with earlier research proposing Klf14 function in the regulation of T-regulatory cells
(Sarmento et al., 2015).
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Fig. 2.4 GO enrichment analysis of Klf14 transcriptional targets. Bar plot illustrating sig-
nificantly over-represented GO terms amongst the differentially expressed genes between PAT
and MAT mice (FDR < 0.05, n = 285). The enriched biological processes are displayed on the
y-axis with their respective q-values (FDR) displayed on the x-axis. The gradient colour of the
bars shows the number of differentially expressed genes related with the GO terms.
Next, I compared the Klf14 transcriptional targets in the mouse to the human
trans-network, which revealed a significant (p < 10−6), but small number of genes
common between them; 46 genes with differentially expressed gene set at p < 0.05, 8
genes with differentially expressed gene set at q < 0.05 respectively. This suggests that
species specific Klf14 targets are likely to be responsible for variable Klf14 associated
phenotypes between mouse and human. Though the majority of the Klf14 transcriptional
targets are different between mouse and human, I hypothesised that they may be
engaged in the same functional pathways. A GO enrichment analysis of the genes in the
human trans-network identified only ‘oxidation-reduction process’ (q = 1.41×10−2) as
significant amongst the genes. Therefore, in order to check for possible interactions, I
investigated the protein-protein interactions (PPIs) amongst the human trans-network
and the mouse differentially expressed genes. This identified 255 targets (with 462
interactions) using the p-value gene set and 53 (with 105 interactions) using the q-value
gene set, in the mouse to have a potential PPI with the mouse orthologous of the human
trans-network genes (Fig. 2.5). Simulations conducted by adding random genes show
that these interactions are significantly higher compared to what is expected by chance
(p≤ 0.0004), suggesting that these Klf14 targets in the mouse are likely to interact with
their human trans-network partners compared to random protein-coding genes.
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Fig. 2.5 Protein-protein interaction map amongst Klf14 transcriptional targets in the
mouse and the human trans-network genes. Networks (left panel) display potential PPIs
between the human trans-network genes and the differentially expressed genes between MAT
and PAT mice at (A) p < 0.05, and (B) q < 0.05. PPIs were retrieved from the STRING database
(Franceschini et al., 2013) with the highest confidence (score > 0.9). Colour of the nodes signi-
fies the source of the gene, and interactions (edges) between the mouse and human genes are
highlighted in red. The histograms (right panel) show the results of the PPI network simulations.
The red vertical line shows the observed number of edges between the mouse and human
genes, and the grey distribution (obtained from 1,000 permutations) shows the number of edges
between the mouse and randomly added protein-coding genes.
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2.2.2 De novo motif discovery from Klf14 transcriptional targets
In order to evaluate whether Klf14 directly regulates the differentially expressed genes
between mice expressing and not expressing Klf14 (MAT and PAT respectively), I
employed a de novo motif discovery approach to detect enriched motif sequences
amongst the differentially expressed genes identified earlier. The strategy involved
searching for over-represented motif sequences within upstream regions of differentially
expressed genes (see methods 2.3.3). For input, I extracted two sets of regions upstream
of differentially expressed genes: (1) a dataset including entire promoter sequence within
an upstream distance of 300 bp, 500 bp, 750 bp and 1 kb, from the transcription start sites
(TSSs) of differentially expressed genes; and (2) a dataset including genomic sequence
from DNaseI hypersensitive sites (DHSs) in the fatpad tissue, within an upstream
distance of 1 kb, 3 kb, 5 kb and 10 kb, from the TSSs of differentially expressed genes.
To identify the over-represented motif sequences, I used two prominent community
adopted tools for motif analysis, namely MEME (Bailey and Elkan, 1994a) and Homer
(Heinz et al., 2010). Lastly, I performed this de novo motif analysis using two sets of
genes: (1) differentially expressed genes identified at a statistical significance level of
p < 0.05 (DEGpval); and (2) differentially expressed genes identified at a FDR < 0.05
(DEGqval).
For the majority of the sequence sets, the enriched motifs identified by both MEME
and Homer were not highly significant, or included nucleotide repeats, and hence
are likely to be false positives (Table 2.1 and 2.2, highlighted in grey). However, a
highly significant motif was detected in DHSs 1 kb upstream of DEGpval gene set
(E-value = 2×10−43) (Table 2.2, highlighted in yellow). A similar motif, though not
highly significant (E-value = 2.3× 10−11), was also detected in promoter sequences
300 bp upstream of DEGpval gene set (Table 2.1). Since the Klf14 binding motif in the
mouse genome is not known, I compared this de novo motif with the KLF14 binding
site in humans (Najafabadi et al., 2015). The de novo motif is strikingly similar to the
human KLF14 binding site (q = 2.6×10−3) and contains the CGCCC core, which is
present in the binding sites of other Klf family members in the mouse such as Klf1,
Klf4, Klf5, Klf7, Klf9, Klf12, Klf13 and Klf16 (Kulakovskiy et al., 2018; Mathelier et al.,
2014) (Fig. 2.6). This shows that despite different transcriptional targets, a conserved
regulatory motif between mice and human is involved in Klf14 associated phenotypes.
The highly enriched motif sequence representing the potential binding site of Klf14
in the mouse genome was identified in 142 transcriptional targets amongst DEGpval
(Fig. 2.7). This suggests that these genes may be directly regulated by Klf14, while
the remaining genes may contain this Klf14 motif outside the 10 kb upstream window
scanned here or may be indirectly affected by the Klf14 allele deletion via an interme-
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Table 2.1 Over-represented motifs identified in promoter regions 
  Meme Homer 
Gene 
set 
Upstream 
Distance 
E-value Motif P-value Motif 
D
EG
pv
al
 
(n
= 
15
99
) 
300 bp 2.3e-11 
 
1e-06  
500 bp 1.8e-15 
 
1e-07  
750 bp 4.3e-28 
 
1e-09  
1 kb 1.5e-16 
 
1e-09  
D
EG
qv
al
 
(n
=2
85
) 
300 bp 1.6e-007 
 
1e-07  
500 bp 1.9e+00 
 
1e-08  
750 bp 7.2e-019 
 
1e-10  
1 kb 5.0e+004 
 
1e-09  
Table 2.2 Over-represented motifs identified in upstream DHSs.
 
  Meme Homer 
Gene 
set 
Upstream 
Distance 
E-value Motif P-value Motif 
D
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(n
= 
15
99
) 
1kb 2.0e-43 
 
1e-08  
3 kb 1.2e-07 
 
1e-04  
5 kb 7.4e-14 
 
1e-05  
10 kb 4.6e-05 
 
1e-03  
D
EG
qv
al
 
(n
=2
85
) 
1 kb 8.0e-05 
 
1e-08  
3 kb 7.2e+02 
 
1e-07  
5 kb 2.6e-03 
 
1e-07  
10 kb 9.9e-11 
 
1e-06  
For Table 2.1 and Table 2.2: motifs highlighted in grey represent possible false-positives. E-value
represents the probability of finding the same number of motifs with equal or higher log likelihood ratio
in a set of equally sized random sequences.
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diate pathway. Interestingly, similar to the human trans-network in which SREBF1 is
directly regulated by KLF14, Srebf2 (mouse orthologue of SREBF1) is identified to be
directly regulated by Klf14 in the mouse network. Srebf2, a TF involved in the regulation
of lipid and cholesterol homoeostasis, was differentially expressed between MAT and
PAT mice (p = 0.0006). However, unlike the human trans-network where SREBF1 was
detected to regulate a sub-network of trans genes, Srebf2 motif was not detected to
be enriched in differentially expressed genes between MAT and PAT mice. I further
scanned the promoter regions of these differentially expressed genes specifically for the
presence of the human SREBF1 motif and found no significant enrichment (q≥ 0.163).
Nevertheless, Srebf2 function appears to be one of the potential intermediate pathways
affected by Klf14 in both humans and mice.
Fig. 2.6 Comparison of Klf14 binding motif in human and mouse. Alignment of the human
KLF14 motif with the proposed binding site of Klf14 in the mouse. The highlighted region in
grey is the core of the binding site observed to be common in most of the Klf family members.
Fig. 2.7 Direct transcriptional targets of Klf14 in the mouse. Network displaying the 142
differentially expressed genes enriched for the presence of a potential Klf14 binding motif in
the mouse. The nodes in the network are coloured to signify the direction of the effect in gene
expression; ■ up-regulation, ■ down-regulation.
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2.2.3 Epigenetic profiling of the KLF14 locus
The KLF14 locus in the human genome consists of a set of 23 non-coding T2D associ-
ated SNPs in high mutual LD. These SNPs potentially alter the KLF14 expression via
disrupting one or more regulatory elements associated with KLF14, therefore comparing
the regulatory activity at KLF14 locus between the human and mouse genomes may
reveal insights about the common and species specific regulatory mechanisms related
to KLF14 function. To investigate regulatory activity at the human KLF14 locus, the
McCarthy lab used the chromatin state maps from the Roadmap Epigenomics Project
(Roadmap Epigenomics Consortium et al., 2015). These chromatin state annotations
were produced by integrating multiple histone mark data using a Hidden Markov Model
(Ernst and Kellis, 2012). Comparing these annotations available in a wide range of
tissues, the McCarthy lab identified a 1.6 kb long enhancer annotation ∼5 kb upstream
of KLF14 (chr7:130424000-130425600), which overlaps three of the T2D associated
variants. It should be noted that the large size of this enhancer is maybe due to the way
it was annotated. These chromatin state maps were produced using histone marks which
often inflate the annotation lengths. This enhancer is adipose-specific, with a strong
signal in adipose related cell-types such as adipose nuclei cells derived from adipose,
mesenchymal stem cells derived from adipose, and adipocytes (Fig. 2.8A). There were
no other adipose-specific enhancers detected in the KLF14 locus.
Next, I inspected the region homologous to the human KLF14 enhancer in the mouse
genome. I asked the question whether this human KLF14 enhancer region is active
in the mouse? Also, whether any genomic changes in the mouse genome, possibly at
positions homologous to the human SNPs would affect the expression of Klf14 in the
mouse? To investigate these questions, I scanned the Klf14 locus in the mouse for any
evidence of an active enhancer similar to what is observed in the human genome. Since
no chromatin state or enhancer annotations were available for the mouse genome at the
time of analysing, I used DHSs from ENCODE to explore open chromatin sites which
might indicate enhancer activity. The human KLF14 enhancer mapped to a homologous
region in the mouse ∼4.5 kb upstream of Klf14 (Fig. 2.8B). However, no DHSs were
detected in any of the tissues within this region, suggesting that this region in the mouse
does not exhibit regulatory activity. Furthermore, the homologous T2D associated SNP
positions did not overlap any significant DHSs in the mouse tissues. This indicates that
targeting the homologous T2D associated SNP positions in the mouse might not alter
the Klf14 expression in the mouse genome. Hence, mouse models using CRISPR-Cas9
to create mutations at these positions are likely not to produce the same phenotype
effect as observed in the humans.
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Fig. 2.8 Comparison ofKLF14 epigenomic landscape between human and mouse genomes.
Genome browser snapshot of KLF14 locus in the (A) human and (B-C) mouse genomes. The
human locus displays the chromatin state annotations in different tissues from the Roadmap
Epigenomics Project and SNPs associated with T2D risk. The mouse locus displays the DHSs in
different tissues from ENCODE and homologous positions of T2D associated SNPs. The region
highlighted in green shows the KLF14 associated enhancer in human (A) and its homologous
location in the mouse genome (B, C), and the region highlighted in red shows a highly enriched
fat pad specific DHS identified in the mouse (C). Chromatin state annotations: ■ Active TSS;
■ Enhancers; ■ Weak repressed polycomb; ■ Repressed polycomb; ■ Heterochromatin; ■
ZNF genes & repeats; ■ Bivalent/poised TSS.
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There were no other DHSs observed in the fat pad within the proximal Klf14 locus,
though high DNaseI enrichment was detected ∼106 kb upstream of Klf14, with high
specificity to the mouse fat pad and the genital fat pad (Fig. 2.8C). Apparently, this
∼300 bp long DHS is near the Mir-29 family of microRNAs (Mir29a and Mir29b-1),
which are highly expressed in pancreas and liver, and have been recognised to regulate
insulin signalling and glucose homeostasis in mouse models of obesity and diabetes
(Dooley et al., 2016; He et al., 2007; Massart et al., 2017; Yang et al., 2014). Thus, this
DHS may be associated with the Mir-29 microRNAs and cannot be directly associated
with Klf14 without any other functional data.
Finally, I analysed the human KLF14 enhancer to identify what potential TFs bind
there and if their function is related to T2D pathways (Table. 2.3). Since no active
enhancers were identified in the mouse Klf14 locus, this analysis was not performed in
the mouse genome. I scanned the human KLF14 enhancer region using FIMO for all
the known motifs currently available in the open source motif databases (see methods
2.3.4). Potential TFs binding within the human KLF14 enhancer involves regulators
known to be involved in adipose biology and diabetes, such as HMGA2, known to play a
role in preadipocyte proliferation (Xi et al., 2016) and associated with T2D (Markowski
et al., 2013; Voight et al., 2010); TFL2 (also known as TCF7L2), previously connected
with the T2D risk (Florez, 2007; Grant et al., 2006; Groop, 2010; Groves et al., 2006;
Lyssenko et al., 2007); IRF family members (IRF1, IRF2, IRF3, IRF4, IRF5), which
acts as regulators of adipogenesis (Eguchi et al., 2008; Kumari et al., 2016); STAT
family members (STAT1, STAT2, STAT5A, STAT5B, STAT6), involved in maintenance
of adipocytes (Harp et al., 2001; Stephens et al., 1996); and HNF1, responsible for
Maturity-onset diabetes of the young (MODY) - a monogenic form of diabetes mellitus
(Ellard and Colclough, 2006; Frayling, Bulamn, et al., 1997; Frayling, Bulman, et al.,
1997). However, these potential TFBSs did not overlap any of the T2D associated SNPs
within the KLF14 enhancer (Fig. 2.9). This could be due to the limited number of
motif PWMs in the public domain used in this analysis and also because our current
knowledge about TFs is incomplete. Overall, this data shows that TFs involved in adi-
pose biology and diabetes which bind within the human KLF14 associated enhancer are
potentially missing regulatory activity in the corresponding homologous mouse region,
suggesting that KLF14 associated enhancer regions and their underlying regulatory
mechanisms in the KLF14 locus might have diverged between the human and mouse
genomes.
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Table 2.3 Potential TF PWM matches (q < 0.01) in the human KLF14 associated enhancer
(chr7:130424000-130425600).
Motif Start End Strand p-value q-value Matched sequence
TF7L2 148 159 + 7.81E-07 0.000378 AACATCAAAGAG
IRF3 35 51 + 1.23E-06 0.00058 TGAAAAGGAAACTAGAA
HMGA2 19 33 + 2.30E-06 0.000733 ATAATTGGGGATTAT
STAT2 35 49 + 1.99E-06 0.000943 TGAAAAGGAAACTAG
HMGA2 20 34 - 6.11E-06 0.000973 AATAATCCCCAATTA
NR5A2 83 92 - 1.78E-06 0.00104 TTCAAGGCCA
PITX2 312 321 - 2.17E-06 0.00107 TGGGATTAAT
ISRE 34 48 - 3.46E-06 0.00166 TAGTTTCCTTTTCAA
ARI3A 287 308 - 8.26E-06 0.0018 CATAAATGAATAGTAATACTAA
STA5A 335 346 + 4.60E-06 0.00203 CATTCCTAGAAA
STAT5B 334 348 - 8.41E-06 0.00283 TATTTCTAGGAATGT
STAT5B 334 348 + 1.15E-05 0.00283 ACATTCCTAGAAATA
STA5B 335 347 - 6.38E-06 0.00308 ATTTCTAGGAATG
HAND1 7 18 + 5.36E-06 0.0031 GGGTCTGGAAGT
HNF1 304 318 - 1.14E-05 0.00319 GATTAATAATCATAA
HMGA2 19 33 - 3.23E-05 0.00343 ATAATCCCCAATTAT
STA5B 335 347 + 1.72E-05 0.00416 CATTCCTAGAAAT
BCL6 330 345 + 1.04E-05 0.00423 TTAAACATTCCTAGAA
BCL6 337 352 - 1.87E-05 0.00423 GCAGTATTTCTAGGAA
IRF4 36 51 + 9.05E-06 0.00436 GAAAAGGAAACTAGAA
ARI3A 288 309 - 4.24E-05 0.00462 TCATAAATGAATAGTAATACTA
HNF1 56 70 + 3.35E-05 0.00468 GGTAATTTTTTAATG
HMGA2 50 64 + 5.96E-05 0.00475 AATAAGGGTAATTTT
HNF1A 304 318 - 1.58E-05 0.00498 GATTAATAATCATAA
IRF2 35 48 + 1.12E-05 0.00535 TGAAAAGGAAACTA
GATA4 110 118 - 1.20E-05 0.00553 AGAGATAAC
STAT5A 334 348 + 1.09E-05 0.00562 ACATTCCTAGAAATA
STA5A 336 347 - 2.58E-05 0.00571 ATTTCTAGGAAT
STAT1 334 348 - 1.14E-05 0.00593 TATTTCTAGGAATGT
STF1 83 91 - 1.15E-05 0.0068 TCAAGGCCA
ARI3A 17 38 + 9.37E-05 0.00681 GTATAATTGGGGATTATTTGAA
IRF1 36 47 + 1.55E-05 0.00738 GAAAAGGAAACT
STAT6 337 349 + 1.91E-05 0.00756 TTCCTAGAAATAC
POU3F2 60 73 - 2.89E-05 0.00781 CTGCATTAAAAAAT
HNF1A 56 70 + 5.07E-05 0.00796 GGTAATTTTTTAATG
IRF8 34 48 + 1.53E-05 0.00802 TTGAAAAGGAAACTA
EHF 379 391 - 1.57E-05 0.00816 AAGGCAGGAAGGA
IRF5 94 113 + 2.02E-05 0.00833 TAAATGTTACCAAAATGTTA
IKZF1 116 123 - 1.51E-05 0.00898 TTGGGAGA
MEF2 54 69 - 2.33E-05 0.00904 ATTAAAAAATTACCCT
MEF2 26 41 - 4.34E-05 0.00904 CTTTTCAAATAATCCC
OCT1 289 311 - 4.86E-05 0.00906 AATCATAAATGAATAGTAATACT
OCT1 298 320 + 5.70E-05 0.00906 ATTCATTTATGATTATTAATCCC
HXC6 299 313 + 2.83E-05 0.00957 TTCATTTATGATTAT
Table lists the significant PWM matches (sorted by q-value) in the human KLF14 associated enhancer
analysed using FIMO (Grant et al., 2011). The start and end positions of the motif matches are relative to
the enhancer start region. The p-value represents the probability of a random DNA sequence of the same
length as the motif with as good as or better sequence match score than the motif at that position. The
q-value of a motif occurrence represents the false discovery rate if the occurrence is accepted as
significant.
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Fig. 2.9 Genomic view of the potential motif matches in the human KLF14 associated
enhancer. Genome browser snapshot of the human KLF14 associated enhancer displaying
possible TF PWM matches (FIMO q < 0.01) and T2D risk associated SNPs associated.
2.2.4 Phylogenetic Module Complexity Analysis
The regulatory regions in eukaryotes have a tendency to exist in cis-regulatory modules
(CRMs), which consist of combinations of TFs binding together. These CRMs usually
situated upstream of the TSSs, regulate expression of genes and any changes in the
TFBSs within the CRMs could lead to phenotypic changes. Therefore, non-coding
variants occurring within or near the CRMs could potentially modulate gene expression
and contribute to disease genetics. In order to identify potential cis-regulatory variants
in the human KLF14 locus, I implemented a method called Phylogenetic Module Com-
plexity Analysis (PMCA), outlined in Claussnitzer et al. (2014). PMCA investigates
each non-coding variant by scanning its ±60 bp flanking region for TF binding patterns
conserved across species, to predict cis-regulatory variants occurring in regions of
notably high TF binding complexes. For each flanking sequence, orthologous sequences
are identified across multiple vertebrate species, which are further searched to detect
conserved TFBSs, TFBS modules and TFBSs within those modules (see methods 2.3.5
for the pseudo code). A module is defined as ‘complex’ comprising of two or more
conserved TFBSs appearing in the same order within a distance range, in all or subset
of the orthologous sequences. This method eventually classifies the region around
the non-coding variant to be complex, i.e. significantly enriched in conserved TFBS
patterns, or ‘non-complex’ if the occurrences of TFBSs is less than what is expected by
random. The expected enrichment of conserved TFBSs is estimated by randomising the
sequences in the original set of orthologous sequences.
I applied PMCA to the set of 23 T2D associated non-coding variants in the KLF14
locus. PMCA predictions suggest 16 variants to be in complex regions and 7 in non-
complex regions (Fig. 2.10 and Table. 2.4). The SNPs rs6974400, rs4731702 and
rs12154627 were identified to be the top three complex SNP regions based on the
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number of TFBSs in conserved TFBS modules (Table. 2.4). Next, I investigated the
enrichment of TFs binding around these complex SNP regions, as the TFs recruited
here could give insights into the mechanistic action of these cis-regulatory variants.
To detect potential TF binding near the SNPs, I implemented a previously described
positional bias algorithm (Hughes et al., 2000), which measures the tendency of a
TF to preferentially bind within a particular distance to the cis-regulatory variants.
The ±500 bp sequences flanking the SNPs in complex and non-complex regions were
scanned to detect potential binding of TF families (314 TF PWMs grouped into 100
TF families). The sequences were searched within a sliding window of 50 bp (with
incremental steps of 10 bp) and positional bias score for each TF family was calculated
as the binomial probability to obtain observed number of matches within the window
out of a possible total matches in the sequence (see methods 2.3.6 for the pseudo code).
A B C D
Fig. 2.10 Identification of cis-regulatory variants in the KLF14 locus. Box plots showing
the occurrences of (A) conserved TFBSs ΩT FBS, (B) conserved TFBS modules Ωmodules, (C)
conserved TFBSs in modules ΩT FBS_in_modules, and (D) TFBSs counted in at least half of the
orthologous sequences Ωrestr−T FBS for complex and non-complex SNP regions. The number
of TFBSs were calculated by repeated counting with different number of sequences in the
orthologous sequence set to weigh the extent of conservation in TFBSs (see methods 2.3.5 for
details). Each box plot shows: the median, middle bar; interquartile range, the box; 1.5 times
the interquartile range, the whiskers.
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Table 2.4 Classification of T2D associated variants in the KLF14 locus using the PMCA
SNP ΩT FBS Ωmodules ΩT FBS_in_modules Ωrestr−T FBS Sall PMCA result
rs10954284 20 4 8 6 9 Complex SNP region
rs11762784 10 5 10 0 9 Non-complex SNP region
rs11765979 56 35 280 34 9 Complex SNP region
rs11979110 213 25 177 128 7.37 Complex SNP region
rs12154627 133 73 729 14 9 Complex SNP region
rs13228906 3 1 2 0 8.4 Non-complex SNP region
rs13230111 115 33 200 60 9 Complex SNP region
rs13233731 24 21 93 14 9 Complex SNP region
rs13234269 0 0 0 0 0 Non-complex SNP region
rs13234407 10 5 14 4 9 Complex SNP region
rs13241165 35 12 42 18 9 Complex SNP region
rs13241538 17 4 12 8 9 Complex SNP region
rs17185445 5 0 0 3 3 Non-complex SNP region
rs17789506 38 29 266 16 9 Complex SNP region
rs34072724 42 13 48 24 9 Complex SNP region
rs34748838 21 16 126 1 7.96 Complex SNP region
rs3996350 20 14 48 0 9 Non-complex SNP region
rs3996352 61 39 326 35 9 Complex SNP region
rs4731702 171 42 784 81 7.72 Complex SNP region
rs6973807 0 0 0 0 0 Non-complex SNP region
rs6974288 23 15 60 0 9 Non-complex SNP region
rs6974400 128 86 1084 34 9 Complex SNP region
rs972283 66 6 12 36 7.7 Complex SNP region
For the complex SNP regions, a significant positional bias around the SNPs (±25 bp)
was detected for the forkhead family (FKHD) of TFs (Fig. 2.11). This preferential
binding was not detected to be as strong at the SNPs in non-complex regions. However,
an inspection of the SNPs loci in complex regions revealed that none of the TFs in
FKHD family overlaps the exact position of the SNPs. Despite this, forkhead TFs
namely FOXP3, FOXJ3 and FOXO1 were detected to potentially bind within ±25 bp
of the variants rs11979110, rs17789506 and rs4731702 respectively. The FOX genes
have been identified to have numerous important biological functions including a role
in insulin signalling (Hannenhalli and Kaestner, 2009; Yang et al., 2009). Especially,
FOXO1, which is involved in insulin secretion and glucose production (Dong et al.,
2008; Nakae et al., 2002; Nakae et al., 2008). Consequently, FOXO1 could conceivably
be involved in the underlying mechanisms by which T2D risk variants in the KLF14
locus produce metabolic traits.
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A B
Fig. 2.11 TF binding positional bias with respect to the T2D SNPS in the KLF14 locus.
Distribution of TFBS occurrences of various TF families relative to the T2D SNP positions
in the KLF14 locus. The region around (A) complex and (B) non-complex SNPs (±500 bp)
was searched in windows of 50 bp for potential TFBS matches and their preferential binding
positions using the positional bias analysis. A strong enrichment of FKHD TFs is observed
within ±25 bp (grey dashed lines) of the T2D SNPs in the complex regions.
2.3 Methods
2.3.1 Datasets
The set of variants associated with T2D in the KLF14 locus were retrieved from
Voight et al. (2010) and their hg19/GRCh37 genome coordinates were used for all
the analysis. For investigating the epigenetic activity within the human KLF14 locus,
primary 15 state chromHMM annotations from the Roadmap Epigenomics Project were
used by the McCarthy lab. These annotations were accessed and visualised using the
Roadmap Epigenomics data public hub on the UCSC genome browser. The Roadmap
Epigenomics Project dataset consists of three tissues related to adipose, namely adipose
nuclei cells derived from adipose, mesenchymal stem cells derived from adipose, and
adipocytes. Since no chromHMM annotations were available for the mouse genome,
DHS data from the ENCODE (University of Washington) was used as an indicator for
potential distal enhancer activity. This ENCODE dataset consists of mouse adipose
tissue derived from the fat pad and the genital fat pad.
2.3.2 RNA-seq data analysis
The RNA-seq reads were aligned to the mouse genome (mm10) using TopHat (Trapnell
et al., 2012). The read counts for each gene were calculated from the aligned reads
using HTSeq (Anders et al., 2015), and differentially expressed genes were identified
using three tools; EdgeR (Robinson et al., 2010), DESeq (Anders and Huber, 2010)
61
Klf14 transcriptional networks in human and mouse
and Cufflinks (Trapnell et al., 2012), default parameters were used for all of them. The
raw counts in each sample were used to calculate the RPKM (Reads per million per
kilo-base) and were visualised in a heatmap using R. The GO enrichment analysis for
differentially expressed genes was performed using ToppFun (Chen et al., 2009) and
the enriched GO terms with a FDR < 0.05 were considered significant.
2.3.3 De novo motif discovery
To identify over-represented motif sequences, the entire promoter and DHSs upstream
of differentially expressed genes were scanned. The DHSs were retrieved from the
fat pad tissue available in the mouse ENCODE dataset. Multiple upstream distance
windows were used and every case was run individually and independently. The
upstream sequences were extracted from the mouse genome (mm9) using BEDTools
(Quinlan, 2014). Two different tools, namely MEME (Bailey and Elkan, 1994a) and
Homer (Heinz et al., 2010), were employed to detect de novo motifs enriched amongst
the differentially expressed genes. A workflow of the de novo motif strategy used
here is described in Fig. 2.12. This analysis was performed on two sets of genes: (1)
differentially expressed genes identified at a significance level of p < 0.05 (DEGpval),
and (2) differentially expressed genes identified at FDR < 0.05 (DEGqval). Due to the
high rate of false-positives in motif enrichment analysis, only highly significant motifs
(p≤ 10−30) were considered for further analysis.
2.3.4 Identifying known transcription factor binding sites
In order to scan a genomic sequence for potential TFBSs of known motifs, the tool
FIMO (Find Individual Motif occurrences) (Grant et al., 2011) from the MEME suite
was employed. FIMO requires a database of motif sequence PWMs for known TFs from
the user. Each TF motif from the database is treated independently and searches for its
occurrences in the provided sequence. A custom database of motif PWMs from publicly
available JASPAR (Mathelier et al., 2014) and TRANSFAC (Wingender et al., 1996)
motifs was constructed for this purpose, which comprised of 554 and 398 motifs for the
human and mouse genome respectively. FIMO estimates a p-value for each motif which
describes the probability of a random sequence of the same length to achieve same or
higher score at that particular position, and further calculates the false discovery rate
(q-value). To reduce false positives, only the motif matches achieving a q-value < 0.01
were considered for further analysis.
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Fig. 2.12 De novo motif discovery strategy. Workflow demonstrating the de novo motif
discovery approach employed to search enriched motif sequences upstream of differentially
expressed genes.
2.3.5 Phylogenetic Module Complexity Analysis
A previously described phylogenetic module complexity analysis (PMCA) algorithm
was used to identify potential cis-regulatory variants within the CRMs. The PMCA
method described in Claussnitzer et al. (2014) uses commercially available Genomatix
software suite for the analysis and commercial TF databases like TRANSFAC for the
TF PWMs. Therefore, a modified version of PMCA using open source tools and TF
databases was written in perl by me. For each SNP, 60 bp surrounding sequence on each
side was retrieved (hg38/GRCh38) and orthologous sequences to this region (if any)
in 13 mammalian species were extracted from Ensembl multiple alignments (EPO set,
version 82). FIMO was then used to identify potential TFBS matches in these sequences.
TFBS matches conserved across all or subset of the orthologous sequences were identi-
fied and TFBSs conserved in the same order within a distance range were defined into
conserved TFBS modules. These phylogenetically conserved TFBSs and modules were
repeatedly counted to estimate the degree of conservation, and the occurrences of TF-
BSs (ΩT FBS), TFBS modules (Ωmodules) and TFBSs in modules (ΩT FBS_in_modules) were
calculated. To estimate the background probabilities, these steps were repeated 1,000
times using randomly shuffled sequences from the orthologous set, and the number
of conserved TFBSs (ΩT FBSrnd ), TFBS modules (Ωmodulesrnd ) and TFBSs in modules
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(ΩT FBS_in_modulesrnd ) occurring by random chance were calculated. The sequences were
locally shuffled in windows of 10 bp to preserve the local nucleotide frequency. Finally,
based on the observed and expected number of conserved TFBS patterns, an overall
score (Sall) was calculated which classified the input non-coding variant into a complex
or a non-complex SNP region. The pseudo code of the modified PMCA is outlined as
below:
Algorithm 1 PMCA - Phylogenetic Module Complexity Analysis
1: for each non-coding SNP do
2: Select the region around the SNP
3: start position = SNP position - 60 bp
4: end position = SNP position + 60 bp
5: Extract orthologous sequences
6: Extract orthologous sequences from multiple alignments of 13 mammals using Ensembl API
(set S)
7: Calculate modular complexity
8: for each sequence set S do
9: NS ← number of sequences in S
10: Run FIMO to identify potential known TFBSs
11: Calculate conserved TFBSs in S (q < 0.01)
12: Define TFBSs in modules
13: for i = 2 to NS do
14: ωT FBS = number of conserved TFBSs in atleast i sequences of S
15: ΩT FBS =ΩT FBS +ωT FBS
16: ωrestr−T FBS = number of conserved TFBSs in atleast i×100NS sequences of S
17: Ωrestr−T FBS =Ωrestr−T FBS +ωrestr−T FBS
18: γ ←number of conserved TFBSs required in a module to be counted
19: for γ = 2 to 10 do
20: ωγ−modules = number of modules with γ TFBSs in atleast i sequences of S
21: ωT FBS_in_γ−modules = number of TFBSs in modules with γ TFBSs in atleast i se-
quences of S
22: Ωmodules =Ωmodules +ωγ−modules
23: ΩT FBS_in_modules =ΩT FBS_in_modules +ωT FBS_in_γ−modules
24: end for
25: end for
26: end for
27: Randomly shuffle sequence set S- repeat 1,000 times
28: permute the bases in each 10 bp window to generate a randomised sequence set similar in local
nucleotide distribution to S
29: calculate modular complexity to obtainΩT FBSrnd ,Ωrestr−T FBSrnd ,Ωmodulesrnd , andΩT FBS_in_modulesrnd
30: Estimate probabilities
31: p− estT FBS = f (ΩT FBSrnd ≥ΩT FBS)
32: p− estrestr−T FBS = f (Ωrestr−T FBSrnd ≥Ωrestr−T FBS)
33: p− estmodules = f (Ωmodulesrnd ≥Ωmodules)
34: p− estT FBS_in_modules = f (ΩT FBS_in_modulesrnd ≥ΩT FBS_in_modules)
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35: if count(Ωirnd ≥Ωi) = 0 then
36: p− esti = 1/1001
37: where i← TFBS, rest-TFBS, modules or TFBS_in_modules
38: end if
39: Calculate overall score
40: Sall =−log(p− estT FBS× p− estmodules× p− estT FBS_in_modules)
41: Classify the non-coding SNP
42: if Sall > 6.5 & p− estrestr−T FBS < 0.15 & p− estT FBS < 0.075 then
43: SNP ← complex region
44: else
45: SNP ← non-complex region
46: end if
47: end for
2.3.6 Positional bias algorithm
The positional bias analysis (Hughes et al., 2000) was employed to further identify the
TFs with preferential binding patterns at T2D SNP positions. The ±500 bp sequences
flanking the set of T2D SNPs were scanned to identify potential binding of TF family
PWMs using FIMO. For this analysis, 314 TF PWMs were grouped into 100 TF families,
as searching for a TF family instead of the individual TFs removes redundancy and
identifies the best match within a TF family. The TF family motifs were searched
using a sliding window of 50 bp, with a 10 bp step increase after every iteration. The
positional bias binomial probability for each TF family and each window was estimated
using the formula:
P =
t
∑
i=m
(
t
i
)(
w
l
)i(1− w
l
)t−i (2.1)
where m is the exact number of TF family matches within the scan window, t is the
total number of matches in the sequence, w is the size of the scan window (i.e. 50) and
l is the length of the sequence (i.e. 1,000). For visualisation of the results, -log10(p)
and the distance of the SNP from the middle of the scan window was calculated. This
positional bias algorithm using open source tools and public TF databases was written
in perl and its pseudo code is described below:
Algorithm 2 Positional Bias Analysis
1: for each SNP in complex/non-complex set do
2: Select the region around the SNP
3: start position = SNP position - 500 bp
4: end position = SNP position + 500 bp
5: extract FASTA genomic sequence
6: Identify TFBSs
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7: use FIMO to identify potential TF family PWM matches (q < 0.01)
8: end for
9: Calculate positional bias - binomial probability
10: for each TFBS family do
11: calculate t ← total number of matches in the sequences
12: set window start to 0
13: set window size (w) to 50 bp
14: set sequence length (l) to 1,000 bp
15: for window start = 0 to 950 do
16: calculate m← number of TFBS matches within this window
17: Positional Bias, P =
t
∑
i=m
( ti )(
w
l )
i(1− wl )t−i
18: increment window start by 10 bp
19: end for
20: end for
21: END
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2.4 Discussion
T2D associated variants in the KLF14 vicinity disrupt a trans-network of genes regulated
by KLF14 leading to metabolic defects in humans. The mouse model with Klf14
deletion display reduced HDL-cholesterol in males, yet contrary to the human data, no
phenotypes are observed in the female mice. Besides, no evidence of T2D characteristics
are found in these Klf14 knockout mice. Investigating the Klf14 associated regulatory
networks and phenotypes in the mouse and human genomes revealed species specific
Klf14 transcriptional targets, which may potentially be the reason for somewhat different
Klf14 associated phenotypes observed in mice and humans. Nevertheless, some Klf14
transcriptional targets amongst the two species are recognised to interact with each other,
suggesting their involvement in the same functional pathway. Moreover, a conserved
regulatory motif associated with the Klf14 phenotypes is identified between mice and
humans. The regulatory networks of Klf14 in the two species also share Srebf2 (mouse
orthologue of SREBF1), an important TF for lipid and cholesterol homeostasis. This
data suggests that the functional role of Klf14 in mice may have diverged to be largely
involved in the cholesterol metabolism.
A comparative epigenetic profiling of the KLF14 locus shows that the human
adipose-specific enhancer harbouring few of the T2D risk variants is likely to be
functionally inactive in the mouse. The region homologous to the human enhancer do
not display any DNaseI hypersensitive activity in any of the mouse tissues available in
ENCODE, which indicates a low probability of open chromatin or regulatory function
at this loci. This suggests that distal regulatory elements associated with Klf14 have
possibly migrated and diverged in function, which reflects in the phenotypes associated
with Klf14 in mice and humans. This chapter specifically focuses on the epigenetic
profile of the KLF14 locus between the mouse and human genome. However, it would
be interesting to compare the KLF14 locus across several intermediate species as it
could provide a detailed map of the functional divergence associated with KLF14
locus regulatory activity. For instance, it could provide insights into the changing
activity and position of the KLF14 enhancer during evolution. Therefore, future study
should focus on analysing the KLF14 enhancer activity across several mammalian
species with high quality genome builds such as human (Homo sapiens), macaque
(Macaca mulatta), marmoset (Callithrix jacchus), mouse (Mus musculus), rat (Rattus
norvegicus), rabbit (Oryctolagus cuniculus), cow (Bos taurus), pig (Sus scrofa), dog
(Canis familiaris), and cat (Felis catus). However, such an analysis would require
regulatory activity data such as enhancer annotations and/or DNase-seq profiles, in
multiple tissues (or in at least adipose related tissues) across several species, which is
not available at the moment. Some examples of cross-species regulatory data publicly
available at present include H3K27ac and H3K4me3 profiles in adult liver across 20
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mammalian species (Villar et al., 2015); H3K27ac profile in embryonic limb across
human, rhesus and mouse (Cotney et al., 2013); and H3K27ac and H3K4me2 profiles
in embryonic cortex across human, rhesus and mouse (Reilly et al., 2015). However,
there is no repository with standardised H3K27ac profiles across different mammalian
species in adipose tissue, therefore the data mining and processing for this analysis
would be extensive. In addition to performing a cross-species analysis, comparing the
KLF14 locus within the different sub-strains of mice could detect the presence of any
strain-specific variation in the KLF14 locus associated enhancer activity (Lilue et al.,
2018). Again, such cross-strain cross-tissue regulatory data in mice is not available
in standardised repositories such as ENCODE, and hence very limited. However, an
example of cross-strain regulatory data available in mice is the H3K27ac, H3K4me2
and ATAC-seq profiles in bone marrow derived macrophages across five mouse inbred
strains - C57BL/6J, BALB/cJ, NOD/ShiLtJ, PWK/PhJ and SPRET/EiJ (Link et al.,
2018). In the future when regulatory data for more species, strains and tissues become
available, we will be able to study the KLF14 regulatory function in adipose tissue
across several genomes.
Overall, this chapter shows that such epigenetic differences should be taken into
account when using or producing mouse models, especially if one intends to generate
mouse models with non-coding mutations to model disease-associated SNPs (DA-
SNPs) from humans. Mouse models with point mutations at homologous positions to
the human non-coding DA-SNPs, which harbour no enhancer activity in the mouse are
unlikely to produce phenotypes similar to the observed human traits. Additionally, this
study highlights the need for enhancer annotations in the mouse genome to aid in the
study of mammalian regulatory mechanisms and for systematic comparisons of regions
between the human and mouse genomes.
By utilising the TFBS patterns conserved across species, I identified potential cis-
regulatory variants in the KLF14 T2D locus that may modulate KLF14 expression and
may contribute to the disease. A further positional bias analysis uncovered forkhead
TFs to preferentially bind near three of the cis-regulatory variants in humans. Though
none of the FKHD binding sites directly overlapped the SNP positions, forkhead TF
FOXO1 which binds within ±25 bp of rs4731702, is known to be involved in insulin
secretion and glucose production, and therefore, could be potentially involved in the
mechanistic mode of action of these variants to cause metabolic defects. The SNP
rs4731702 which has been previously identified to correlate with KLF14 expression,
emerged as one of the top candidates in both PMCA and positional bias analysis, hence
providing evidence for the usefulness of such methods.
The methodologies applied here have limitations. First, the PMCA and positional
bias analysis involves searching for only known TFBSs. This makes it dependent on
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the current knowledge of TFs and their known binding sites, which is not complete.
Also, the number of TF PWMs in publicly available databases is almost four times less
compared to the commercial TF databases like TRANSFAC (Wingender et al., 1996),
which further constraints this analysis. Second, detecting TFBSs using known PWMs
involves a high rate of false positives which could lead to identifying binding sites with
no functional significance in vivo - known as the “futility theorem" (Wasserman and
Sandelin, 2004). Third, conservation of a sequence does not always correspond with
regulatory activity. Many exceptionally conserved sequences have been recognised
to show no important functional role (Ahituv et al., 2007). Conversely, numerous
enhancers with weak or no conservation across distant species have been experimentally
confirmed to be functionally active (Friedli et al., 2010; Taher et al., 2011). Moreover,
the parameters applied to detect the CRMs would fail if the regulatory sequences
have largely diverged across the species. These limitations could be addressed by
using ChIP-seq profiles to detect the binding of a particular TF. However, as ChIP-seq
profiles are tissue-specific and each experiment profiles a single TF, there is limited
data available at the moment. Additionally, there is room for improvement in the
implementation of the PMCA method. For instance, alignment of the input sequences
and identification of conserved PWMs could be enhanced by modifying existing refined
tools like CONREAL (Berezikov et al., 2004) and ConSite (Adams et al., 2000).
Identification of the CRMs could also be improved by incorporating tools which do not
depend on multiple genome alignments and take into account largely diverged regions
(Cai et al., 2010). The lack of TF PWM data could be compensated by adding epigenetic
information to the analysis such as DNaseI hypersensitive and histone modification
data, which could help in detecting functionally active TFBSs with greater accuracy
(Schwessinger et al., 2017).
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Chapter 3
Identification of regulatory elements in
the mouse genome
In this chapter, I model histone modification data from ENCODE to identify and
characterise potential enhancer domains in a diverse set of mouse tissues and cell-types.
The results described in this chapter contributes towards the following article:
Sethi, S., I. E. Vorontsov, I. V. Kulakovskiy, S. Greenaway, J. Williams, V. J. Makeev, S.
D. M. Brown, M. M. Simon, A.-M. Mallon (2019).“Deciphering the impact of enhancer
architecture on gene function and mouse phenotypes”. Under review in Cell Reports.
3.1 Introduction
The previous chapter displayed how examining regulatory elements such as enhancers
can help unveil insights into molecular and disease mechanisms. If we look beyond
the KLF14 locus, over 90% of the GWAS SNPs associated with human disorders
occur within non-coding regions (Hindorff et al., 2009), of which ∼76% are identified
either within DHSs or in high LD with a SNP within a DHS (Maurano et al., 2012).
This observation restates the possible role of active regulatory elements in human
diseases. Moreover, a recent study identified 64% of the non-coding DA-SNPs from
GWASs to occur in regions marked by H3K27ac (Hnisz et al., 2013), suggesting that
the majority of these regulatory regions harbouring DA-SNPs are active enhancers.
However, only a small number of functional enhancers (out of tens of thousands of
putative enhancers) have been associated to gene expression changes. Additionally, the
functional consequence of most of the DA-SNPs occurring within the enhancer regions
stays unexplained, indicating that our insights about enhancers and their contribution in
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diseases still remain insufficient. Given their functional importance, it is essential to
identify mechanisms underlying transcriptional control by enhancers.
In order to understand the mechanisms involved in transcriptional regulation by
enhancers, we need to: (1) identify the location of potential enhancer regions in the
genome; (2) identify what TFs bind there; and (3) recognise the genes they potentially
regulate. However, identification of enhancers is challenging as they are spread across
the non-coding part of the genome. As ∼98% of the human genome is non-coding,
we would have to scan billions of base pairs to distinguish potential enhancers from
non-functional regions which is similar to looking for a needle in a haystack. Moreover,
enhancer function is independent of its orientation and location, and could be present
upstream; downstream; or within their target gene. Some enhancers can regulate genes
several Mbs away, while some have been identified to regulate multiple genes (Mohrs
et al., 2001), hence making the enhancer discovery process more confounded.
With the rapid progression of next-generation sequencing technologies in the past
decade, it has become possible to more accurately predict genome-wide enhancer activ-
ity. Large scale programs such as the ENCODE (ENCODE Project Consortium, 2012),
the FANTOM5 (FANTOM Consortium et al., 2014) and the NIH Roadmap Epige-
nomics project (Bernstein et al., 2010) have generated an initial detailed exploration of
active enhancer and promoter regions in a plethora of tissues and cell-types, forming
a crucial data source for the study of regulatory regions. ChIP-seq analysis of histone
modifications has been most widely used by these consortiums to catalogue potential
enhancer and promoter regions in humans, however, data and knowledge in the mouse
is relatively low. At the time of analysing, no systematically defined genome-wide
enhancer annotations were available in mouse tissues and cell lines. However, in the
recent years, dense clusters of active enhancers known as super-enhancers (SEs), have
been identified and characterised in an assortment of cells and tissues (Hnisz et al.,
2013; Whyte et al., 2013), but they are limited to relatively few tissue types in the
mouse (Adam et al., 2015; Fang et al., 2015; Ohba et al., 2015; Siersbæk et al., 2014;
Vahedi et al., 2015; Whyte et al., 2013). Although two SE databases (Khan and Zhang,
2016; Wei et al., 2016) have been produced which provide SE locations generated using
a standard analysis pipeline on publicly available data, they lack characterisation and
do not provide other essential data such as the location of typical-enhancers (TEs) and
their individual enhancer elements.
SEs have been shown to regulate important genes and master regulators that define
the cell state (Whyte et al., 2013). Furthermore, significant enrichment of DA-SNPs
from GWASs occur in SEs of disease-relevant tissues compared to TEs (Farh et al., 2015;
Hnisz et al., 2013; Parker et al., 2013), but no study has systematically compared the
enrichment of these SNPs in human and mouse SE domains. Therefore, identification
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of SEs and other enhancer domains in a diverse set of mouse tissues could help in
further comprehension of the regulatory mechanisms underlying gene function and
disease causation. Knowing the location of enhancers in the mouse genome is important
as it can facilitate molecular experiments to investigate the regulatory mechanisms in
disease models. Furthermore, the location of enhancer regions can be further analysed
to identify the binding sites of TFs within them. Additionally, techniques like CRISPR-
Cas9 can be utilised to create mouse models mimicking the disease-causing genetic
variation occurring within the enhancers in humans.
The majority of human diseases are a consequence of distorted interactions between
cell- and tissue-type specific functions (Lage et al., 2008). For decades, pathologists
have examined tissues from the affected organs to identify the presence, cause and
extent of a disease. The relationship between cellular organisation, tissue structure
and disease is well established. The cells in a tissue are required to perform common
functions important for sustaining the tissue, and also unique functions that define the
cell identity. These common and cell- or tissue-specific functions are governed by
regulatory elements, which regulate the gene expression patterns. Therefore, studying
tissue-specific regulatory regions and their networks have been of keen interest as they
could provide insights into the biology of cell-type specific lineages. For instance, tissue-
specific enhancer regions could aid in the identification of lineage-specific TFs and
biomarkers. Although these elements have been comprehensively identified, numerous
questions still remain on the interpretation of their biological relevance, effect on gene
expression and overall impact on disease causation.
The aim of this chapter is to produce a catalogue of well defined enhancers in
multiple mouse tissues and cell-types, which will allow us to further investigate the
properties of these elements. In order to do this, I annotate potential regulatory ele-
ments in 22 mouse tissues using histone modification data. To investigate tissue-type
specific biology, I systematically identify highly tissue-specific enhancer states across
the tissues and further characterise them into SEs and TEs, henceforth producing a
catalogue of multiple enhancer types in a diverse range of mouse tissues and cell-types,
which includes previously unexplored tissues. Furthermore, I analyse open chromatin
activity, TF binding occupancy and evolutionary sequence conservation within these
newly identified enhancers. Finally, I investigate to what extent the occurrence of
non-coding DA-SNPs from GWASs correlate between human and mouse enhancer
domains. Overall, the results from this chapter provide valuable data and a platform
to further characterise the mechanisms of gene regulation by enhancers in the mouse
genome.
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3.2 Results
3.2.1 Chromatin state segmentation across 22 mouse tissues
To systematically identify genome-wide chromatin states and potential regulatory re-
gions in the mouse genome, I applied a multivariate Hidden Markov model called
ChromHMM (Ernst and Kellis, 2012) which models different patterns of histone marks
observed in a dataset and assigns a state to each genomic position. Several ChromHMM
models were produced consisting of 4-8 chromatin states (Appendix A.1) using ChIP-
seq data of three primary histone marks (namely H3K4me1, H3K4me3 and H3K27ac)
in 22 mouse tissues and cell lines. Visual inspection of these models identified the 6 state
model to provide sufficient resolution in order to isolate chromatin states associated with
promoters and enhancers. Using this model, I annotated the genome with 6 chromatin
states (Fig. 3.1A) and assigned them likely biological roles based on the enrichment of
histone marks (Fig. 3.1B). These chromatin states can be broadly categorised into active
promoter, weak promoter, strong enhancer and weak enhancer states. To validate the
predicted chromatin states, they were compared to promoters of known protein-coding
genes, mouse enhancers from VISTA and other functional elements (such as known
CpG islands, TSSs and gene coordinates) in the mouse genome. Active promoter
and strong enhancer states achieved a recall sensitivity of 81.7% (18,543/22,707) with
known promoters and 91.2% (331/363) with VISTA enhancers (described in section
1.6.3), respectively. As expected, chromatin states linked to promoters (state 1 and
2) overlap known CpG islands, TSSs and regions within 2 kb of TSSs (Fig. 3.1C).
Conversely, chromatin states linked to enhancers (state 4 and 6) lack enrichment over
TSSs and mostly overlap gene bodies and regions within 2 kb of TSSs. Examples of
learned chromatin states are shown in Fig. 3.2. Overall, using ChromHMM, I annotated
427,251 weak promoter (state 1), 309,581 active promoter (state 2), 432,380 weak
enhancer/promoter (state 3), 923,791 strong enhancer (state 4) and 2,531,993 weak en-
hancer (state 6) chromatin states across the 22 tissues, each chromatin state region being
200 bp in length and with a posterior probability > 0.95 in at least 1 tissue. It should be
noted that these numbers represent the 200 bp resolution segmentations outputted by the
ChromHMM, and not the actual number of predicted regulatory elements. To calculate
the actual number of predicted regulatory elements, I concatenated adjacent chromatin
state annotated regions together - this approach annotated on average 15,667 active
promoter and 28,336 strong enhancer elements per tissue; or 54,564 non-redundant
active promoter and 259,954 non-redundant strong enhancer elements across 22 tissues.
These numbers are consistent with the mouse ENCODE study (Shen et al., 2012) which
reported 53,834 putative non-redundant promoters and 234,764 potential enhancers
across 19 mouse tissues.
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Fig. 3.1 Chromatin state segmentation and characterisation across 22 mouse tissues. (A)
Heatmap showing the 6 state model emission parameters learned jointly across tissues by
applying ChromHMM. Columns show the various histone marks used in the model, rows show
the chromatin states with their potential functional annotation (interpreted from combinations
of histone marks in each state), colour denotes the frequency with which a histone mark is
observed in the genome, and genome-wide coverage of each state is shown on the right. (B)
Table describing the histone mark signals enriched in each chromatin state and their functional
interpretation. (C) Box plots showing the enrichment of each chromatin state over functional
annotations across all the tissues (in order: CpG islands, TSSs, within 2 kb from TSSs, VISTA
enhancers and genes). A higher enrichment value denotes a higher abundance of the chromatin
state.
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Fig. 3.2 Genomic view of chromatin state segmentation output. Genome browser snapshots
displaying ENCODE ChIP-seq binding profiles of H3K4me1, H3K4me3 and H3K27ac; DNaseI
hypersensitive (HS) signal; and this study’s learned chromatin states. Chromatin states: ■ weak
promoter; ■ active promoter; ■ weak enhancer/promoter; ■ strong enhancer; ■ weak/poised
enhancer.
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In order to validate the number of active promoter and strong enhancer elements
predicted in this study, I compared them with two previously reported studies in mice:
(1) study published by Shen et al. 2012 where they predicted enhancer, active promoter
and insulator regions in 19 mouse tissues and cell types using genomic locations
of H3K4me1, H3K27ac, H3K4me3, pol II binding and CTCF binding; (2) a study
published by Bogu et al. 2015 where they predicted active promoters and enhancers by
performing ChromHMM chromatin segmentation in 9 mouse tissues/cell lines using
histone modifications (H3K4me1, H3K4me3, H3K27ac, H3K36me3, H3K27me3),
CTCF binding and pol II binding. I found for most of the tissues, the number of
predicted strong enhancer and active promoter elements are reduced in this study
compared to previous studies (Fig. 3.3). This under-prediction may be due to: (1) a
greater number of histone marks or other ChIP-seq data used by other studies in their
prediction methods; (2) a strict threshold on posterior probability employed in this
study (> 0.95 as opposed to the default > 0.75) to capture only the highly confident
predictions. Compared to Shen et al. 2012 who reported to collectively annotate 11%
of the mouse genome, this study assigned a potential regulatory function to 8.4% of the
mouse genome.
Fig. 3.3 Number of predicted regulatory elements in the mouse genome from three differ-
ent studies. Comparison of the number of predicted regulatory elements in the mouse genome
from Shen et al. 2012 (17 tissues), Bogu et al. 2015 (9 tissues) and the current study (22 tissues).
In order to compare the chromatin states between the different tissues, I computed the
jaccard statistic which represents the similarity between two sets of genomic coordinates
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based on their intersection. More specifically, the jaccard statistic represents the ratio
of the intersection of two sets to the union of the two sets. Its value ranges between
0 and 1, where ‘0’ represents no similarity between the two sets and ‘1’ represents
that the two sets are identical. Overall, the pairwise jaccard statistic correlations show
that weak promoter and active promoter regions (state 1 and 2 respectively) are more
similar between the tissues compared to strong enhancer and weak enhancer regions
(state 4 and 6 respectively) (Fig. 3.4). As expected, one can also see that the chromatin
states, especially active promoter and strong enhancer states, tend to have more overlap
between physiologically similar tissues. For instance, functionally related tissues such
as the cerebellum, cortex, whole brain and olfactory bulb cluster together in most
chromatin states. Likewise, tissues and cell-types such as the spleen, thymus, bone
marrow, MEL and CH12 group together. These observations support the functional
relevance of these annotated enhancer and promoter states in gene expression and
function. The number of annotations varies across different chromatin states, however,
they are similar within the same chromatin state across majority of the tissues. The
testis appears to be an exceptional case with a surprisingly high number of weak
promoter annotations (state 1). Although it also contains large number active promoters
(state 2), they are comparable to the numbers (for state 2) in other tissues. It remains
undetermined as to why testis have a high number of promoter annotations. This could
be an artefact or indicate the presence of noise in the data.
3.2.2 Open chromatin and TF binding activity
Chromatin organisation in DNA regulates TF binding activity by controlling the acces-
sibility state of DNA. Regions of DNA which are accessible (or open chromatin) for
TFs to bind are indicative of potential regulatory activity. To examine the relationship
between the predicted regulatory elements and open chromatin regions, I compared
the enhancer and promoter regions with DHSs in 11 mouse tissues (Fig. 3.5). On
average, 93% of active promoters and 72% of strong enhancers overlap with DHSs
across 11 tissues respectively. To examine if this overlap is more than what one would
expect if these datasets were independent, a permutation test (with 1,000 permutations)
was performed by shuffling the locations of enhancer and promoter regions to random
locations in the mouse genome (see methods 3.3.2), which shows that strong enhancers
and active promoters significantly overlap with DHSs (p < 0.001). A relatively small
fraction of weak promoters (63%) and weak enhancers (30%) overlap DHSs (data not
shown). This result further validates the predicted strong enhancer and active promoter
annotations in the mouse tissues.
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Fig. 3.4 Comparison of chromatin states across the tissues. Heatmaps display the pairwise
jaccard statistic between the tissues in each chromatin state. A higher jaccard statistic denotes a
higher two way intersection overlap of the chromatin state regions between the tissues. The bar
plots on the right of the heatmaps display the number of chromatin state annotations in each
tissue. BAT: brown adipose tissue; Bmarrrow: bone marrow; BmarrowDm: bone marrow derived
macrophage; CH12: B-cell lymphoma; Esb4: mouse embryonic stem cells; Es-E14: mouse
embryonic stem cell line at day E14.5; MEF: mouse embryonic fibroblast; MEL: leukaemia;
Wbrain: whole brain.
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Fig. 3.5 Correlation between predicted regulatory elements and DHSs. Bar plot displaying
the fraction of strong enhancers and active promoters overlapping DHSs in 11 mouse tissues.
Statistical significance was computed by a permutation test. The permutation test was performed
by shuffling the locations of enhancer and promoter regions to random locations in the mouse
genome (‘***’ denotes p < 0.001). Grey bars display the median of the permuted distribution
(random locations).
Next, I investigated the abundance of TF binding within enhancers and promoters.
In order to do this, I compared the binding site locations of 71 different TFs (from 127
independent ChIP-seq datasets) to enhancer and promoter regions in the correspond-
ing tissues. These 127 ChIP-seq datasets were manually extracted from open access
databases and analysed to identify the TFBSs (Table 3.1) (see methods 3.3.2). Overall,
approximately half of the TFs (60/127) have at least 30% of their binding sites overlap-
ping strong enhancers and active promoters (permutation test, p < 0.001) (Fig. 3.6A-C).
The fraction of binding sites correlating with strong enhancers and active promoters is
variable between different TFs and possibly dependent on the biological function of the
TF. Indeed, TFs have been previously shown to have a significant preference to bind
either in promotors or distal regulatory elements (Cheng et al., 2014). Contrary to strong
enhancers and active promoters, weak enhancers and weak promoters only harbour
∼13% of the TFBSs (Fig. 3.6D). These observations confirm that strong enhancer and
active promoter regions are occupied with TFBSs.
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Table 3.1 List of TFs analysed and the source of their ChIP-seq data.
 ID TF Tissue PMID / 
Project 
TF1 Ar Kidney 24451200 
TF2 Batf Spleen 22992523 
TF3 Bhlhe40 CH12 ENCODE 
TF4 Bhlhe40 MEL ENCODE 
TF5 Chd1 CH12 ENCODE 
TF6 Chd1 MEL ENCODE 
TF7 Chd2 CH12 ENCODE 
TF8 Chd2 MEL ENCODE 
TF9 CTCF Brain ENCODE 
TF10 CTCF Cbellum ENCODE 
TF11 CTCF CH12 ENCODE 
TF12 CTCF Es-E14 ENCODE 
TF13 CTCF Heart ENCODE 
TF14 CTCF Kidney ENCODE 
TF15 CTCF Limb ENCODE 
TF16 CTCF Liver ENCODE 
TF17 CTCF Lung ENCODE 
TF18 CTCF MEL ENCODE 
TF19 CTCF Spleen ENCODE 
TF20 CTCF Thymus ENCODE 
TF21 CTCF Es-E14 18555785 
TF22 Egr2 Thymus 22306690 
TF23 Ep300 CH12 ENCODE 
TF24 Ep300 Es-E14 ENCODE 
TF25 Ep300 Heart ENCODE 
TF26 Ep300 MEL ENCODE 
TF27 Esrrb Es-E14 18555785 
TF28 Ets1 CH12 ENCODE 
TF29 Ets1 MEL ENCODE 
TF30 Foxa1 Liver 22737085 
TF31 Foxa2 Liver 21623366 
TF32 Gabpa CH12 ENCODE 
TF33 Gabpa MEL ENCODE 
TF34 Gata1 MEL ENCODE 
TF35 Gata4 Heart 25249388 
TF36 Hcfc1 CH12 ENCODE 
TF37 Hcfc1 Es-E14 ENCODE 
TF38 Hcfc1 MEL ENCODE 
TF39 Hnf4a Kidney 24451200 
TF40 Hoxb4 Es-E14 22438249 
TF41 Ikzf3 Thymus 22080921 
TF42 Irf4 Spleen 22983707 
TF43 Jun CH12 ENCODE 
 
ID TF Tissue PMID / 
Project 
TF44 Jun Spleen 22992523 
TF45 Junb Spleen 22992523 
TF46 Jund CH12 ENCODE 
TF47 Jund MEL ENCODE 
TF48 Jund Spleen 22992523 
TF49 Kat2a CH12 ENCODE 
TF50 Kat2a MEL ENCODE 
TF51 Klf4 Es-E14 18555785 
TF52 Mafk CH12 ENCODE 
TF53 Mafk Es-E14 ENCODE 
TF54 Mafk MEL ENCODE 
TF55 Max CH12 ENCODE 
TF56 Max MEL ENCODE 
TF57 Maz CH12 ENCODE 
TF58 Maz MEL ENCODE 
TF59 Mxi1 CH12 ENCODE 
TF60 Mxi1 MEL ENCODE 
TF61 Myb MEL ENCODE 
TF62 Myc CH12 ENCODE 
TF63 Myc MEL ENCODE 
TF64 Nanog Es-E14 18555785 
TF65 Nelfe CH12 ENCODE 
TF66 Nelfe MEL ENCODE 
TF67 Nfe2 Liver 25128499 
TF68 Nfya Brain 22474351 
TF69 Nkx2-5 Heart 22706305 
TF70 Nr5a2 Es-E14 20096661 
TF71 Otx2 Es-E14 24905168 
TF72 Pol2ra Brain ENCODE 
TF73 Pol2ra Cbellum ENCODE 
TF74 Pol2ra CH12 ENCODE 
TF75 Pol2ra Heart ENCODE 
TF76 Pol2ra Kidney ENCODE 
TF77 Pol2ra Limb ENCODE 
TF78 Pol2ra Liver ENCODE 
TF79 Pol2ra Lung ENCODE 
TF80 Pol2ra MEL ENCODE 
TF81 Pol2ra Spleen ENCODE 
TF82 Pol2ra Thymus ENCODE 
TF83 Pou5f1 Es-E14 24905168 
TF84 Ppara Liver 22158963 
TF85 Prdm4 Es-E14 23918801 
TF86 Prep1 Es-E14 25875616 
 
ID TF Tissue PMID / 
Project 
TF87 Rad21 CH12 ENCODE 
TF88 Rad21 MEL ENCODE 
TF89 Rcor1 CH12 ENCODE 
TF90 Rcor1 MEL ENCODE 
TF91 Rest Es-E14 22297846 
TF92 Runx1 Thymus 22325351 
TF93 Runx3 Spleen 24421391 
TF94 Rxra Liver 22158963 
TF95 Sin3a CH12 ENCODE 
TF96 Sin3a MEL ENCODE 
TF97 Six2 Kidney 22902740 
TF98 Smc3 CH12 ENCODE 
TF99 Smc3 MEL ENCODE 
TF100 Sp1 Es-E14 24850855 
TF101 Spi1 MEL 22357756 
TF102 Stat3 Es-E14 18555785 
TF103 Stat5b Liver 22158971 
TF104 Tal1 MEL 25409824 
TF105 Tbp CH12 ENCODE 
TF106 Tbp MEL ENCODE 
TF107 Tbx3 Heart 22706305 
TF108 Tcf3 Spleen 20543837 
TF109 Tfcp2l1 Es-E14 18555785 
TF110 Tp53 Es-E14 22387025 
TF111 Untf CH12 ENCODE 
TF112 Untf MEL ENCODE 
TF113 Usf2 CH12 ENCODE 
TF114 Usf2 MEL ENCODE 
TF115 Yy1 Es-E14 22210892 
TF116 Zc3h11 CH12 ENCODE 
TF117 Zc3h11 Es-E14 ENCODE 
TF118 Zc3h11 MEL ENCODE 
TF119 Zfx Es-E14 18555785 
TF120 Zkscan1 CH12 ENCODE 
TF121 Zkscan1 MEL ENCODE 
TF122 Zmiz1 CH12 ENCODE 
TF123 Zmiz1 MEL ENCODE 
TF124 Znf143 Es-E14 23408857 
TF125 Znf384 CH12 ENCODE 
TF126 Znf384 Es-E14 ENCODE 
TF127 Znf384 MEL ENCODE 
 
TF: transcription factor; PMID: Pubmed ID
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Fig. 3.6 Enrichment of TFBSs within regulatory elements. (A) Bar plot displaying the
fraction of TFBSs within strong enhancers and active promoters. (B-C) Comparison between
fraction of observed and randomly generated TFBSs within (B) strong enhancers and (C) active
promoters. Grey data points denote the median of the permuted distribution for each TF. (D)
Bar plot displaying the fraction of TFBSs within weak enhancers and weak promoters. The
x-axis shows the ID of the TF from Table 3.1.
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3.2.3 Identification of tissue-specific regulatory elements
Using the chromatin state probability outputted by ChromHMM for every 200 bp
window in the genome, I constructed chromatin state posterior probability matrices of
strong enhancer (consisting of 923,791 chromatin state annotations) and active promoter
(consisting of 309,581 chromatin state annotations) such that each annotation had a
posterior probability > 0.95 in at least one tissue. To identify tissue-specific regulatory
elements (TSREs), I initially implemented k-means clustering to group elements with
similar activity profiles across multiple tissues. Using this unsupervised clustering
approach, strong enhancers and active promoters were grouped on the basis of their
genomic locations across different tissues, revealing common and distinct clusters
between the tissues. The strong enhancers and active promoters were grouped into 27
and 23 distinct clusters respectively (Fig. 3.7A-B).
Through visual inspection of the clusters, one can see that clusters 1-23 in strong
enhancers and 1-14 in active promoters show a high to intermediate degree of tissue-
specificity i.e. active in only one or few tissues. Whereas, clusters 24-27 in strong
enhancers and 15-23 in active promoters display activity in multiple tissues. To quantify
the amount of tissue-specificity amongst these cluster sets, the proportion of enhancers
and promoters with respect to their activity in tissues was calculated (Fig. 3.7C-D).
Enhancer cluster set 1-23 consisting of 843,239 chromatin state annotations (91% of
total strong enhancers) are active in approximately three tissues on average (Fig. 3.7C),
of which 491,525 (58% of chromatin state annotations in cluster set 1-23 or 53% of total
strong enhancers) are specific to a single tissue. Likewise, a similar pattern is observed
for promoter cluster set 1-14 consisting of 224,708 chromatin state annotations (73%
of total active promoters), of which 140,587 (62% of chromatin state annotations in
cluster set 1-14 or 45% of total active promoters) are active in only one tissue (Fig.
3.7D). These cluster sets display groups of enhancers and promoters common between
tissues of organs which have similar functions or which work together. For instance,
common enhancer regions were grouped together in immunity related tissues (clusters
4, 20, 22); brain tissues (clusters 6, 16, 23); placenta and ESCs (cluster 18); kidney
and liver (cluster 10); and heart and lung (cluster 13). Interestingly, some enhancers
and promoters are shared between BAT and heart (cluster 1) revealing a novel group of
tissues which could possibly be connected. Recent studies have expanded the function
of BAT in cardiovascular risk factors (such as glucose and lipid metabolism) and heart
failure (Panagia et al., 2016; Thoonen et al., 2015; Thoonen et al., 2016). These
enhancers which are active specifically in BAT and heart could possibly play a role in
regulation of mechanisms associated with the cardiovascular system.
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Fig. 3.7 Clustering of strong enhancers and active promoters across 22 mouse tissues. (A-
B) Heatmaps displaying groups of (A) strong enhancers and (B) active promoters obtained by
clustering their genomic locations across 22 tissues using k-means. Each row in the heatmap
represents the location of an enhancer/promoter chromatin state and columns shows its corre-
sponding posterior probability across different tissues. (C-D) Distribution of chromatin state
annotations in (C) enhancer and (D) promoter cluster sets.
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On the other hand, enhancer cluster set 24-27 consisting of 80,552 chromatin state
annotations (9% of total strong enhancers) are not tissue-specific and are active in
nine tissues on average (Fig. 3.7C). This suggests that only a small proportion of
the enhancer landscape is similar across physiological different tissues. Compared to
enhancers, a larger proportion (27%) of active promoters (cluster set 15-23 with 84,873
chromatin state annotations) is shared across the tissues, with activity in 15 tissues on
average (Fig. 3.7D). This finding is consistent with previous studies (Ernst et al., 2011;
Guenther et al., 2007b; Heintzman et al., 2009) where promoter groups were observed
to be active across multiple cell lines and tissues. Overall, applying clustering to strong
enhancer and active promoter regions identified moderately TSREs shared across ∼3
tissues on average.
In order to more accurately identify and classify TSREs, I implemented a previously
described Tau algorithm (Kryuchkova-Mostacci and Robinson-Rechavi, 2017; Yanai et
al., 2005) to calculate the tissue-specificity index of every regulatory element. The Tau
algorithm has been utilised in past studies to quantify tissue-specific expression. The
Tau method computes a score representing the tissue-specificity index ranging between
0 and 1, where a score of ‘0’ indicates no tissue-specificity, while ‘1’ indicates absolute
tissue-specificity (see methods 3.3.4). Using the previously recommended thresholds
of Tau score (represented as τreg for a regulatory element), I categorised enhancers
and promoters into low (τreg ≤ 0.15), intermediate (0.15 < τreg < 0.85), high (0.85≤
τreg < 1) and absolute tissue-specific (τreg = 1). Chromatin state annotations with
τreg ≥ 0.85 are observed to be highly tissue-specific, with the majority of annotations
specific to a single tissue (strong enhancers: 96%, active promoters: 88%) (Fig. 3.8A-B).
Whereas, chromatin state annotations with τreg ≤ 0.15 are shared across the tissues,
with activity in 18 and 21 tissues on average for strong enhancers and active promoters
respectively. This shows that the classification based on the Tau score is more specific
compared to clustering. However, a portion of chromatin state annotations categorised
as intermediate tissue-specific were active only in one tissue (strong enhancers: 32%,
active promoters: 9%), possibly due to the strict thresholds used for τreg score. Lowering
the τreg threshold used for highly tissue-specific group would help to recover some
of the tissue-specific chromatin states, but it would also include noise i.e. chromatin
states active in more than one tissue, therefore, the strict thresholds on τreg score were
retained.
In total, I identified 284,677 (∼31%) and 134,188 (∼43%) highly tissue-specific
(τreg ≥ 0.85) strong enhancer and active promoter chromatin states respectively across
all the tissues, each region being 200 bp in length (Fig. 3.8C). Moreover, 3% of active
promoters are shared across almost all the 22 tissues (τreg ≤ 0.15), while only 0.15% of
strong enhancers are shared, suggesting enhancers to be variable across different tissues
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and cell-types. Additionally, the Tau classification was implemented to weak promoter
and weak enhancer states. Interestingly, ∼39% of weak promoter annotations are also
identified to be highly tissue-specific. On the contrary, weak enhancer annotations are
not tissue-specific, with only 2% as highly tissue-specific and the majority (97%) of
them falling under the category of intermediate tissue-specificity. Since open chro-
matin regions can indicate potential active regulatory activity, I compared the captured
highly tissue-specific strong enhancers and active promoter regions to DHSs in order
to validate them. Both, tissue-specific strong enhancers and active promoters have a
high degree of positive correlation with DNaseI signal in the corresponding tissues
(Pearson’s correlation, p< 2.2× 10−16), confirming these mammalian TSREs to be
highly tissue-specific (Fig. 3.9). These TSREs identified by the Tau method were used
for all the subsequent analysis.
Fig. 3.8 Distribution of tissue-specific regulatory elements. (A-B) Distribution of chromatin
state annotations in (A) enhancer and (B) promoter groups categorised according to their tissue-
specificity index, as measured by τreg. (C) Percentage of chromatin state annotations in different
chromatin states categorised according to their tissue-specificity index.
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Fig. 3.9 Tissue-specific regulatory elements in 22 mouse tissues. (A) Strong enhancers (B)
Active promoters. Heatmaps showing chromatin state posterior probability of tissue-specific
chromatin states (τreg ≥ 0.85) (left) and their corresponding DNAseI signal (right) in every
tissue. Each row is a genomic location and columns represent different mouse tissues and
cell lines. Grey columns show tissues for which data was not available. The heatmaps have
been sorted by the order of the tissues across the columns. (C-D) Heatmaps showing pairwise
Pearson’s correlations between (C) tissue-specific strong enhancers and DHSs; and (D) tissue-
specific active promoters and DHSs. The order of the tissues is sorted by hierarchical clustering
and the boxes represents clusters obtained from the clustering of the correlation matrix.
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3.2.4 Detection of super-enhancers in the mouse genome
To detect SEs in the mouse genome, the ROSE algorithm (Whyte et al., 2013) was
used to stitch together tissue-specific enhancers within a span of 12.5 kb into cohesive
units and rank them based on H3K27ac signal (Fig. 3.10A). The stitched enhancers
with high H3K27ac enrichment are defined as SEs and are systematically segregated
from the TEs. The tissue-specific enhancers form the building blocks of these cohesive
units (for both categorised as SEs or TEs) and are referred to as constituent enhancers
(Fig. 3.10A). Using this approach, 6.6% (5,082) of all cohesive units (or 24% of all
tissue-specific enhancers) were identified as SEs while 93.4% (71,824) are TEs (76%
of all tissue-specific enhancers), hence generating a comprehensive catalogue of SEs
and TEs in 22 mouse tissues (Appendix A.2). Consistent with previous research, SE
cohesive units are occupied on average by 2.4× H3K27ac and span large genomic
regions (median size = 12.4 kb) compared to TEs (median size = 0.4 kb) (Appendix
A.3). Enrichment of H3K4me1 and DNaseI at SEs is observed to be in agreement with
H3K27ac levels (Appendix A.4). High enrichment of these histone marks and pol II
is also detected at constituent enhancers within the SEs compared to TEs (2× higher
H3K27ac; 1.3× higher H3K4me1; 1.4× higher pol II), suggesting increased levels of
chromatin activity in SEs (Appendix A.5). As an example, the segregation of SEs in
cerebellum is shown in Fig. 3.10B-E.
3.2.5 Evolutionary conservation of mouse enhancers
Prior investigations to understand enhancer evolution have indicated that enhancers
and TF binding have diverged significantly across some mammals (Odom et al., 2007;
Shibata et al., 2012; Yue et al., 2014). A recent study of enhancers across 20 mammalian
species (Villar et al., 2015) demonstrated that enhancers have evolved at a faster rate
compared to promoters and are rarely conserved across mammals. However, most
enhancer regions associated with embryonic development are highly conserved due to
highly similar key developmental programs across mammals (Pennacchio et al., 2006).
For instance, highly conserved long stretches (> 200 bp) of DNA segments (referred
to as‘ultraconserved’ regions) are preferentially located near TFs which are known to
be involved in embryonic development, suggesting their potential role in controlling
essential developmental genes (Bejerano et al., 2004; Dickel et al., 2018b; Sandelin
et al., 2004).
In order to gain evolutionary insights about these newly identified SEs and TEs
in the mouse, I investigated the sequence conservation of SE and TE constituent
enhancers. The sequence conservation of enhancer regions was quantified using the
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Fig. 3.10 Detection of SEs in the mouse genome. (A) A schematic illustrating the methodology
used to classify tissue-specific enhancers into SEs and TEs. The tissue-specific enhancers are
stitched together into cohesive units and ranked on their H3K27ac density. High ranking stitched
enhancers are defined as SEs. The original tissue-specific enhancer elements within SEs and
TEs are referred to as constituent enhancers. (B) Distribution of H3K27ac ChIP-seq signal over
cerebellum-specific enhancers stitched together within 12.5 kb (n = 3,741). Stitched cohesive
units (x-axis) are ranked in an increasing order of their input-normalised H3K27ac signal (reads
per million, y-axis). This approach identified 237 SEs (highlighted in blue) and 3,504 TEs in
the cerebellum. (C) Metagene profile of mean H3K27ac ChIP-seq signal across all the SEs and
TEs in cerebellum. The profiles are centred on the enhancer regions and the surrounding 2 kb
regions around each enhancer is shown. The length of the enhancer region is scaled to represent
the median size of SEs (22,600 bp) and TEs (600 bp) in cerebellum. The shaded area shows
the standard error (SEM). See also Appendix A.3. (D) Distribution of H3K4me1, H3K27ac
and DNaseI signal across stitched enhancers in the cerebellum. The stitched enhancers for each
feature on the x-axis are ranked according to the H3K27ac ChIP-seq signal. See also Appendix
A.4. (E) Comparison of H3K27ac, H3K4me1 and pol II ChIP-seq signal between SE and TE
constituent enhancers in the cerebellum. See also Appendix A.5. p: p-values from Wilcoxon
Rank Sum Test; ES: non-parametric effect size (see methods 3.3.6).
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phastCons score (Siepel et al., 2005) calculated from alignments of 20 mammalian
species (see methods 3.3.7). The average phastCons score of enhancers was compared
to a background set of random size-matched genomic regions (control regions). It is
observed that SEs either have equal (p > 0.05, ES = 0), or significantly lower (p < 10−3,
ES≤−0.43) conservation scores compared to control regions in adult tissues, though
the magnitude of difference in the majority of the tissues is small (ES <−0.20) (Fig.
3.11). This suggests that SEs generally lack sequence conservation across mammalian
species. However, in embryonic tissues (such as Esb4, Es-E14, placenta and whole
brain), SEs exhibit significantly higher sequence conservation compared to control
regions (p < 10−4, ES≤ 0.26). Likewise, TEs exhibit either equal (p > 0.05, ES = 0),
or lower (p < 10−2, ES <−0.20) sequence conservation relative to control regions in
adult tissues, with the exception in bone marrow derived macrophages, liver, MEL and
thymus, where TEs have significantly higher conservation scores (p < 10−4, ES = 0.15)
(Fig. 3.11). Similar to SEs, TEs are also highly conserved compared to control regions
in embryonic tissues such as Esb4, Es-E14, limb and whole brain (p < 10−4, ES≤ 0.53).
This result substantiates with previous research showing enhancers in embryonic tissues
to be more conserved and possibly under a stronger evolutionary constraint compared
to enhancers in adult tissues (He et al., 2011; Nord et al., 2013).
Next, I compared the sequence conservation between SE and TE constituent en-
hancers. Compared to TEs, SE constituents in majority of the tissues (13/22) have
significantly lower sequence conservation scores (p < 10−2, ES≤−0.49), indicating
that TEs are generally more conserved than SEs. Whereas for the remaining tissues,
the sequence conservation scores are not different between SE and TE constituents
(p < 0.05), with 7 out of 9 tissues achieving an effect size of 0. Overall, SE and TE
constituents appear to be poorly conserved across the 20 mammalian species anal-
ysed here, with SEs showing substantially lower sequence conservation. A previous
study comparing functional enhancers (identified using H3K27ac) in the liver across 20
mammalian species (Villar et al., 2015) revealed that enhancers are rarely functionally
conserved across mammals, suggesting that they evolved more recently. Since SEs have
poor sequence conservation, it is possible that they evolved more recently, however it
is difficult to confirm this based on only sequence conservation, as a lack of sequence
conservation does not necessarily mean that the sequences are not functional (Cooper
and Brown, 2008).
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Fig. 3.11 Sequence conservation of mouse enhancers across 20 mammalian species. Box
plots displaying the sequence conservation score (phastCons) of SE and TE constituent enhancers
in each tissue. ‘SE_ctrl’ and ‘TE_ctrl’ represent the background size-matched control regions
for SEs and TEs respectively. The control regions were generated by shuffling the enhancer
locations to random genomic sites with identical size and number (1,000 permutations). P-values
were calculated using the Wilcoxon Rank Sum Test (‘***’ denotes p < 0.0001, ‘**’ denotes
p < 0.001, ‘*’ denotes p < 0.01, ‘ns’ denotes not significant).
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3.2.6 Disease-associated SNPs in mouse enhancers
Recent studies have shown DA-SNPs from GWASs to be more enriched in SEs com-
pared to TEs (Farh et al., 2015; Hnisz et al., 2013). Moreover, DA-SNPs tend to
occur in SEs of disease-relevant tissues and cell-types. For instance, 19% (13/67) of
non-coding SNPs associated with type 1 diabetes occur within SEs of primary T-helper
cells as opposed to 9% (6/67) in TEs (Hnisz et al., 2013). Therefore, I sought to
examine whether disease-associated genetic variation occurs in mouse enhancer regions
of disease-relevant tissues, which could identify potential regions in the mouse for
functional characterisation of DA-SNPs. For this purpose, I compared the enrichment of
1,592 non-coding DA-SNPs, comprising of 26 different phenotypic traits and diseases
from GWASs, between SEs and TEs in the human and mouse genomes (Fig. 3.12)
(see methods section 3.3.8 for details of SNP and trait selection). The human SEs
and TEs were retrieved from Hnisz et al. (2013) in tissues and cell-types which were
similar to the tissues in the mouse dataset for an unbiased comparison (n=15). The
coordinates of human DA-SNPs were converted to mouse positions which resulted in
820 (∼51%) mouse SNPs homologous to the human DA-SNPs, while the remaining
49% of non-coding DA-SNPs did not have a homologous position in the mouse genome.
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Fig. 3.12 Non-coding DA-SNPs associated with 26 phenotypic traits and diseases. Chart
displaying the number of non-coding DA-SNPs associated with each of the GWAS trait analysed
in this study.
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To summarise the analysis, the comparison of each GWAS trait was placed into
four categories: (1) category A, DA-SNPs enriched in enhancers of disease-relevant
tissues in both human and mouse; (2) category B, DA-SNPs enriched in enhancers of
disease-relevant tissues in only human; (3) category C, DA-SNPs enriched in enhancers
of disease-relevant tissues in only mouse; and (4) category D, DA-SNPs not enriched in
enhancers of disease-relevant tissues in both human and mouse. Of the 26 GWAS traits,
5 were placed in category A, 7 in category B, 4 in category C and 10 in category D (Table
3.2). Further inspection of trait enrichment in category C revealed that for 3 traits (out
of 4), the disease-relevant tissue was not available in the human enhancer dataset which
is possibly the cause for DA-SNPs not enriched in human enhancers. Another potential
reason could be the different datasets and processing used to identify human enhancer
regions by Hnisz et al. (2013), which could lead to differences in enhancer annotation.
An example from each category is displayed in Fig 3.13 (see Appendix A.6 for all traits).
Table 3.2 Comparison of DA-SNPs enrichment in human and mouse enhancer regions.
 
Phenotypic trait/disease 
(GWAS) 
Result 
category 
Celiac disease A 
Multiple sclerosis A 
Rheumatoid arthritis A 
Systemic lupus erythematosus A 
Type 1 diabetes A 
Alzheimer's disease B 
Coronary heart disease B 
Crohn's disease B 
Inflammatory bowel disease B 
Platelet counts B 
Red blood cell traits B 
Schizophrenia B 
Asthma C 
Chronic kidney disease C 
Fasting glucose-related traits C 
HDL cholesterol C 
Adiponectin levels D 
Bipolar disorder D 
Bone mineral density D 
Body mass index D 
Metabolite levels D 
Obesity D 
Parkinson's disease D 
Pulmonary function D 
Type 2 diabetes D 
Triglycerides D 
 
Table displaying the comparative enrichment of DA-SNPs within human and mouse enhancers. Result
category codes: A, DA-SNPs enriched in enhancers of disease-relevant tissues in both human and mouse;
B, DA-SNPs enriched in enhancers of disease-relevant tissues in only human; C, DA-SNPs enriched in
enhancers of disease-relevant tissues in only mouse; D, DA-SNPs not enriched in enhancers of
disease-relevant tissues in both human and mouse.
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Furthermore, confirming previous reports, DA-SNPs were more enriched in SEs of
disease-relevant tissues relative to TEs in both the human and mouse genomes. Overall,
excluding the GWAS traits in category D in which the DA-SNPs were not enriched in
human enhancers, 9 out of 16 GWAS traits have SNPs enriched in mouse enhancers of
disease-relevant tissues, suggesting potentially conserved regulatory pathways between
the human and mouse genomes. Interestingly, all the GWAS diseases in category A are
related to the immune system (Table 3.2), however, translating data from mouse models
of immune diseases into human research has been largely unsuccessful, due to the
differences in immune response mechanisms between the mouse and humans (Zschaler
et al., 2014). Perhaps targeting the category-A DA-SNPs homologous positions in
the mouse could produce disease models to better translate the disease understanding
into human research. This emphasises the importance of taking the differences in
the enhancer landscape between human and mouse into account when using mouse
models to study gene regulation (as discussed in chapter two). Such analysis can help
in predicting the DA-SNPs and phenotypic domains which could be better replicated in
mouse models via genome editing techniques.
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Fig. 3.13 Enrichment of disease-associated genetic variants in human and mouse en-
hancers. Radar plots displaying examples of DA-SNP enrichment in SEs and TEs of human
and mouse. Each respective axis shows the SNP density (SNP per Mb of enhancer) in SE
and TE domains (green and orange dots respectively). Brain_HM: Brain hippocampus middle;
Brain_MFL: Brain mid frontal lobe; Brain_ITL: Brain inferior temporal lobe; Heart_LV: Heart
left ventricle; Heart_RV: Heart right ventricle; Heart_RA: Heart right atrium.
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3.3 Methods
3.3.1 Learning Chromatin states in the mouse genome
Firstly, the ChIP-seq data for histone H3 lysine 4 monomethylation (H3K4me1), histone
H3 lysine 4 trimethylation (H3K4me3) and histone H3 lysine 27 monoacetylation
(H3K27ac) in 22 mouse tissues was collected from the the ENCODE project (LICR lab)
in the form of sequence alignments (BAM files mapped to mm9 mouse genome). The
dataset includes 14 adult tissues: BAT (brown adipose tissue), bone marrow, cerebellum,
cortex, heart, kidney, liver, lung, olfactory bulb, placenta, small intestine, spleen, testis
and thymus; 2 embryonic tissues: limb and whole brain; and 6 cell lines: bone marrow
derived macrophage, CH12 (B-cell lymphoma, GM12878 analogue), Esb4 (mouse
embryonic stem cells), Es-E14 (mouse embryonic stem cell line at E14.5), MEF (mouse
embryonic fibroblast), MEL (leukaemia, K562 analogue). Next, I used ChromHMM (a
multivariate Hidden Markov model) to integrate all the ChIP-seq data and summarise
into easily illustratable annotations. The chromatin states were jointly learned across 22
mouse tissues using default parameters. Several ChromHMM models were produced
consisting of 4-8 chromatin states, of which the 6 state model was identified to provide
sufficient resolution in order to isolate biologically meaningful chromatin states. The
resulting chromatin states were then annotated based on the biological significance of
the frequencies of combined histone marks (Fig. 3.1). Using this approach, potential
active promoter (404,016), weak promoter (647,185), strong enhancer (1,075,608)
and weak enhancer (2,068,844) chromatin state annotations were mapped across 22
mouse tissues and cell-types. To validate the predicted promoter states (states 1 and
2), I compared 217,678 unique non-overlapping predicted promoter chromatin states to
22,707 known protein-coding genes (mm9 ensembl genes v67; 10 kb upstream, 100 bp
downstream of TSSs) and recovered 81.66% of known promoters. Similarly, to validate
the strong enhancer predictions (state 4), I compared 386,222 unique non-overlapping
enhancer chromatin states to 363 experimentally validated VISTA mouse enhancers
and recovered 91.18% of VISTA enhancers. Chromatin states with ≤0.95 posterior
probability were filtered resulting in 923,791 strong enhancer (state 4); 309,581 active
promoter (state 2); 2,531,993 weak enhancer (state 6); and 427,251 weak promoter
(state 1) high confidence chromatin state annotations respectively.
3.3.2 Comparing regulatory elements with DHSs and TFBSs
To compare strong enhancers and active promoters with open chromatin regions, DHSs
in 11 epigenomes (Cerebellum, CH12, Es-E14, Heart, Kidney, Liver, Lung, MEL,
Spleen, Thymus, Wbrain) were collected from the ENCODE (University of Washington
96
3.3 Methods
lab) in the form of hotspots. The fraction of enhancer/promoter regions overlapping
DHSs was calculated as: number of base pairs in enhancers/promoters intersecting
DHSs divided by the total enhancer/promoter coverage. In order to examine if this
overlap was statistically significant compared to what one would expect if they were
independent, a permutation test was performed by shuffling the enhancers and promoters
to random locations in the genome (n=1,000). These random locations were compared
to DHSs to build a background distribution and the p-value was calculated as the number
of permuted overlap greater than the observed overlap, divided by the total number
of simulations. In order to investigate TF binding within enhancers and promoters,
127 TF ChIP-seq datasets were manually extracted from different publicly available
resources. The binding sites for 7 TFs were extracted from JASPAR, while the rest of
the TF ChIP-seq peaks were extracted from the Cistrome browser (Mei et al., 2017) and
the ENCODE project. The ChIP-seq peaks were then analysed using Homer to find the
enriched motifs and the binding sites of the canonical motif associated with the TF. The
overlap between TFBSs and enhancer/promoter elements along with permutation test
was computed in a similar fashion as described above for the overlap with DHSs.
3.3.3 Clustering of promoters and enhancers across 22 tissues
Clustering was performed on active promoter (state 2) and strong enhancer (state 4)
states. The complete mouse genome was segmented into 200 bp intervals and regions
annotated as active promoter or strong enhancer states (posterior probability > 0.95)
in at least one tissue were extracted to be used in clustering. Using this approach, a
chromatin state posterior probability matrix was constructed for strong enhancers (state
4 posterior probability > 0.95) and active promoters (state 2 posterior probability > 0.95)
with dimensions n× s, where n is the number of chromatin state annotations and s is
the number of tissues (i.e. 22). Each row of the matrix was a genomic location of the
chromatin state and columns represented its posterior probability across all the tissues.
The clustering was performed on the rows of this matrix using the k-means algorithm in
R. By calculating the sum of squared distances of samples to the nearest cluster centre
combined with visual inspection, I found 23 and 27 to be the optimal number of clusters
into which the promoter and enhancer data could be divided to reveal distinct groups
respectively. The clusters were then reordered for better visualisation in a heatmap.
3.3.4 Tissue-specificity index of regulatory elements
To identify tissue-specific regulatory regions across the 22 tissues, I implemented the
Tau method which has been used to detect tissue-specific expression in previous studies
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(Kryuchkova-Mostacci and Robinson-Rechavi, 2017; Yanai et al., 2005). Tau is a
measure of tissue-specificity index which takes into account the number of tissues
and normalised expression in each tissue, and outputs a score for each gene. The Tau
method was applied to the posterior probability matrices constructed in section 3.3.3.
The Tau score for each regulatory element was calculated by the following equation:
τreg =
∑Ni=1(1− xˆi)
N−1 ; xˆi =
xi
max(xi)
(3.1)
where N is the number of tissues and xi is the posterior probability profile component.
Using the thresholds suggested in Yanai et al. (2005), the TSREs were categorised
into low (τreg ≤ 0.15), intermediate (0.15 < τreg < 0.85), high (0.85 ≤ τreg < 1) and
absolute tissue-specific (τreg = 1). This method was similarly applied to weak enhancer
(state 6 posterior probability > 0.95) and weak promoter (state 1 posterior probability >
0.95) matrices.
3.3.5 Correlating TSREs with DHSs
DNase-Seq data from the ENCODE project was used to inspect the DNA accessibility
of tissue-specific enhancers and promoters across multiple tissues. The mean of DNaseI
signal was computed wherever multiple replicates were available within the ENCODE.
The genomic coordinates of tissue-specific enhancers and promoters were compared
with DNaseI hypersensitive hotspots using BEDTools (Quinlan, 2014) and the DNaseI
signal in each tissue or cell line was extracted. I restricted the extraction of DNaseI
signal to cases where 100% of the enhancer or promoter region overlapped the DHS
hotspot, otherwise no DNaseI activity was assumed and a value of ‘0’ was assigned to
that enhancer or promoter. This resulted in a matrix of DNaseI signal corresponding to
the posterior probability matrix of tissue-specific enhancers and promoters. To quantify
the concordance between TSREs (tissue-specific enhancers and promoters) and DHSs,
Pearson’s correlation between posterior probability of their respective chromatin state
and the corresponding DNaseI signal was calculated. The pairwise correlations between
the tissues were visualised in a heatmap, and rows and columns were ordered based on
hierarchical clustering (Fig. 3.9C-D).
3.3.6 Identifying SEs in the mouse genome
To identify SEs in the mouse genome, I implemented an approach similar to that
previously used by Whyte et al. (2013). Using the ROSE algorithm, tissue-specific
enhancers within a distance of 12.5 kb were stitched together into cohesive units and
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ranked based on their H3K27ac signal. A TSS exclusion size of 2,000 bp was used to
exclude tissue-specific enhancers within ±2 kb of known TSSs to remove any promoter
bias. The algorithm calculates a threshold of the inflection point for H3K27ac signal
(Fig. 3.10B). The stitched cohesive units with H3K27ac signal higher than the estimated
threshold are defined as SEs while the remaining cohesive units are termed as TEs. The
metagene profiles of mean H3K27ac signal across all the SEs and TEs (Fig. 3.10C)
were generated using ngs.plot (Shen et al., 2014). Metagene plots are centered on the
enhancers and display average ChIP-seq read density over all the enhancer regions and
2 kb window surrounding them. For visual comparison between profiles of SEs and TEs,
the range of the y-axis were synchronised. For comparing the H3K4me1, H3K27ac
and DNAseI hypersensitive signal over the stitched enhancers (Fig. 3.10D), the read
density over these regions was calculated in reads per million. For H3K4me1 and
H3K27ac ChIP-seq signal, the input control density was subtracted from the calculated
read density. The read density for each feature was then normalised by dividing the
signal at each enhancer by the maximum signal in each feature.
The non-parametric effect size (ES) was calculated as the difference in medians of
the two groups divided by the pooled median absolute deviation (MAD). The following
formula was used:
ES =
Median1−Median2
MADpooled
;
MADpooled =
√
MAD21 +MAD
2
2
2
;
MAD = median(|x−median(x)|)
(3.2)
3.3.7 Sequence conservation of mouse enhancers
The sequence conservation of SE and TE constituents was analysed using the phastCons
scores for the mouse genome (mm9) across 20 mammalian species. The phastCons
scores for the placental mammal subset (mouse, rat, guinea pig, rabbit, human, chimp,
orangutan, rhesus, marmoset, bushbaby, tree shrew, shrew, hedgehog, dog, cat, horse,
cow, armadillo, elephant and tenrec) was downloaded from the UCSC genome browser.
The mean phastCons score for each constituent enhancer was calculated as: sum of
the phastCons score of each bp in enhancer divided by the total length of the enhancer
(i.e. 200). To generate a background set of regions (control), the location of enhancers
were shuffled to random non-overlapping genomic positions such that the size, number
and chromosome information of enhancers was preserved. The mean phastCons score
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for the control set was calculated in a similar way to enhancers. This was repeated
1,000 times to produce a distribution of phastCons scores for the control regions. The
p-values were computed using the Wilcoxon Rank Sum Test and the non-parametric
effect size was calculated as described in section 3.3.6.
3.3.8 Enrichment of DA-SNPs in the mouse enhancers
The curated list of non-coding DA-SNPs reported in Hnisz et al. (2013) was used in this
analysis. Hnisz et al. (2013) retrieved all the DA-SNPs in GWASs from the NHGRI
database (Welter et al., 2014) and further selected the SNPs with: a dbSNP identifier;
and those associated with a trait in at least two independent studies. For the comparison
of these DA-SNPs with mouse enhancers, GWAS traits with at least 25 SNPs and those
relevant to the mouse tissues in our dataset were selected, resulting in 26 phenotypic
traits and diseases comprising of 1,592 SNPs. The coordinates of human SNPs (hg19)
were converted to mouse genome (mm9) using UCSC liftover which resulted in 820
mouse homologous SNPs. For calculating the density of DA-SNPs in the mouse SEs
and TEs, the number of DA-SNPs overlapping the SE and TE constituents in each tissue
were counted. The count was then divided by the total genomic coverage (in bp) of SE
and TE constituents in the corresponding tissue, and multiplied by a million to get the
density in SNP per Mb. For a relative comparison, the density of DA-SNPs was also
calculated in the human SEs and TEs. The coordinates of SEs and TEs in the human
genome were retrieved from Hnisz et al. (2013) in 15 tissues and cell-types which were
similar to the tissues in the mouse dataset for an unbiased comparison. These tissues
and cell-types were: Adipose, B-cell, Brain Hippocampus Middle (Brain_HM), Brain
Mid Frontal Lobe (Brain_MFL), Brain Inferior Temporal Lobe (Brain_ITL), GM12878,
H1, Heart Left Ventricle (Heart_LV), Heart Right Ventricle (Heart_RV), Heart Right
Atrium (Heart_RA), K562, Lung, SmallIntestine, Spleen, Thymus.
To calculate the significance of DA-SNPs overlapping the SE and TE constituents
in the mouse genome, a permutation test was performed by shuffling the positions of
DA-SNPs to random non-overlapping locations on the same chromosome. The density
of the random SNPs in mouse enhancers was computed in a similar fashion to the
real DA-SNPs. This process was repeated 1,000 times to produce a distribution of
SNP density scores for background SNPs. The p-value was calculated by dividing the
number of times the permuted SNP density was greater than the observed SNP density,
by the total number of permutations. For all the DA-SNPs occurring in mouse enhancer
regions, the permutation test shows that the overlap is significant (p≤ 0.007).
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3.4 Discussion
In this chapter, I mapped potential regulatory elements in 22 mouse tissues by modelling
multiple histone marks. Taking advantage of these annotations in a diverse range of
tissues, I sought to identify tissue-specific regions to get better insights into tissue-
type specific regulation. Previous studies have mostly utilised clustering techniques
to identify shared and tissue-specific groups of regulatory elements across multiple
tissues (Ernst et al., 2011; Roadmap Epigenomics Consortium et al., 2015; Shen et al.,
2012). As an alternative to clustering, I implemented the Tau metric to calculate the
tissue-specificity index of each regulatory element and systematically identified highly
tissue-specific enhancers and promoters across 22 tissues. I believe this approach is a
powerful method to identify and better quantify tissue-specific regions in a dataset. To
gain a more profound understanding of enhancer regulation, I further classified tissue-
specific enhancers into SEs (24%) and TEs (76%), henceforth generating a catalogue of
different enhancer classes in 22 tissues, which includes previously unexplored tissues
in the mouse.
Both SE and TE constituents appear to have low evolutionary conservation across
the 20 mammalian species analysed here. However, SE constituents substantially lack
sequence conservation compared to TEs, indicating SEs may have recently evolved
possibly as a result of rapid functional evolution. But, it is difficult to confirm this solely
on the basis of sequence conservation and further comparative analysis of functional
data (such as that from ChIP-seq) across these mammalian species would be required.
If true, these results would be consistent with the concept that key genes that regulate
cell state have evolved to be regulated by SEs (Hnisz et al., 2015). To the best of
my knowledge, only one study (Khan and Zhang, 2017) has analysed the sequence
conservation of SE and TE constituents in two tissues, namely mESCs and pro-B cells.
The authors compared the average phastCons score between SE and TE constituents (but
not to the background regions) and identified SE constituents to have higher sequence
conservation in pro-B cells. My dataset expands this analysis to a diverse range of
tissues and cell lines, and also identifies a novel pattern which could not have been
captured in a dataset comprising of a small number of tissues.
As more than 60% of the non-coding DA-SNPs in the human genome have been
estimated to occur within enhancer regions (Hnisz et al., 2013), I investigated whether
homologous positions of these SNPs in the mouse also overlap enhancers, which
could help identify DA-SNPs with a greater potential to phenocopy in mouse models.
Surprisingly, out of 1,592 non-coding DA-SNPs from GWASs, only ∼51% (820) were
identified to have a homologous position in the mouse. Out of the 26 GWAS traits and
diseases, DA-SNPs from16 traits were enriched in enhancers of human disease-relevant
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tissues. DA-SNPs from 9 of these traits were also enriched in enhancers of mouse
disease-relevant tissues. Whereas DA-SNPs from the remaining 7 traits occurred in
enhancer regions specific to humans. Although cis-regulatory regions have diverged
between the human and mouse genomes (Yue et al., 2014), some disease-associated
non-coding regions appear to have conserved regulatory connections. Such regions
could be potentially targeted to generate mouse models of DA-SNPs from GWASs.
Taking into account such conserved regulatory pathways along with other epigenetic
differences will help us to better translate the biomedical understanding acquired from
mouse models into human research.
This study has a number of limitations that could influence my results. First, the
association between histone modifications and enhancer activity is not completely
comprehended as even combinations of histone marks do not correlate perfectly with
enhancer occupancy (Arnold et al., 2013; Bonn et al., 2012). Moreover, in the scientific
community, there has been a lack of consensus in histone marks being used for enhancer
prediction (Shlyueva et al., 2014). Recent studies have used only H3K27ac as a mark of
active enhancers, as opposed to the combination of H3K27ac, H3K4me1 and H3K4me3
used in earlier studies. The enhancer prediction strategies appear to be dependent
on the availability of the data instead of standard conceptual models. Furthermore, a
recent study (Pradeepa et al., 2016) demonstrated novel acetylation of lysine residues
(H3K64ac and H3K122ac) to correlate with active promoters and enhancers. Therefore,
it is still unknown what combination of histone marks would be sufficient to capture a
high degree of enhancer activity. In this study, only 72% of the mapped strong enhancers
overlapped active DHSs and the known TFBS had a moderate enrichment within the
strong enhancers, which indicates that using only histone marks to predict the location
of enhancers may not be the most accurate method. An alternative strategy would use
open chromatin regions captured from DNase-seq (Boyle et al., 2008) or ATAC-seq
(Buenrostro et al., 2015), which have been proven to unbiasedly predict all regions
with regulatory activity (Thurman et al., 2012). Since open chromatin regions directly
overlay regions with regulatory activity, DNase-seq/ATAC-seq produces narrow peaks
with their summit over the core TF occupancy within the regulatory region. This allows
open chromatin data to more accurately predict the location of regulatory elements as
opposed to histone modifications, which occur at the regions flanking the regulatory
elements and hence produce very broad peaks. At the time of analysis, DNase-seq or
ATAC-seq data was only available in a limited number of mouse tissues and hence was
not implemented in the enhancer prediction strategy.
A second limitation of this study is that histone modification data cannot directly
identify which TFs are bound within these regulatory elements. Again, DNaseI accessi-
bility data could also help in overcoming this limitation. DNase-seq digital footprints
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generated at high sequencing depths can detect TF binding at near base-pair resolution
(Hesselberth et al., 2009; Neph et al., 2012). Such datasets have been modelled to
computationally predict the effect of non-coding regulatory variants on TF binding
(Schwessinger et al., 2017). A third limitation focuses on the dataset. Since the dataset
analysed here comprises of only 22 tissues, some enhancers with high tissue-specificity
may shift towards intermediate tissue-specificity if more tissues are included. Indeed,
applying this method to more tissues would further refine the tissue-specific profiles
of enhancers generated here. Nevertheless, this data provides a platform to conduct
further analysis of transcriptional regulation and better understand the role of enhancers
in disease aetiology.
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Chapter 4
Impact of enhancer architecture on
gene function and mouse phenotypes
In this chapter, I investigate SE and TE properties, how they influence gene expression
and their involvement in disease aetiology. A section of this chapter describes the
enrichment of TF ChIP-seq peaks within enhancers (section 4.2.5), which was carried
out in collaboration with the Makeev lab at the Vavilov Institute of General Genetics,
Moscow. The results described in this chapter contributes towards the following article:
Sethi, S., I. E. Vorontsov, I. V. Kulakovskiy, S. Greenaway, J. Williams, V. J. Makeev, S.
D. M. Brown, M. M. Simon, A.-M. Mallon (2019).“Deciphering the impact of enhancer
architecture on gene function and mouse phenotypes”. Under review in Cell Reports.
4.1 Introduction
The identification of enhancer regions in the genome is just the first step towards
studying the transcriptional regulation. Investigating these potential enhancer regions
to understand gene regulatory networks and mechanisms still remains a challenge. As
discussed in chapter three, more than 60% of the disease-associated genetic variation
from GWASs occurs within potential enhancer regions. Disruptions to any of the
enhancer regions may lead to disease in humans and related phenotypes in model
organisms such as the mouse (Bhatia and Kleinjan, 2014; Kleinjan and Lettice, 2008;
Maston et al., 2006). The number and scale of these observations from GWASs has
driven research to characterise enhancers and their association to pathological states.
Until recently, studying the effect of enhancer disruption in vivo has been difficult.
Though reporter assays in cultured cells have been useful to show that a stretch of
sequence can function as an enhancer outside of their native environment (Patwardhan et
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al., 2012), they cannot show if the enhancer is responsible for initiating the transcription
of a particular target gene in vivo. However, studying enhancers and other non-coding
elements in vivo has been greatly facilitated by CRISPR-Cas9 and on a case-by-case
basis we are beginning to understand the roles of enhancers in the susceptibility and
pathogenicity of diseases (Canver et al., 2015; Cunningham et al., 2018; Diao et al.,
2016; Dickel et al., 2018a; Groschel et al., 2014; Korkmaz et al., 2016; Li et al., 2014;
Moorthy and Mitchell, 2016; Rajagopal et al., 2016; Seruggia et al., 2015). The most
common approach has been to genetically manipulate the enhancer either by deleting
or disrupting it, and examine its effect on gene expression in vivo. Such studies have
demonstrated that deletion of critical enhancer sequences can abolish almost completely
(Canver et al., 2015) or up to 90% (Groschel et al., 2014; Li et al., 2014) of their target
gene expression, whereas some enhancers could be partially redundant and cause subtle
changes to the expression (Cunningham et al., 2018; Moorthy et al., 2017; Osterwalder
et al., 2018). Even single base pair changes within enhancers have been shown to
drastically effect the target gene expression, leading to disease susceptibility (Bauer
et al., 2013; Mansour et al., 2014). However, the degree to which enhancers contribute
to target gene expression on a global scale remains indistinct, as they have been mostly
studied at a few individual genomic loci.
Another question which arises about enhancer function is whether a small number
of enhancers are enough to activate transcription or whether enhancers share their
role across a large number of enhancer elements. The concept of SEs proposes that
dense clusters of enhancers represent a new paradigm in gene regulation, having a
greater role in the control of mammalian cell state. Systematic mapping of SEs using
H3K27ac chromatin mark across diverse human tissues and cell lines has shown that
SEs regulate key genes that define the cell identity, including known master regulators
(Hnisz et al., 2013; Huang et al., 2016; Loven et al., 2013; Pelish et al., 2015). For
instance, SEs in mESCs were detected to regulate key pluripotency genes (such as
Oct4, Sox2 and Nanog) and have higher TF binding for Klf14 and Esrrb (Hnisz et al.,
2013). Furthermore, SEs have been identified to drive high total-expression (aggregated
expression of all exons) of their target genes compared to TEs in a wide range of human
cell-types (Hnisz et al., 2013). While studies in the mouse genome find similar results,
they are currently less comprehensive and limited to relatively few tissue types (Adam
et al., 2015; Fang et al., 2015; Ohba et al., 2015; Shin et al., 2016; Siersbæk et al.,
2014; Vahedi et al., 2015; Whyte et al., 2013). In addition to this total-expression,
a few studies have shown SEs to be associated with tissue-specific gene expression
(tendency of a gene to be specifically expressed in a tissue or cell line) in cell lines. For
instance, genes associated with SEs in multiple myeloma cell line had a tendency to
be specifically expressed in myeloma cells (Loven et al., 2013). Moreover, as shown
in the previous chapter, SEs in human cell-types frequently harbour disease-causing
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variation (Farh et al., 2015; Hnisz et al., 2013; Parker et al., 2013), while TEs have been
considered less important. However, to date there has been no systematic study defining
genome-wide functional differences between SEs and TEs, and their relationship to
phenotypes.
Although, SEs have been characterised in multiple cell-types, it is debatable whether
the concept of SE represents a novel model of regulatory class or simply a cluster of
traditional enhancers. An important question is whether the activity of individual en-
hancers depends or is affected by other enhancers in the cluster or in the nearby vicinity.
It remains unclear whether the individual components in a SE, referred to as constituent
enhancers, work in an additive manner (independent activity) or have a more complex
cooperative effect (dependent activity) on gene expression of their target genes. Several
recent studies investigating the function of constituent enhancers at various individual
genomic loci have shown contrasting results (Hay et al., 2016; Hnisz et al., 2015; Shin
et al., 2016; Suzuki et al., 2017). In vivo studies at Wap and α-globin associated SE
locus show that deleting individual constituent enhancers have variable effect on target
gene expression and most of the single constituent enhancer deletions do not terminate
the enhancer function (Hay et al., 2016; Shin et al., 2016). However, combinatorial
deletions of constituent enhancers result in a higher reduction of target gene expression,
hence demonstrating that constituent enhancers work independently and exhibit more or
less an additive effect (Hay et al., 2016; Shin et al., 2016). Whereas, reporter assay tests
at the Pou5f1 SE locus show that combinatorial deletions of constituent enhancers often
cause a lower reduction in target gene expression compared to deletion of a single con-
stituent enhancer, hence demonstrating a complex influence of constituent enhancers on
each others activity (Hnisz et al., 2015). Furthermore, a recent study which performed
deletions of constituent enhancers in multiple cell lines showed that the majority of the
constituent enhancer deletions can cause drastic reduction (50%-80%) in target gene
expression (Suzuki et al., 2017). Therefore, further studies are required to understand
whether these observations are exceptions or represent a genome-wide pattern.
In this chapter, I aim to study the relationship and functional impact of enhancer
architecture on gene function and mouse phenotypes (Fig. 4.1). Using the genome-
wide enhancer maps produced in chapter three, and gene expression profiles in 22
mouse tissues, I systematically analyse the influence of different enhancer types on
total-expression and tissue-specificity of their target genes. Additionally, I model the
relationship between constituent enhancer density and target gene expression on a
global scale. I further explore and compare the mammalian phenotypes and disease
traits associated with potential target genes associated with different enhancer types.
Using standardised mouse phenotyping data from gene knockout models, I analyse the
phenotype severity and pleiotropic effects of SE and TE associated gene knockouts.
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Finally, I go on to model regulatory data along with other molecular characteristics to
infer mammalian gene-phenotype associations and to identify potential novel pathogenic
genes which may be used for further characterisation. Overall, the results from this
chapter show that genes harbouring different enhancer architecture tend to have distinct
expression patterns, but contribute to phenotype outcomes at a comparable level, thus
providing novel insights to enhancer-phenotype relationship.
Enhancers
Phenotype Expression
Fig. 4.1 Research aims. A schematic displaying the relationships I aim to investigate in this
chapter. The gene expression data in various tissues was collected from the ENCODE project
and mouse phenotypes associated with the genes were retrieved from the Mouse Genome
Database (MGD) (Blake et al., 2017) and the IMPC.
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4.2 Results
4.2.1 Associating regulatory elements to potential target genes
Enhancers have been identified to interact with promoters of adjacent genes through
looping in order to activate their transcription (Gondor and Ohlsson, 2009; Ong and
Corces, 2011; Sanyal et al., 2012; Spitz and Furlong, 2012). Previous investigations
have likewise observed SEs to frequently overlap the genes they regulate (Hnisz et al.,
2013; Whyte et al., 2013). A previous study in murine ESCs identified more than 80%
of SEs and TEs to interact with their nearest active gene using ChIA-PET (Dowen
et al., 2014). In order to explore the functional role of TSREs, I associated each
element to a potential target gene using GREAT (McLean et al., 2010). GREAT defines
computationally derived ‘regulatory domains’ in the genome and associates non-coding
regions to their likely target genes in the same domain. Overall, this approach identified
3,617 and 14,832 protein-coding genes associated with SEs and TEs in at least one
tissue or cell-type, respectively. The resulting enhancer-gene associations were highly
consistent with previously identified TADs in the mouse genome (Dixon et al., 2012);
96% of the enhancer-gene pairs (where both the enhancer and its target gene overlapped
a TAD) were identified to be in same cortex TADs and 93% in the same mESC TADs
(Fig. 4.2A). Similarly, 87% of the enhancer-gene pairs were identified in the same
computationally derived enhancer-promoter units (EPUs) in the mouse genome (Shen
et al., 2012). As expected, the majority of the tissue-specific enhancers (62.53% of
SEs, 57.25% of TEs) are located within 50 kb from the TSSs of their associated genes,
while 42% of active promoters are associated with TSSs within 5 kb (Fig. 4.2B). These
observations are in agreement with previous findings by Chepelev et al. (2012), where
55.80% (1,324/2,373) of the enhancer-promoter interactions detected using ChIA-PET
were identified to occur within < 50 kb of the promoters. These predicted SEs, TEs and
their potential target genes were used for all the subsequent investigations.
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Fig. 4.2 Region-gene associations of regulatory elements. (A) Pie charts displaying the
proportion of gene-enhancer pairs within previously reported TADs and EPUs in the mouse
genome. (B) Bar plots binned by orientation and TSS showing the distance between various
regulatory elements and their putative target genes. For all three graphs, the y-axis represents
the percentage of region-gene associations while the number of associations in each bin are
listed in the graph. The x-axis shows the distance (divided into separate bins) of the region
relative to the TSS of the gene. Negative distance depicts regions upstream of the TSSs; positive
distance depicts regions downstream of the TSSs; 0 represents the TSSs.
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4.2.2 Profiling genome-wide enhancer activity and target gene ex-
pression
Influence of enhancer type on target gene expression
Prior investigations have shown SEs to be related with highly expressed genes in
multiple human cell-types (Hnisz et al., 2013). In addition, a few studies have shown
SEs to be associated with tissue-specific gene expression (Loven et al., 2013). With
the aim of exploring whether this association prevails across multiple tissue types
and different enhancers, I examined the impact of these newly identified enhancers
in 22 tissues. In order to inspect the relationship between various enhancer types
and the expression of genes they potentially regulate, I utilised ENCODE’s RNA-seq
data. To effectively identify any common expression patterns between genes, tissues
and enhancers, I constructed a dataset formed of genes expressed within a particular
tissue, termed gene-tissue pairs, followed by categorisation on their type of enhancer
association, hence grouping them into three classes: (1) gene-tissue pairs associated
with SEs, referred to as super-enhancer class (SEC); (2) gene-tissue pairs associated with
TEs, referred to as typical-enhancer class (TEC); and (3) gene-tissue pairs associated
with weak/poised enhancers, referred to as weak-enhancer class (WEC).
I found that both the SEC and TEC are associated with highly expressed genes
in comparison to the WEC (SEC: ES = 0.95, p< 2.2× 10−16; TEC: ES = 0.86, p<
2.2×10−16; Wilcoxon Rank Sum Test) but that the SEC appears to have the highest
level of total-expression (SEC compared to TEC: ES = 0.56, p< 2.2×10−16) (Fig. 4.3A,
Appendix A.7A). Likewise, I investigated whether these newly identified enhancers in
mouse tissues drive tissue-specific expression of their associated genes. The SEC is
observed to have higher tissue-specific expression (quantified as τexp− f rac, see methods
4.3.3) compared to the TEC (ES = 0.62, p< 2.2× 10−16; Wilcoxon Rank Sum Test)
and WEC (ES = 0.96, p< 2.2×10−16) (Fig. 4.3B). However, not all genes in the SEC
display tissue-specific expression. To further understand tissue-specific expression of
the genes within different enhancer classes, I categorised it into three levels of low,
intermediate and high (see methods 4.3.3). This identified 16.46% (690/4,191) of
the SEC, 4.42% (1,923/43,484) of the TEC and 3.38% (230/6,795) of the WEC to
have high tissue-specific expression (τexp− f rac ≥ 0.85) (Fig. 4.3C, Appendix A.7B).
However, further examination of the high tissue-specific expression category shows
that the absolute number of genes within the TEC (1,923) is notably higher than the
SEC (690) and the WEC (230). Overall this data shows that the ratio of genes within
the SEC with high tissue-specific expression is at least 4 times larger than the genes
within other enhancer classes. However, its absolute number is smaller compared to the
111
Impact of enhancer architecture on gene function and mouse phenotypes
TEC, which contributes the largest amount (68%) of enhancer associated tissue-specific
expression in the genome (Fig. 4.3D) and should also not be overlooked.
Fig. 4.3 Enhancer activity and its influence on gene expression. (A) Box plot showing the
total-expression (in log-transformed RPKM) of different enhancer classes across 22 tissues.
Each box plot shows: the median, middle bar; interquartile range, the box; 1.5 times the
interquartile range, the whiskers. (B) Box plot showing the tissue-specific expression (as
measured by τexp− f rac) of different enhancer classes across 22 tissues. The p-values were
calculated using the Wilcoxon Rank Sum Test. (C) Density plots showing the distribution of
genes within tissue-specific expression categories (low, intermediate, high) in different enhancer
classes. The Y-axis for each tissue displays the density of genes scaled across the tissues but not
across the enhancer classes. (D) Contribution of each enhancer class (in percentage) towards the
total number of enhancer associated genes in the genome, categorised by their tissue-specific
expression. See also Appendix A.7.
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Impact of constituent enhancer density on target gene expression
SEs are likely to be comprised of large number of constituent enhancers (Fig. 4.4A).
The average number of constituents enhancers within SEs is 13 compared to only 3 in
TEs. Therefore, I asked whether constituent enhancer composition have any impact on
total- and/or tissue-specific expression of their associated genes. To investigate this,
I combined both SEs and TEs into a single dataset. I compared the frequency of the
constituent enhancers (total number of constituent enhancers associated with a gene)
within the combined dataset with total- and tissue-specific expression of their associated
genes, which revealed a significant, but weak positive correlation respectively (total-
expression: Spearman correlation r= 0.12, p< 2.2×10−16; tissue-specific expression:
r= 0.18, p< 2.2×10−16) (Fig. 4.4B-C). In contrast, weak-enhancers show little to no
correlation with total-expression (r=−0.03, p= 0.02) or tissue-specific expression r=
0.04, p= 0.001) of their associated genes (Fig. 4.4D-E). Furthermore, using the tissue-
specific expression categories (low, intermediate and high), 31% of genes with high
tissue-specific expression were identified to be associated with 10 or more constituent
enhancers as opposed to 15% in genes with intermediate tissue-specificity and 8% in
genes with low tissue-specificity, showing that genes with high tissue-specific expression
tend to be related with relatively greater number of constituent enhancers (Fig. 4.4F).
Overall this shows that total- and tissue-specific expression modestly increases with
the number of constituent enhancers, which could indicate a non-additive relationship
between them. A weak correlation could suggest the existence of cooperative activity
or partial redundancy amongst the constituent enhancers. Hence, this analysis predicts
that constituent enhancers may exert a complex, instead of a simple additive effect on
the transcriptional output. However, it should be noted that this is a computational
prediction and has limitations. In order to accurately calculate the impact of constituent
enhancers on target gene expression, it is important to know which constituent enhancers
are real/active and which gene(s) they precisely regulate. The presence of false-positives
in these variables can have a significant effect on the prediction from this analysis.
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Fig. 4.4 Impact of constituent enhancer density on target gene expression. (A) Distribution
of constituent enhancers within SEs and TEs across all 22 tissues. (B-C) Correlation analysis
between number of constituent enhancers (within SEs and TEs) and (B) total-expression;
(C) tissue-specific expression of their associated genes. (D-E) Correlation analysis between
number of weak enhancers and (D) total-expression; (E) tissue-specific expression of their
associated genes. Correlation coefficient (r) was calculated using Spearman rank correlation.
(F) Distribution of enhancer associated genes as a function of number of constituent enhancers
within their associated SEs and TEs. The genes are categorised based on their tissue-specific
expression into: highly tissue-specific, intermediate tissue-specific and low tissue-specific.
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Impact of multiple enhancer-gene associations on tissue-specific expression
Since a gene could be related to active SEs or TEs in multiple tissues, not necessarily
at the same genomic location across the different tissues, I inspected these multiple
enhancer-gene associations and their effect on tissue-specific expression. For this
purpose, I assessed the number of distinct tissues, where an enhancer associated with a
gene occurs, which I define here as ‘enhancer tissue-types’ (Fig. 4.5A). A large portion
(∼78%, 2,838 out of 3,617) of the SEC is associated with one enhancer tissue-type, i.e.
the genes are associated with SEs of only one tissue. However, only ∼27% (3,955 out
of 14,832) of the TEC have one enhancer tissue-type, while the remaining 73% of genes
in the TEC are associated with TEs of two or more tissues (Fig. 4.5B). Furthermore, the
genes with a high number of enhancer tissue-types are observed to be associated with
low values of τexp− f rac (Fig. 4.5C), hence increasing enhancer tissue-type association
increases ubiquitous expression.
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Fig. 4.5 Distinct enhancer tissue-types associated with genes. (A) A schematic to illustrate
the calculation of enhancer tissue-types for a gene. The number of distinct tissue types of
various enhancers associated with the gene of interest are added to compute the number of
enhancer tissue-types. (B) Heatmaps displaying the enhancer tissue-types of SEC and TEC.
Each row is a gene and columns represent its association with enhancers across 22 tissues and
cell-types. (C) Box plot showing the correlation between the number of enhancer tissue-types
and tissue-specific expression of SEC and TEC. The trend lines (green: SEs; orange: TEs) were
calculated using linear regression.
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4.2.3 Influence of enhancer architecture on phenotypes
Previous studies have identified SEs to be associated with genes that regulate cell state
and therefore unlikely to be involved in a housekeeping role (Hnisz et al., 2013; Whyte
et al., 2013). To explore the functional role of SE and TE associated genes in my
dataset, I performed Gene Ontology (GO) enrichment analysis in 22 mouse tissues.
Genes associated with SEs belonging to the SEC category are enriched for transcription
factor binding activity (p= 10−10), regulation of cell differentiation (p= 10−23) and
regulation of cell development (p= 10−16) (Appendix B.1). The breadth of this analysis
demonstrates novel cell identity associations in unexplored tissues in the mouse. As
expected, SEs are associated with genes known to be important in the control and
regulation of tissue or cell identity. Some examples of these novel SE associated
genes include Ucp1 (responsible for generating body heat in mammals (Cannon and
Nedergaard, 2004)), Pparg (involved in differentiation of brown adipocytes (Nedergaard
et al., 2005)), and the key TF Ebf2 (which determines the fate and function of brown
fat cells (Rajakumari et al., 2013)) in BAT; key TFs like Gata4, Nkx2-5 and Myocd
(critical for heart development and regulation of cardiomyocytes (Akazawa and Komuro,
2003)) in heart; Cxcr2 (which regulates the emigration of neutrophils from bone marrow
(Martin et al., 2003)) in bone marrow; and Rbfox3 (splicing regulator of neuronal
transcripts (Kim et al., 2009; Kim et al., 2013)) in cerebellum. Previously well studied
master TFs in mESCs such as Pouf51 (also known as Oct4), Sox2, Klf4, Esrrb, and
Prdm14 were also identified to be associated with SEs. On the other hand, the TEC
appear to have different enrichments in GO analysis and are linked with genes involved
in nucleotide and protein containing-complex binding (p= 10−6), cellular protein
localisation (p= 10−7) and cell morphogenesis (p= 10−5) (Appendix B.2). The TEC
also includes a weak enrichment of transcription co-activator activity (p= 10−2), though
no association with transcription factor binding activity is observed. Furthermore, the
TEC is significantly enriched for housekeeping genes (p= 2.7× 10−11, Odds Ratio
(OR)= 1.49, 95% CI [1.32, 1.68]), while the SEC is depleted (p= 0.012, OR= 0.82,
95% CI [0.69, 0.98]).
Phenotype associations of enhancer associated genes
In order to explore the role of enhancers in phenotypes, I investigated the mammalian
phenotypes and human diseases associated with the genes within the SEC and TEC. For
this purpose, I used the ToppFun tool (Chen et al., 2009) to calculate the enrichment
of mammalian phenotype terms and human disease annotations in the SEC and TEC
of each tissue individually. For computing the enrichments, ToppFun uses mammalian
phenotype terms from the Mouse Genome Database (MGD) (Blake et al., 2017) and hu-
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man disease annotations from databases like ClinVar (Landrum et al., 2014), DisGeNet
(Pinero et al., 2017), GWASs and OMIM (Hamosh et al., 2005). Significant enrichment
of both mammalian phenotypes and disease annotations in the corresponding tissue types
was identified (Fig. 4.6 and Appendix B.3), suggesting a strong relationship between
both SEC and TEC, and the resulting pathological outcomes (disease causation). For in-
stance, genes associated with cerebellum-specific enhancers are enriched for phenotypes
Fig. 4.6 Mammalian phenotype and human disease annotations enriched in the SEC and
TEC. Heatmap displaying the most enriched mammalian phenotypes and human diseases
amongst the SEC and TEC in each tissue. The cells in the heatmap display the FDR (q-value)
associated with the enriched terms and was calculated using the Benjamini-Hochberg method.
The enrichment analysis was performed using ToppFun, which retrieves mammalian phenotype
annotations from the MGD and human disease annotations from ClinVar, DisGenNet, GWASs
and OMIM. See also Appendix B.3.
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such as impaired coordination (q= 4.83×10−8) and abnormal synaptic transmission
(q= 2.46×10−7), and diseases such as bipolar disorder (q= 8.52×10−7) and unipolar
disorder (q= 6.26× 10−5). Likewise, genes related to heart-specific enhancers are
enriched for phenotypes like abnormal cardiac muscle contractility (q= 9.05×10−16)
and diseases like cardiomyopathy (q= 5.45× 10−14). Furthermore, enrichment of
blood-related cancers (such as Hodgkin Disease, q= 1.90×10−12; T-cell Leukemia,
q= 1.41×10−5) in CH12 enhancer associated genes is consistent with the idea that
oncogenes are placed under the effect of strong enhancers during cancer development
leading to over-expression of these genes (Loven et al., 2013; Mansour et al., 2014).
On the other hand, the WEC display either an insignificant or a weak association with
phenotypes in the majority of the tissues (Appendix B.4). These findings confirm the
role of tissue-specific enhancers in active gene regulation, tissue function and disease
development.
As a validation to my above approach, i.e. examining the enrichment of mam-
malian phenotypes in enhancer associated genes, I likewise calculated its inverse, i.e.
enrichment of enhancer-associated genes in mammalian phenotypes. For this anal-
ysis, the genes associated with various mammalian phenotypes were extracted from
the MGD. The mammalian phenotypes were most notably enriched in the SEC and
TEC of phenotype related tissue-types, subsequently reproducing the previously ob-
served relationship amongst SEC and TEC with mammalian phenotypes (Fig. 4.7).
For instance, genes associated with nervous system phenotype are most enriched for
SEC and TEC in the whole brain, cortex and cerebellum. Next, I sought to exam-
ine the prevalence of enhancer associated genes in specific mouse phenotype traits.
For this purpose, mouse phenotyping data was collected from the IMPC for several
standardised phenotype procedures. Genes showing phenodeviancy for open field test
(n = 299), grip strength (n = 216), body composition (n = 206), hematology (n = 384),
acoustic startle and pre-pulse inhibition (n = 151), and heart weight (n = 76) were com-
pared to enhancer associated genes to calculate their enrichment. These phenotype
procedures and tests performed in the IMPC are described in the IMPReSS database
(https://www.mousephenotype.org/impress). Contrary to the enrichment observed using
the MGD data, no notable enrichment of enhancer associated genes is observed amongst
these specific phenotype attributes from the IMPC (Fig. 4.8). A possible explanation
for this observation could be the modest number of genes in the IMPC database at
the moment, especially compared to the MGD which comprises of gene-phenotype
associations from all genetic studies and not just gene knockouts.
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Fig. 4.7 Enrichment of enhancer-associated genes in mammalian phenotypes. Bar plots dis-
playing the enrichment of SEC and TEC amongst genes associated with mammalian phenotypes
in the MGD. The enrichment p-values and ORs were calculated using the Fisher’s exact test.
The p-values were further corrected for multiple testing (q-value) using the Benjamini-Hochberg
method.
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Fig. 4.8 Enrichment of enhancer-associated genes in IMPC phenotypic traits. Bar plots
displaying the enrichment of SEC and TEC amongst genes associated with various phenotype
procedures in the IMPC. The enrichment p-values and ORs were calculated using the Fisher’s
exact test. The p-values were further corrected for multiple testing (q-value) using the Benjamini-
Hochberg method.
Examples of enhancer-phenotype correlation
Despite no significant enrichment of enhancer associated genes within the IMPC phe-
notypes, I inspected a few genes whose phenotype data from the IMPC correlates
with the corresponding enhancer activity. In order to explain the enhancer-phenotype
relationship, I describe the epigenomic landscape of two genes in the following section.
The first example describes the relationship between enhancers and mouse pheno-
types for the gene Adenylate Cyclase 1 (Adcy1, MGI:99677). Adcy1 is a neural-specific
protein which converts ATP to cAMP (cyclic adenosine monophosphate) (Xia et al.,
1993) and has been implicated in memory, learning, synaptic plasticity and brain de-
velopment (Wang et al., 2004; Wang and Zhang, 2012). Enhancer annotations in my
dataset contains two novel SEs in the vicinity of Adcy1 in mouse cerebellum: (1)
∼2.7 kb upstream of its TSS which span 14.2 kb and contain 25 constituent enhancers,
and (2) ∼11.5 kb downstream of its TSS which spreads over 81 kb within its gene
body and is composed of 47 constituent enhancers (distance calculated from the nearest
end of the SEs) (Fig. 4.9A). The constituent enhancers forming the Adcy1 SEs are
highly cerebellum-specific and notably, Adcy1 is observed to be highly and distinctly
expressed in the mouse cerebellum (Fig. 4.9B). Interestingly, the phenotypes associ-
ated with the gene knockout of Adcy1 correlates with the enhancer annotations; the
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Fig. 4.9 Epigenomic landscape and phenotype associations of Adcy1. (A) Genome browser
snapshot of Adcy1 locus displaying enhancer profiles in various tissues and cell lines, along with
ChIP-seq binding profiles of H3K4me1, H3K4me3 and H3K27ac in the cerebellum. Enhancer
annotations: ■ tissue-specific enhancers; ■ super-enhancers. Tissues with no tissue-specific
enhancers in this genomic window are not shown. (B) Box plot showing the expression (in
RPKM) of gene Adcy1 across 22 tissues. Adcy1 is observed to be highly and specifically
expressed in the cerebellum. (C) Summary of gene-phenotype associations of Adcy1 knockout
mouse model from the IMPC. The columns show (from left to right) the mammalian phenotype
annotation assigned; name of the phenotyping test; parameter of the phenotyping test; p-value of
the statistical test performed to compare mutant mice data with the wild-type controls. (D) Box
plot comparing periphery average speed between the homozygous Adcy1 knockout mice and
the wild-type controls indicating hyperactive nature of Adcy1-/- mice. (E) Box plot comparing
whole arena resting time between the homozygous Adcy1 knockout mice and the wild-type
controls indicating abnormal behaviour of Adcy1-/- mice. For both periphery average speed and
whole arena resting time: female (F) control (WT), n = 1753; female homozygous, n = 8; male
(M) control (WT), n = 1791; male homozygous, n = 8; linear mixed-effects model was used for
the statistical test.
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Adcy1 knockout mouse line (Adcy1tm1b/tm1b) generated by the IMPC shows significant
behavioural/neurological associated phenotypes (summarised in Fig. 4.9C). For in-
stance, the Adcy1tm1b/tm1b mice exhibit a hyperactive and abnormal behaviour compared
to the wild-type controls (Fig. 4.9D-E). Moreover, recent GWAS reports identified
two moderately significant SNPs mapped to Adcy1; an intron variant (p= 9× 10−6,
rs1521470) in a schizophrenia study (Goes et al., 2015; Welter et al., 2014) and a
downstream variant (p= 5×10−7, rs116927879) in a bipolar disorder study (Douglas
et al., 2016; Le-Niculescu et al., 2009). These observations provide evidence for the
potential involvement of cerebellum-specific enhancers in Adcy1 regulation.
The second example describes the gene Ikaros family zinc finger 3 (Ikzf3). Ikzf3,
a member of the Ikaros group of zinc finger proteins, is a TF which regulates B-cell
differentiation and proliferation, and is also important for maturation of T-cells (Morgan
et al., 1997; Wang et al., 1998; Winandy et al., 1995). The mouse enhancer annotations
in my dataset show that multiple SEs associated with immune system related tissues
such as thymus, CH12 and spleen are present near and within the Ikzf3 gene (Fig.
4.10A). The impact of these enhancers is accordingly reflected in its expression pattern
as Ikzf3 is highly expressed in thymus, CH12 and spleen relative to other tissues (Fig.
4.10B). Consistent with the mouse enhancer annotations, Ikzf3 is mostly associated with
immunological disorders in human and mice. Up-regulation of Ikzf3 expression has been
related with various lymphomas. Billot et al. (2011) observed elevated promoter activity
of Ikzf3 (quantified using H3K4me3) in chronic lymphocytic leukaemia, suggesting
epigenetic modifications to play a role in its altered expression. In another investigation,
a Ikzf3 null mutation in mice caused an increase in B-cell precursors and prompted the
development of B-cell lymphomas in ageing mutants (Wang et al., 1998). Moreover,
Ikzf3 lacking mice develop phenotypes similar to systemic lupus erythematosus in
humans (Sun et al., 2003). Not surprisingly, Ikzf3 knockout mice characterised within
the IMPC also displays predominant immunological phenotypes (Fig. 4.10D-E). In
humans, several SNPs mapped to Ikzf3 in GWASs have been associated to multiple
immunological traits including systemic lupus erythematosus, inflammatory bowel
disease, asthma and rheumatoid arthritis. The majority of these SNPs are non-coding,
mostly occurring within the introns of Ikzf3. Overall, these observations demonstrate
that gene function is governed by tissue-specific enhancers. However, although genes
within the SEC and TEC show significant enrichment of tissue-related phenotypes
compared to the background, the enhancer-phenotype relationship is not observed for
all the genes. This could be attributed to methodological limitations such as limited
number of tissues in my dataset, finite knowledge about gene-phenotype associations,
potentially missed/false-positives enhancers, or other genetic and environmental factors
affecting the gene function.
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Fig. 4.10 Epigenomic landscape and phenotype associations of Ikzf3. (A) Genome browser
snapshot of Ikzf3 locus displaying enhancer profiles along with ChIP-seq binding profiles of
H3K4me1, H3K4me3 and H3K27ac. Enhancer annotations: ■ tissue-specific enhancers; ■
super-enhancers. (B) Box plot showing the expression (in RPKM) of gene Ikzf3 across 22
tissues. Ikzf3 is observed to be highly and specifically expressed in CH12, spleen and thymus.
(C) Summary of gene-phenotype associations of Ikzf3 knockout mouse model from the IMPC.
The columns show (from left to right) the mammalian phenotype annotation assigned; name of
the phenotyping test; parameter of the phenotyping test; p-value of the statistical test performed
to compare the mutant mice data with the wild-type controls. (D-E) The homozygous Ikzf3
knockout mice predominantly show immunological phenotypes like decreased lymphocyte and
white blood cell numbers. Female control (WT), n = 7; female homozygous, n = 6; male control
(WT), n = 7; male homozygous, n = 6; linear mixed-effects model was used for the statistical
test.
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Severity and breadth of phenotypes associated with enhancer target genes
Investigating the phenotypic associations of SEC and TEC showed that both classes are
significantly enriched for the corresponding tissue-related phenotypes. However, there
is a marked difference in the expression patterns of the SEC compared to TEC (section
4.2.2), which is not observed in their relationship with phenotypes. This dichotomy
was further explored by comparing the phenotyping data from knockout mouse lines of
genes in SEC and TEC across all tissues within the IMPC data. I reasoned that if SE
associated genes are predominantly related to phenotype occurrence, their associated
gene knockouts would cause a more severe phenotype condition (a phenotype with an
increased effect size) relative to knockouts of other genes (such as those associated
with TEs). I compared several standardised phenotyping procedures within the IMPC
and observed a significant difference in phenotype severity only for acoustic startle and
pre-pulse inhibition (ES=−0.63, p= 0.001) (Fig. 4.11). However, for the majority of
procedures, no significant difference in severity of phenotypes was observed between
the SEC and TEC (Open field test: ES = 0.19, p= 0.13; Grip strength: ES = 0.19,
p= 0.55; Dual Energy X-ray Absorptiometry (DEXA): ES=−0.02, p= 0.75; Heart
weight: ES = 0.16, p= 0.63; Hematology: ES = 0.16, p= 0.1) (Fig. 4.11). Next, I
sought to examine the breadth of the phenotypes associated with the SEC and TEC. For
this purpose, I computed the number of top-level phenotype ontology terms associated
with SE and TE associated gene knockouts from the IMPC (Fig. 4.12). No notable
difference was observed in the breadth of phenotypes between the SEC and TEC
(ES = 0, p = 0.42), indicating that both SE and TE associated gene knockouts are likely
to produce comparable number of phenotypes and therefore, have similar pleiotropic
effects. Furthermore, I explored the mouse essential genes by retrieving all the genes
from IMPC which generate a lethal knockout (Dickinson et al., 2016) to examine
if the SEC is enriched with lethality. There was no significant enrichment of lethal
genes amongst the SEC (p = 0.24, OR= 1.08, 95% CI [0.88, 1.30]) and TEC (p = 0.83,
OR= 0.93, 95% CI [0.79, 1.09]). Overall these results highlight that tissue- and
cell-specific relevant traits are associated with both SEC and TEC.
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Fig. 4.11 Phenotype severity of SE and TE associated gene knockouts. Violoin plots dis-
playing the percentage change (normalised effect size) in phenotype procedures measured
between enhancer associated gene knockouts and wild-type controls. The area under the violin
is proportionate to the number of data points in each category. The p-values were calculated
using the Wilcoxon Rank Sum Test.
Fig. 4.12 Breadth of phenotypes associated with SE and TE gene knockouts in the mouse.
Box plot displaying the number of top-level phenotype terms associated with SE and TE gene
knockouts in IMPC. The p-values were computed using Wilcoxon Rank Sum Test. p: p-value;
ES: effect size
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4.2.4 Protein-protein interactions amongst enhancer associated genes
Having shown that enhancer associated genes are enriched for tissue-specific traits, I
hypothesised that the proportion of these with no prior phenotypic annotations related
to the tissue maybe involved in disease-causing pathways. These genes are particularly
interesting as they might serve as novel candidates for the corresponding tissue-type
phenotypes or diseases. Most genes work together with other genes to perform their
biological function, thus forming molecular networks where the proteins encoded
by the genes interact with each other. These protein-protein interactions (PPIs) are
commonly used to examine the relationships between associated genes, based on the
well established fact that proteins interacting in a network are likely to be involved in
similar metabolic pathways, signalling pathways and cellular processes (Gonzalez and
Kann, 2012). Although PPIs are incomplete and susceptible to errors (De Las Rivas
and Fontanillo, 2010), several studies have confirmed their usefulness in discovering
novel protein function (Sharan et al., 2007) and in identifying functional modules
(Dittrich et al., 2008; Spirin and Mirny, 2003). In an event where the normal state
of a cell is altered as a result of environmental factors or a disease condition, the
PPI networks are also affected (Safari-Alighiarloo et al., 2014). Thus, highlighting
the proteins encoded by disease-causing genes in a PPI network can identify other
disease-associated risk targets for therapeutic purposes. Therefore, I investigated the
PPIs amongst enhancer-associated genes in each of the 22 tissues.
In order to examine the PPIs, I extracted the potential protein interactions from
the STRING database (Franceschini et al., 2013) with the highest confidence score
(STRING combined score > 0.9). Then in each network, I identified the genes currently
known to be associated with the corresponding tissue-type phenotypic annotations
from the MGD, while the genes with no-priori phenotypic information were labelled
as ‘novel’. For each tissue, both the known and unknown disease genes (referred to
as known and novel respectively) in the PPI network of enhancer associated genes are
observed to be connected in a remarkably dense interactome (Fig.4.13, Appendix A.8).
Interestingly, the novel genes (blue nodes) are highly connected with the phenotype-
associated genes (pink nodes), suggesting a potential functional relationship between
them. Simulating these PPI networks with random protein-coding genes show that novel
genes connect significantly more with known phenotype-associated genes, compared
to randomly added genes (p≤ 0.016, except thymus p= 0.056) (Appendix A.9). This
outcome demonstrates that enhancer associated genes are potentially engaged in the
same functional pathway as the known phenotype genes and therefore, could also
contribute to the corresponding phenotypes and ultimately disease causation.
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Fig. 4.13 PPI maps of enhancer associated genes. Networks displaying PPIs amongst en-
hancer associated genes. Nodes in each network represent enhancer associated genes and edges
represent potential PPIs. Genes associated with tissue-type relevant phenotypes are highlighted
in pink and the shape of the node displays SE and TE associated genes (squares: SEC, circles:
TEC). See also Appendix A.8 and A.9.
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4.2.5 Transcription factor binding in SEs and TEs
Enhancer regions facilitates binding sites for TFs which contribute to important tissue-
specific functions by regulating the target genes (Ong and Corces, 2011). These TFs
bind within enhancer regions and recruit additional co-factors to control the expression
of their target genes. To investigate TF binding activity within SEs and TEs, with the
aim of identifying potential key regulators in each tissue, the Makeev lab used publicly
accessible ChIP-seq data for mouse TFs. For many TFs, the information available
on their specific binding in various cell-types is rather sporadic, thus the Makeev
lab flattened all available ChIP-seq peaks for each TF into single binding profiles
referred to as‘cistrome’ (see methods 4.3.6). Next, for each cell-type, the Makeev lab
systematically identified TFs, for which cistrome peaks significantly colocalised with
their corresponding active enhancers (see methods 4.3.7).
First, we found that TFs which have significant colocalisation with enhancers in-
clude regulators known to be implicated in the corresponding tissue-specific regulation.
For example, Spi1, with cistrome peaks colocalised with bone marrow enhancers, is im-
plicated in myeloid and B-lymphoid cell development (Scott et al., 1994b); Gata4, with
cistrome peaks colocalised with heart enhancers, is involved in myocardial differentia-
tion and function (Pikkarainen et al., 2004); and Dmrt1, with cistrome peaks colocalised
with testis enhancers, plays a key role in male sex determination and differentiation
(Raymond et al., 2000). Overall, we observed cistrome peaks of 214 TFs (509 TF-tissue
pairs) to significantly colocalise with TEs (with OR > 1; corrected p-value < 10−3)
and 113 TFs (148 TF-tissue pairs) with SEs across all tissues and cell-types (Fig. 4.14
shows the top three TFs in each tissue). The 214 TFs colocalised with TEs included
all the 113 TFs identified for SEs. Second, we observed that some TFs with cistrome
peaks significantly colocalised with enhancers are expressed in a tissue-specific manner
in the corresponding tissues (Fig. 4.15A). In total, we identified 56 such TFs with
highly tissue-specific expression (τexp− f rac ≥ 0.85) and significant colocalisation with
corresponding TEs, and 29 TFs with SEs across all tissues and cell-types. Examples of
such TFs include Hnf6 in liver (τexp− f rac = 1), Nkx2-5 in heart (τexp− f rac = 1), Gata1
in MEL cells (τexp− f rac = 0.93) and Neurog2 in whole brain (τexp− f rac = 0.98).
Overall, TF cistrome peaks were identified to significantly colocalise with both SEs
and TEs, but a greater number of TFs were identified to colocalise with TEs compared
to SEs. This could be explained by the relatively large number of TEs in the genome. To
investigate this further, for each TF with significant enhancer localisation, the Makeev
lab computed their TFBS density in SEs and TEs. The TFBS density could be defined
as a measure of TFBS clustering in SEs or TEs (see methods 4.3.8). To summarise this
analysis, the Makeev lab counted the number of TF-tissue pairs which have significantly
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greater TFBS density in SEs compared to TEs, and vice-versa for TEs. Overall, we find
that SEs have more TF-tissue pairs with higher TFBS density compared to TEs (Fig.
4.15B). Altogether, this data indicates that although TEs are more often colocalised by
TF cistrome peaks, frequency and degree of TFBS clusters is higher in SEs.
Fig. 4.14 Master regulators enriched in SEs and TEs. Heatmap showing the top three
enriched TFs identified in SE and TE constituents in each tissue. The motifs associated with
the enriched TFs are shown on the right. NA is shown for TFs with motifs not present in
HOCOMOCO v11 (Vorontsov et al., 2018). The rows of the heatmap are clustered using
hierarchal clustering.
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Fig. 4.15 Transcription factor binding within SE and TE constituents. (A) Density plot
showing the distribution of TFs whose cistrome significantly colocalised with enhancer segments,
plotted against the tissue-specific expression of the TF in the corresponding tissues. (B) Bar plot
displaying the number of TF-tissue pairs which have significantly greater TFBS density in SE
compared to TEs (green bars), and vice-versa for TEs (orange bars). For each TF-tissue pair, a
Wilcoxon Rank Sum Test was used to compare its TFBS density between SEs and TEs. The TF-
tissue pairs are binned by the logarithmic significance of the difference in TFBS density between
SEs and TEs obtained from the Wilcoxon Rank Sum Test. For e.g. the first pair of bars represents
the TF-tissue pairs with a p-value of difference lying in the range 0≤−log10(p− value)< 1.
4.2.6 Combinatorial learning approach for phenotype prediction
Up until now, the analysis presented here shows that the mouse enhancer regions
are correlated to a great extent with total-expression, tissue-specific expression and
phenotypes. While PPI and gene expression data has been previously used to infer
mammalian function (Pena-Castillo et al., 2008; Tasan et al., 2008; Yuan et al., 2012), I
sought to evaluate the capability of predicting gene-phenotype associations by utilising
regulatory data predicted here such as TSREs and TF binding. I implemented the
random forest algorithm to predict gene-phenotype associations from 13 different
phenotypic domains, where each domain is relevant to at least one tissue type in my
dataset. For this approach, I extracted gene features from TSRE profiles, expression
data, TFBSs and PPI data in 22 mouse tissues (see methods 4.3.9) (features summarised
in Table 4.1). To make gene-phenotype predictions, a random forest classifier was
first trained on a subset of protein-coding genes using a combination of various gene
features as predictor variables and the top level mammalian phenotype terms from
the MGD as the response variable (true positives), while genes not associated with
a phenotype in the MGD were considered as true negatives. This model was used
to predict gene-phenotype associations in the remaining set of genes not used in the
training of the model.
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Table 4.1 Summary of the gene features used in the random forest classifier.
Data Feature Description n Symbol 
Regulatory 
elements 
Tissue-specific 
enhancer profiles 
Sum of posterior probabilities for all tissue-specific 
strong enhancers associated in each tissue 
22 
TSRE 
Tissue-specific 
promoter profiles 
Sum of posterior probabilities for all tissue-specific 
active promoters associated in each tissue 
22 
Transcription factor 
binding 
Enrichment of motifs within cistrome regions 
overlapping 500 bp upstream and 100 bp downstream of 
TSS 
297 
TF 
Protein-protein 
interactions 
(PPI) 
PPI with genes 
associated with 
enhancers 
PPI score of a gene within tissue-specific enhancer 
network 
22 
TSRE_PPI 
PPI with genes 
associated with 
promoters 
PPI score of a gene within tissue-specific promoter 
network 
22 
PPI with genes 
associated with the 
phenotype 
PPI score of a gene within a phenotype associated 
network 
1 
PPI 
Expression Expression profiles Expression of a gene in each tissue 22 Exp 
	
By integrating various features together, 10 combinations were formed, construct-
ing 10 distinct classifiers for each phenotypic domain. The predictive power of each
classifier was assessed by generating Receiver Operating Characteristic (ROC) and
precision-recall (PR) curves based on 5-fold cross validation repeated 10 times with
different seeds. The random forest classifiers trained on just the regulatory elements
(enhancers, promoters and TFs) achieved the poorest performance compared to other
models with a mean AUC-ROC (area under the ROC curve) of 0.71 and AUC-PR (area
under the PR curve) of 0.19 across all the phenotypes (Fig. 4.16A). Conversely, the
classifier trained on all the gene features combined (Exp+PPI+TSRE+TSRE_PPI+TF)
achieved the best performance with a mean AUC-ROC of 0.78 and AUC-PR of 0.27
across all the phenotype domains (Fig. 4.16A). For all phenotypes, the mean AUC-ROC
for this model exceeded 0.74 and AUC-PR ranges between 0.11 and 0.43. However,
high precision recall rate (AUC-PR > 0.35) was observed in phenotypes with a high
number of known mammalian phenotype annotation counts in the MGD (such as be-
havioural/neurological, nervous system, cardiovascular, immune and hematopoietic
system) (Fig. 4.16B), indicating that precision in predicting gene-phenotype associa-
tions is dependent on the amount of true positives used to train the classifier.
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Fig. 4.16 Evaluation of classifiers to predict gene-phenotype associations in the mouse. (A)
Bar plots comparing the predictive power of various random forest classifiers across various
phenotypes. Top panel displays the area under the curve (AUC) measured for ROC curves while
bottom panel displays AUC for PR curves. The range of y-axis has been adjusted to clearly
show the differences between the various models. Error bars denote the standard deviation.
(B) Scatter plot showing the relationship between the precision rate and the number of known
phenotype annotation counts in the MGD for each phenotype domain.
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As an example, I describe here the results of predicting gene-phenotype associations
within the nervous system domain. For nervous system phenotype, the classifier trained
on all the gene features achieved the greatest mean AUC-ROC of 0.80 and AUC-PR of
0.42 (Fig. 4.17A-B). From the cross validation results of this classifier (5-fold cross
validation repeated 10 times i.e. 50 runs in total), one can clearly observe the modelled
classifier to be robust with a low standard deviation (Fig. 4.17C-D). The PPI score
with genes known to be associated with nervous system phenotype was identified to
contribute the most in predicting nervous system gene-phenotype associations, followed
by expression data in whole brain and cortex (Fig. 4.17E). In fact, PPI data was the
most informative and the main contributor to the performance of these classifiers in all
the 13 phenotypes (Appendix A.10). The classifier trained on only expression and PPI
data also performed well (AUC-ROC = 0.79) and the predictions were comparable to
the best performing model. While the models trained solely on regulatory features had
limited predictive power, they improved the performance of models when integrated
with other features, suggesting that regulatory data are a useful addition for modelling
mammalian phenotypes.
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Fig. 4.17 Predicting genes associated with nervous system phenotype. (A) ROC and (B) PR
curves comparing the performance of 10 random forest classifiers modelled to predict genes
associated with nervous system phenotype. ROC and PR of various models was measured
by calculating the AUCs. (C) ROC and (D) PR curves displaying the cross validation results
for the best performing model (Exp+PPI+TSRE+TSRE_PPI+TF). Grey lines represent the
cross validation runs, blue lines represent the mean of the cross validation and the blue shaded
area shows the standard deviation. (E) Feature importance chart of the best performing model
showing the top 20 predictor variables important in contributing to the nervous system phenotype
predictions, as measured by the mean decrease in accuracy (x-axis) determined by the random
forest model. Exp: expression; Enh: enhancer; Prom: promoter; TF: transcription factor. See
also Appendix A.10.
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Next, I investigated the novel gene-phenotype predictions made by these classifiers.
The predictions from these classifiers were evaluated based on the current knowledge of
gene-phenotype associations. However, there may be cases where there is no, or little
prior knowledge about the function of a gene. For such cases, the predictions from the
classifier would be categorised as incorrect, but it is possible that these associations
could be novel. These cases also leads to undermining of the true predictive power
of a classification model. For such reasons, the top false-positive predictions are the
most interesting as they could provide new hypotheses about gene function. In order
to capture all the novel predictions, I trained the classifiers on all the protein-coding
genes and extracted top scoring false-positives with a prediction probability ≥ 0.90. As
an example case study, I further investigated the top novel predictions for the nervous
system phenotype. For the 76 false-positive predictions (prediction probability≥ 0.90)
identified for nervous system domain, I examined their PPIs with genes associated
with Alzheimer’s disease (AD) - which is the most enriched neurodegenerative disorder
amongst the mouse genes currently annotated with nervous system phenotype (Appendix
B.5). Out of the 76 predicted novel genes, 42 were connected to known AD genes
while 34 genes had no available PPI data. Eleven genes (Wnt3, Vip, Adcy2, Esrrg,
Htr5a, Apln, Lpar4, Pnoc, Sstr3, Htr6, Calcr) stood out in this network as they were
densely connected (≥ 10 interactions) with AD associated genes while a further 31
had at least one interaction (Fig. 4.18). Interestingly, out of these 11 highly connected
genes, 8 were associated with G-protein coupled receptor signalling pathway (Table 4.2).
Numerous previous studies have documented the role of G-protein coupled receptors
in the pathogenesis of AD (Qiu, 2017; Thathiah and De Strooper, 2011; Zhao et al.,
2016), which suggests that these novel predictions might serve as useful candidates to
investigate the AD functional pathway.
In order to systematically examine the top false-positive predictions (prediction
score≥ 0.90) from all phenotype domains, I used the Open Targets Platform (Koscielny
et al., 2017) which links potential novel genes to diseases via evidence based on genetic
associations, somatic mutations, animal models, expression, pathways, drugs and text
mining from literature. Overall, I identified that ∼75% (495/659) of the examined
false-positive predictions could be potentially associated with the corresponding disease
(Fig. 4.19) and hence, could serve as potential novel disease targets. For instance,
out of the 76 top scoring false-positives examined for nervous system phenotype, 72
are likely to be associated with nervous system disease (p= 5.00× 10−9) based on
evidence integrated from a range of data sources. Figure 4.20 displays the top 10 gene
predictions associated with the corresponding disease for various phenotype domains
and the evidence supporting their association.
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Fig. 4.18 PPI map of novel nervous system phenotype predictions with AD associated
genes. Nodes in the network represent genes and edges represent PPIs obtained from STRING.
Yellow nodes represent genes known to be associated with AD, while blue nodes display
potential novel genes predicted to be associated with nervous system phenotype by the random
forest classifier. Grey edges represent PPIs between two known AD associated genes or two
novel predicted genes, while PPIs between a known AD gene and a novel gene are highlighted
in blue.
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Table 4.2 GO enrichment analysis of 11 novel nervous system phenotype predictions iden-
tified to be densely connected with AD associated genes.
Term name Term id Domain Query 
size 
Overlap 
size 
Corrected 
P-value 
Genes 
G-protein coupled 
receptor signalling 
pathway, coupled to 
cyclic nucleotide second 
messenger 
GO:0007187 BP 11 4 9.47E-04 Vip, Calcr, Htr5a, Sstr3 
signal transduction GO:0007165 BP 11 11 1.69E-03 Wnt3, Vip, Adcy2, Calcr, 
Esrrg, Htr6, Apln, Htr5a, 
Sstr3, Pnoc, Lpar4 
G-protein coupled 
receptor signalling 
pathway 
GO:0007186 BP 11 8 2.83E-03 Vip, Calcr, Htr6, Apln, 
Htr5a, Sstr3, Pnoc, Lpar4 
signalling GO:0023052 BP 11 11 3.47E-03 Wnt3, Vip, Adcy2, Calcr, 
Esrrg, Htr6, Apln, Htr5a, 
Sstr3, Pnoc, Lpar4 
cell communication GO:0007154 BP 11 11 3.81E-03 Wnt3, Vip, Adcy2, Calcr, 
Esrrg, Htr6, Apln, Htr5a, 
Sstr3, Pnoc, Lpar4 
cellular response to 
stimulus 
GO:0051716 BP 11 11 1.33E-02 Wnt3, Vip, Adcy2, Calcr, 
Esrrg, Htr6, Apln, Htr5a, 
Sstr3, Pnoc, Lpar4 
cAMP-mediated 
signalling 
GO:0019933 BP 11 3 1.64E-02 Vip, Calcr, Htr5a 
cyclic-nucleotide-
mediated signalling 
GO:0019935 BP 11 3 2.26E-02 Vip, Calcr, Htr5a 
cAMP biosynthetic 
process 
GO:0006171 BP 11 3 3.54E-02 Vip, Adcy2, Calcr 
 
Fig. 4.19 Evaluation of the top scoring false-positives from random forest classifiers. Bar
plot displaying the number of genes in each phenotype domain with potential association to the
corresponding disease.
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Fig. 4.20 Top scoring novel gene predictions. Heatmap displaying the top 10 gene predictions
in various phenotype domains along with the evidence source for their potential association to
the corresponding disease. The Open Targets Platform was used to link the novel predictions to
diseases using integrated genome-wide public datasets.
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4.3 Methods
4.3.1 Datasets
For investigating the expression of enhancer associated genes, RNA-seq data for all
22 tissues and cell lines was collected from ENCODE as read alignments (BAM files).
Data for cell lines CH12 and Es-E14 was collected from Standford/Yale lab while rest
of the data was retrieved from LICR lab. From the BAM files, the read counts over
all genes (mm9, ensembl v67) were quantified using HTSeq (Anders et al., 2015) and
expression of each gene was calculated in RPKM in each tissue/cell line. A mean
RPKM value was calculated for multiple biological replicates from ENCODE.
4.3.2 Associating TSREs to potential target genes
GREAT (McLean et al., 2010) was used to associate tissue-specific regulatory elements
to potential target genes in each tissue. In cases where GREAT predicted multiple
target genes for a particular TSRE, the gene nearer to the TSRE was selected as
the primary predicted target for all further downstream analysis. GREAT was run
using default parameters on mm9 assembly and the whole genome was selected for
control background regions. To examine the consistency of predicted enhancer-gene
assignments with other datasets, they were compared to previously reported TADs
(Dixon et al., 2012) and EPUs (Shen et al., 2012) in the mouse genome. The enhancer-
gene pairs across the 22 tissues were merged together for this comparison. The TADs
(in mESCs and cortex) were compared to the enhancer-gene pairs to examine if the
enhancer-gene pair overlaps the same TAD. Only the cases where both the enhancer and
its associated gene overlapped a TAD were used. This analysis identified 96.62% and
93.57% of enhancer-gene pairs to be in the same TAD annotated in cortex and mESCs
respectively. A similar comparison was done with EPUs which revealed 87.23% of
predicted enhancer-gene pairs to be in the same EPU.
4.3.3 Expression analysis of enhancer associated genes
To examine the relationship between enhancers and expression of their target genes, data
from all 22 tissues was combined into gene-tissue pairs and grouped into three classes
based on their enhancer association: (1) gene-tissue pairs associated with SEs (SEC), (2)
gene-tissue pairs associated with TEs (TEC), and (3) gene-tissue pairs associated with
weak enhancers (WEC). In order to quantify tissue-specific expression of target genes,
I calculated the tissue-specificity index of each gene using the Tau method described
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earlier in chapter three (section 3.3.4). A matrix of expression values was constructed
with dimensions t × s, where t is the total number of genes and s is the number of
tissues/cell lines. Genes not expressed in any tissue were deleted from the matrix
leaving genes expressed in at least one tissue. The RPKM values were log2 transformed
and quantile normalised (using the normalize.quantiles function in preprocessCore R
package) to allow easier comparison of gene expression across tissues. Genes were
then sorted by ascending quantile normalised values and divided into deciles of equal
density and placed into 10 bins. The lowest decile (lowest 10% of genes by QN value)
was placed in bin 1, the next lowest was placed in bin 2, and so on until the top 10% of
quantile normalised values were placed in bin 10. The Tau value (τexp) for each gene
was calculated as:
τexp =
∑Ni=1(1− yˆi)
N−1 ; yˆi =
yi
max(yi)
(4.1)
where N is the total number of tissues, yˆi is the normalised expression bin profile
component of the gene in tissue i. In order to associate τexp values to tissues, the Tau-
fraction (represented as τexp− f rac) for each gene in every tissue was calculated as
τexp×yi
M ,
where yi is the expression of the gene in tissue i and M is the maximum expression of
the gene across all the tissues. Genes with τexp− f rac ≥ 0.85 were categorised as having
high tissue-specific expression in the corresponding tissue (Kryuchkova-Mostacci and
Robinson-Rechavi, 2017; Yanai et al., 2005). Housekeeping genes were identified
based on a strict τexp threshold. Genes with low τexp score (≤ 0.20) are uniformly
expressed across all the tissues and were considered to be ‘housekeeping’ genes. A total
of 1,252 housekeeping genes were identified using this threshold out of which 1,171
were protein-coding genes.
To visualise the distinct number of enhancer tissue-types calculated for each
enhancer-associated gene (Fig. 4.5B), binary matrices for SEC and TEC in 22 tis-
sues were generated such that the rows in the matrix represent enhancer associated
genes and column represent different tissues. A value of ‘1’ or ‘0’ was assigned to
the cells in the matrix depending on if the gene was identified to be associated with
the enhancer of that tissue or not respectively. The heatmaps in Figure 4.5B were first
sorted on number of tissue-type associations of genes and then sorted by the order of
tissues across the columns.
4.3.4 GO, mammalian phenotype and disease enrichment analysis
To investigate the molecular functions and biological processes linked with enhancer
associated genes, I combined the SE and TE associated genes across the 22 tissues
to make two unique list. This resulted in 3,617 genes to be associated with only SEs
and 11,437 genes to be associated with only TEs. These gene sets were then used
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for GO enrichment analysis using the ToppGene suite (Chen et al., 2009) (Appendix
B.1, B.2). The enrichment of mammalian phenotypes and human diseases in SEC and
TEC was calculated individually in each tissue using the ToppFun tool in ToppGene
suite. Fisher’s exact test was used for calculating the enrichment of housekeeping
genes amongst the SEC and TEC. For background, the total number of protein-coding
genes in the genome was used. The SEC was observed to be significantly depleted for
housekeeping genes (155/3,617; p = 0.012, OR = 0.82), while the TEC was enriched
(686/11,437; p= 2.7×10−11, OR = 1.49).
The enrichment of enhancer associated genes in mammalian phenotypes was com-
puted using gene-phenotype associations in the MGD, collected on 14th June 2017. The
total number of genes associated with a phenotype in the MGD (16,494) were used as
the background in this case. For enrichment using the IMPC data, all the statistically sig-
nificant genotype-phenotype associations and their phenotyping data for IMPC release
version 5.0 were collected from the IMPC website. This compromised of phenotype
data for 3,323 gene knockouts, with 2,900 genes significantly associated with at least
one phenotype attribute (p≤ 10−4). The IMPC consists of data from various standard-
ised phenotype procedures whose protocols are described in the IMPReSS database
(https://www.mousephenotype.org/impress). For each phenotype procedure, the total
number of genes tested for that particular procedure were used as the background for
calculating enrichments. To quantify the severity of phenotypes, I used the percentage
change value from each procedure. The percentage change is the normalised effect size,
which is scaled to make it comparable across various procedures and parameters (Kur-
batova et al., 2015). The percentage change between SE and TE associated genes was
compared for several standardised phenotyping procedures. All the parameters within a
procedure were grouped together for this analysis. For computing the enrichment of
mouse essential genes in the SEC and TEC, genes producing a lethal knockout (960
genes out of 2,900) were used.
4.3.5 Protein-protein interaction maps
The predicted PPIs amongst the genes of interest were extracted from the STRING
database (Franceschini et al., 2013) using the R package STRINGdb. A score threshold
of 900 was implemented to extract potential interactions with the highest confidence
and reduce false-positives. The interaction maps were visualised as networks using
the iGraph package in R. The known gene-phenotype associations (from MGD) in
the network were labelled ‘known’ while the remaining genes were marked ‘novel’.
A permutation test was performed to identify if the observed number of interactions
between known and novel genes are more than what one would expect by random. I
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added randomly selected protein-coding genes equal to the number of genes known
to be associated with phenotypes in the network and extracted their interactions from
STRING. The number of interactions (edges) between randomly added genes and
known phenotype genes were then counted. This was repeated 1,000 times to produce a
distribution of expected number of edges and the p-value was calculated as p = y/N,
where y is number of permuted random-known edges greater than the observed novel-
known edges and N is the total number of items in the distribution (i.e. 1,000).
4.3.6 Cistrome data
For the analysis of TFBSs colocalised with different enhancer sets, the Makeev lab
used a cell-type independent cistrome, the general genomic map of regions bound
by particular TFs in any cell-type (Vorontsov et al., 2018). The cistrome is based
on uniformly reprocessed ChIP-seq data from the GTRD database (Yevshin et al.,
2018) across all the cell-types and conditions. The cistrome regions were classified
into four reproducibility categories (A,B,C,D): A - regions supported by ChIP-seq
data from two different experimental data sets (at least one was accompanied by
control data) and different ChIP-seq peak calling tools; B - regions supported by peak
calls from two different experimental data sets (at least one was accompanied by
control data); C - regions supported by peak calls from a single experimental data set
with control data and different peak calling tools; D - all other reproducible regions
(supported by more than one peak). A and B categories were taken into the analysis
by default. For TFs with a limited number of ChIP-seq data sets, the Makeev lab
added regions from C and D categories when it was necessary to get at least 100
peaks. As an additional filter for cistrome, the Makeev lab used TF binding motifs
from HOCOMOCO (Vorontsov et al., 2018) to annotate motif occurrences in cistrome
regions with SPRY-SARUS (Kulakovskiy et al., 2016) using the default motif p-value
threshold of 5×10−4 (Kulakovskiy et al., 2013) and then discarded cistrome segments
without motif occurrences.
4.3.7 Enrichment of TFBSs in SEs and TEs
To calculate the enrichment of TF binding within SE and TE constituents, the Makeev
lab first merged the neighbouring constituent enhancers within 400 bp into prolonged
extended enhancer segments in each tissue. These extended enhancer segments were
then used to generate the control regions; more precisely, for each enhancer segment of
length L, the Makeev lab located two segments (enhancer shades) of length L, one at
100×L upstream and the other at 100×L downstream. This produced a set of control
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segments of the same lengths and similar global genomic context as the enhancer
segment under study. The Makeev lab checked if any control segments overlapped
other constituent enhancers, but such cases contributed only 1-2% of the total number
of control regions and were safely ignored. The extended enhancer segments and
control regions were then intersected with the cistrome peaks of each TF and split
into two groups; overlapping (if least 1 bp overlapped) and non-overlapping with the
cistrome. The Fisher’s exact test on 2× 2 contingency tables was used to assess the
statistical significance of TF cistrome peaks overlapping constituent enhancers (SE or
TE) versus control regions. The resulting p-values were corrected for multiple testing
using Bonferroni correction. Note that the cistrome segments of a TF can significantly
colocalise with enhancers in several different cell-types, therefore, the Makeev lab
counted the number of significant enrichments as TF-tissue pairs. The Makeev lab
also performed the analysis with only the cistrome segments that contain high scoring
motif hits from HOCOMOCO. The results were very similar to the analysis where all
cistrome segments were considered; about 10% of TFs did not have known binding
motifs, and for TFs with known motifs, about 90% of significant TF-tissue pairs were
independent from whether the motifs were considered or not.
4.3.8 TFBS density analysis
To calculate the TFBS density of each TF, the Makeev lab intersected each enhancer
with the TF cistrome peaks. Within these overlapping regions, the Makeev lab predicted
the binding motif occurrences of the corresponding TF using HOCOMOCO-v11 motifs.
In cases where HOCOMOCO contained multiple motif models for a single TF, all
motifs were used and the binding sites exceeding the cistrome p-value threshold of
0.0005 were retained. Density was calculated as the total genomic coverage of motifs
(in bp) divided by the total coverage of enhancer-cistrome intersection (in bp). The
Makeev lab calculated densities for only those enhancers (constituent enhancers of SEs
or TEs) which had at least one motif occurrence in its intersection with the cistrome.
The Wilcoxon Rank Sum Test was then used to compare the TFBS densities of TF-tissue
pairs in SEs and TEs (each TF-tissue pair was compared individually between SEs and
TEs). The non-corrected p-values were used to order the TF-tissue pairs by their level
of TFBS density disparity between SEs and TEs. The TF-tissue pairs were grouped into
bins based on their p-value and the number of TF-tissue cases where its TFBS density
was more in SEs compared to TEs, or vice versa, were counted (Fig. 4.15B).
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4.3.9 Predicting gene-phenotype associations
To predict mammalian gene-phenotype associations, features were extracted from
TSREs, expression, TF binding and PPI data for all protein-coding genes. From the
TSRE profiles across 22 tissues, strong-enhancers and active promoters associated
with each protein-coding gene were extracted. A score representing the tissue-specific
enhancers and promoters in each tissue was computed as Sgt =∑Ni=1(P), where Sgt is the
score of gene g in tissue t; N is the total number of strong enhancers or active promoters
associated with the gene g; and Pi is the posterior probability of the associated strong
enhancer or active promoter emitted by the ChromHMM model. The RPKM values
for each gene quantified using ENCODE’s RNA-seq data in 22 tissues were used as a
feature for expression data.
The feature for TF binding associated with each gene was calculated by the Makeev
lab. They first selected all cistrome regions overlapping −500 bp and +100 bp of TSSs
(for each gene, all transcripts from gencode vM15 were considered). Then, the Makeev
lab calculated the −log10(p-value) of HOCOMOCO motif hits within these cistrome
regions (aggregating over all motifs if there were multiple models for a particular TFBS).
The respective values for each TF were taken as the TFBS features. The final set of the
TFBS features covered all TFs for which we had the ChIP-seq cistrome peaks and a
binding motif model (n = 297).
For PPIs, all the protein interactions in mouse were collected from STRING database
version 10.5. For a gene g, its PPI connectivity with all strong enhancer and active
promoter associated genes in tissue t was calculated as PPIgt = ∑Ni=1(I), where N is
the total number of enhancer or promoter associated genes in tissue t and Ii is the
combined interaction score between gene g and ith gene. Similarly for each gene, its
PPI connectivity with all genes known to be associated with the phenotype domain to
be predicted was computed as PPIg−phen = ∑Mi=1(I), where Ii is the interaction score
and M is the total number of known phenotype associated genes from the MGD.
The random forest classifier was implemented in R using randomForest and caret
package (Kuhn, 2008). I sought to predict gene-phenotype associations from 13 different
phenotypes relevant to at least one tissue type in my dataset. The known gene-phenotype
associations from the MGD (top level MP annotations) served as true-positives for the
classifier models. The random forest classifier was trained on a subset of genes, where
features described above were used as predictor variables and phenotype calls from
the MGD as the response variable. This model was used to predict gene-phenotype
associations in the remaining set of genes not used in the training of the model. The
preProcess function in caret was used to centre and scale all the gene features. Down-
sampling was employed on the training data to avoid the impact of class imbalance on
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model fitting. Model optimisation across these parameters was performed using k-fold
cross validation technique, to choose the model with the best ROC (parameters used:
method = ‘repeatedcv’, number = 5, repeats = 5, metric = ‘ROC’). In order to compare
the predictive capability of various gene features, 10 different models with different
gene feature combinations were built for each phenotype domain (130 models in total).
Each of these classifier was assessed by generating ROC and PR curves based on 5-fold
cross validation repeated 10 times. For each cross validation run, the true-positive rate
(TPR, also called the sensitivity), false-positive rate (FPR) and precision were calculated
as follows:
T PR =
T P
T P+FN
FPR =
FP
FP+T N
precision =
T P
T P+FP
(4.2)
where TP, FP, TN and FN represents the number of true-positives, false-positives,
true-negatives and false-negatives respectively. The cross validation results were then
averaged for comparison and reporting purposes. The ROC and PR curves along with
their area under the curve were computed using the ROCR and PRROC R packages. The
top false positives hits (prediction probability ≥ 0.90) from each model were examined
using OpenTarget validation platform to validate the novel predictions from the random
forest classifier.
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4.4 Discussion
Regulatory elements have been identified in a plethora of cell-types and tissues, however
there is limited understanding about their relationship to overall gene function and
the resulting disease or phenotype. To gain insights into the mammalian regulatory
landscape and its potential impact on phenotypic outcome, I focused the analysis
on tissue-specific enhancers. By generating a catalogue of super, typical and weak
enhancers in multiple mouse tissues, I systematically investigated their roles in gene
function. From multiple aspects such as gene expression, PPI networks and phenotypes,
this study provides evidence that SE and TE associated genes share common phenotypic
outcomes even though their expression profiles and overall numbers in the genome
differ.
A major challenge in the functional characterisation of enhancers is to identify
the enhancer target genes. Identifying genes regulated by specific enhancers is not
straightforward as an enhancer can often control multiple genes, while in some cases
the target gene could be several Mbs away and therefore, not the nearest gene. In this
chapter, GREAT was used to associate SEs and TEs to their potential target genes,
which do so by computationally defining a ‘regulatory domain’ for each gene and links
a regulatory region to genes within the same domain. GREAT has been widely used
in the past to computationally assign TF bound peaks (Benton et al., 2019; Diéguez-
Hurtado et al., 2019; Hsu et al., 2019; Nacht et al., 2019) and enhancer associated
regions (Hashimoto et al., 2019; Istaces et al., 2019; Li, Kvon, et al., 2019; Li, Yang,
et al., 2019; Stone et al., 2019; Zhu et al., 2019) to their potential target genes in
various tissues and cell lines. Based on findings in previous chromatin interaction
studies, this approach would incorrectly predict or disregard target genes in many cases.
Despite of false-positives, analysis based on enrichment or common patterns have
shown genome-wide GREAT results to be accurate enough to capture and visualise
significant functional patterns associated with the non-coding regions. However, a better
alternative to this method would be an integrated approach using Hi-C data to more
accurately link enhancers to their target genes. This would also remove noise from the
data for subsequent downstream analysis.
SEs have been previously reported to drive high total-expression and regulate tissue-
specific expression (Adam et al., 2015; Hnisz et al., 2013; Liu and Lefebvre, 2015;
Loven et al., 2013; Siersbæk et al., 2014; Vahedi et al., 2015; Whyte et al., 2013),
while TEs have been considered less important regardless of their huge numbers in
the genome. To get a more profound understanding of enhancer regulation, the tissue-
specific enhancers were classified into SEs (24%) and TEs (76%). Although, SEs
constitute approximately a quarter of the total tissue-specific enhancer pool, the SEC
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have higher total- and tissue-specific expression compared to other enhancer classes,
and the current study extends this association across multiple mouse tissues (Fig. 4.3).
Further detailed analysis of tissue-specific expression revealed that while only a fraction
(16%) of SEC could be associated with high tissue-specific expression, this was at least
4 times larger than the fraction of genes within TEC (4%) and WEC (3%). However,
due to large number of TEs in the genome, TEC contribution towards all levels of
tissue-specific expression is substantially more compared to the SEC. This shows that
tissue-specific gene regulation is not confined to SEs, and TEs are also involved in
tuning the gene expression landscape.
SEs are comprised of dense enhancer clusters spanning large genomic regions
and have been shown to be associated with master TFs and other key cell identity
genes (Hnisz et al., 2013; Whyte et al., 2013). It was observed that compared to TEs,
SEs consists of a large number of constituent enhancers, however, the mechanistic
mode of action of these individual constituent enhancers is not well understood. It
remains unclear whether the constituent enhancers exert an additive or a more complex
cooperative effect on target gene expression. Using these genome-wide enhancer maps,
I sought to predict the effect of constituent enhancer density on a gene’s total- and tissue-
specific expression at a genome-wide scale. This data shows that globally, total- and
tissue-specific expression levels are weakly correlated with the number of constituent
enhancers. The constituent enhancer density explains a small fraction of the variation
in gene expression (total-expression: r2 = 0.01; tissue-specific expression: r2 = 0.03),
indicating that there may exist a complex rather than a linear additive relationship
between constituent enhancers and target gene expression (Fig. 4.4). Not all constituent
enhancers appear to contribute to the transcriptional output with the same strength,
suggesting some constituent enhancers may make small contributions therefore helping
to fine tune the expression patterns of their associated gene. This prediction is consistent
with previous in vivo experiments showing deletion of individual constituent enhancers
within a SE leads to variable amount of reduction in target gene mRNA levels (Shin et al.,
2016; Suzuki et al., 2017). The SE constituents have also been identified to have frequent
chromatin interactions amongst themselves (Dowen et al., 2014), suggesting these
constituent enhancers may have an effect on one another’s contribution towards the target
gene transcriptional activity. However, it cannot be precisely extrapolated from this
computational analysis that the non-additive relationship between constituent enhancers
and gene expression is a result of only cooperative activity between them. Therefore, the
possibility that some constituent enhancers may be inactive/false-positives or may have
a redundant function in transcriptional activation cannot be ruled out (Moorthy et al.,
2017). These redundant enhancers termed as ‘shadow enhancers’ in Drosophila, have
been shown to be critical for phenotypic robustness under conditions of environmental
or genetic disturbance, and proposed as a mechanism to gain new regulatory functions
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during evolution without disturbing the existing robust regulatory networks (Cannavo
et al., 2016; Frankel et al., 2010; Hong et al., 2008).
The majority (78%) of SEC was also observed to be associated with one enhancer
tissue-type compared to only 27% in TEC, suggesting genes in SEC are likely to be
associated with SEs of only one tissue (Fig. 4.5). The number of distinct enhancer
tissue-types associated with a gene influences its expression across multiple tissues.
Genes associated with a low number of enhancer tissue-types have a tendency to be
expressed in a tissue-specific manner, while genes associated with a high number of
enhancer tissue-types have a relatively low tissue-specific expression. Altogether, the
large number of constituent enhancers and an association with a low number of enhancer
tissue-types could possibly explain the up-regulated total- and tissue-specific expression
in the SEC.
Prior research has thoroughly investigated the role of SEs in complex traits, showing
that disease-causing SNPs are more enriched in SEs of disease-relevant cell-types
(Farh et al., 2015; Hnisz et al., 2013; Parker et al., 2013). However, little research has
been conducted to systematically examine the effect of SEs and TEs on diseases. In
this chapter, I investigated the mammalian phenotype and disease associations of SE
and TE associated genes. Both the SEC and TEC were detected to be significantly
enriched in phenotypes and diseases in the corresponding tissue-types, emphasising that
phenotypes are governed by tissue-specific enhancers. Using phenotyping data from
knockout mouse lines of enhancer associated genes, I showed that there is no significant
difference in severity and breadth of phenotypes produced from knockouts of SEC and
TEC (Fig. 4.11 and 4.12), which highlights the importance of both enhancer classes in
disease causation. In addition, no difference in enrichment of mouse essential genes was
identified amongst SEC and TEC. Overall, I did not find any significant contrast between
the potential phenotypic impact of SEC and TEC, suggesting that functional testing
of all enhancers irrespective of categories is fundamental in making any conclusions
about their functional significance and phenotypic impact. Although the majority of key
cell identity genes and TFs are associated with SEs, the ‘peripheral’ genes associated
with TEs appear to equally contribute towards disease aetiology. A possible explanation
to this surprising result is the existence of an ‘omnigenic’ architecture (Boyle et al.,
2017) where regulatory networks are densely inter-related such that TE associated
genes expressed in disease-relevant cell-types can collectively impact the regulation
of key cell identity genes. To this end, I hypothesised that tissue-specific enhancer
associated genes are components of protein complexes involved in aberrant disease-
causing biochemical processes and could be potential therapeutic targets. The PPI
analysis shows that enhancer associated genes with no prior corresponding tissue-type
phenotypic associations preferentially interact with known phenotype-associated genes.
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This observation suggests that these enhancer associated genes are potentially involved
in the same functional pathway as the known phenotype genes and could serve as novel
targets for diseases.
Finally, using a machine learning approach, I systematically evaluated the capability
of TSREs and other molecular properties to predict gene-phenotype associations in
the mouse (Fig. 4.16). By comparing classifiers trained on different gene features, the
classifier with all the gene features combined was found to perform the best in predicting
gene-phenotype associations. This analysis also revealed that PPI data have a high
predictive capacity to infer mammalian gene-phenotype associations, while regulatory
data provides a modest but additive source of information. Further examination of the
top scoring false-positive predictions showed their promising application in generating
hypothesis about gene function and in identification of potential novel disease targets.
Such prediction models can assist in prioritising genes in mouse knockout and genome
editing studies. They could also help in selecting the most relevant phenotyping pro-
cedures (which often involves costly assays) for transgenic mouse models. It should
be noted that the gene features computed from various datasets for the current random
forest implementation are not exhaustive. Other genomic and molecular features that
could be added to the prediction model includes gene structure information (such as
gene length, transcript count, exon count, intron size, UTR length, GC content), splicing
information, isoform expression, tissue-specific expression, genetic variation, distance
of regulatory element from gene, and protein expression. It would be interesting to
see whether incorporating these gene features could improve the classifier’s perfor-
mance. Another limiting factor contributing to the poor performance in predicting some
phenotype domains (such as adipose tissue phenotype) is the low number of known
phenotype associations to serve as true positives in the classifier training phase. To
predict genes associated with such phenotypes appears to be relatively difficult with the
current number of annotations, but the accuracy of such models would improve as the
number of known annotations increases in future.
In summary, the findings in a diverse range of mouse tissues from this chapter present
opportunities for molecular experiments to investigate regulatory mechanisms in mouse
models of human diseases. Further in vivo studies are required to more thoroughly
understand the impact of enhancers on gene expression. Ideally, one would disrupt all
the enhancer loci individually and examine its effect on their target gene expression.
This would be extremely time consuming given the large number of enhancers in the
mouse genome, but with the swift advancement in genome editing techniques, a large
proportion of these potential enhancers might be characterised in the near future.
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Assessing the role of Zfhx3 as a
circadian regulator in the SCN
In this chapter, I describe the RNA-seq and ChIP-seq analysis of a novel mouse model
Short Circuit (Sci) with a circadian phenotype caused by a mutation in the Zfhx3 gene.
During this project, I worked closely with the neurobehavioral genetics group (Nolan
lab) at the MRCHI. The transcriptome analysis of Sci described here has been published
in the following article:
Parsons, M. J., M. Brancaccio, S. Sethi, E. S. Maywood, et al. (2015). “The Regulatory
Factor ZFHX3 Modifies Circadian Function in SCN via an AT Motif-Driven Axis”. In:
Cell 162.3, pp. 607-621. ISSN: 0092-8674. DOI: 10.1016/j.cell.2015.06.060.
5.1 Introduction
The neurobehavioral genetics group at the MRCHI focuses on understanding the genet-
ics of mammalian behaviour and circadian rhythms, where they use mouse models to
investigate genes that regulate our inner body clock. Circadian (from the latin words
circa and diem, meaning ‘about a day’) rhythms are 24 hour cycles of internal molecular
clocks that influence mammalian physiology and behaviour. Many important functions
at the molecular and behavioural level can be influenced by circadian rhythms such
as food intake, metabolism, body temperature, DNA repair mechanisms and sleep
cycles. Abnormal circadian rhythms have been associated with many disorders like
obesity, neurodegenerative and mood disorders, depression, insomnia, and high risk
of breast cancer and metabolic diseases (Bass and Lazar, 2016). These rhythms are
controlled by molecular clocks which are present in most cells, further regulated by
a ‘master clock’ located in the suprachiasmatic nucleus (SCN) (Ralph et al., 1990).
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The master clock in the SCN receives light signals from retina and synchronises the
molecular clocks to the external environment and to each other. This process involves an
interconnected network of TFs, genes and regulatory motifs such as the E-box, D-box
and Rev-erbα/ROR-binding elements (RREs) (Ukai and Ueda, 2010).
The core circadian gene network in mammals consists of two transcriptional-
translational feedback loops (TTFLs) (reviewed in Partch et al. (2014)) (Fig. 5.1).
The TTFL comprises of four important clock proteins: Clock and Bmal1 acting as acti-
vators; and Per and Cry acting as repressors. Clock and Bmal1 activate the transcription
of Per and Cry genes (along with other clock genes) via the E-box motif. Per and
Cry protein products in turn translocate to the nucleus and interact with Clock:Bmal1
complex to negatively regulate them, hence restraining their own further activation. As
Per and Cry proteins get degraded, the restriction on Clock:Bmal1 is inactivated and
the cycle starts again. The casein kinases (CKI) determines the rate at which Per and
Cry are degraded and enter the nucleus. This positive and negative loop is connected
to another TTFL comprising of a clock gene called Rev-erbα . Similar to Per and Cry
genes, Rev-erbα is also activated by Clock and Bmal1 complex via the E-box motif in
its promoter. Interestingly, Rev-erbα protein in turn acts as a transcriptional repressor
for Bmal1 by binding retinoic acid-related orphan receptor response elements (ROREs)
in Bmal1 promoters. Hence, due to Bmal1 involvement in activation of Rev-erbα ,
Bmal1 indirectly plays a role in repressing its own transcription. The presence of such
interlocking TTFLs creates a stable circadian model against environmental changes
and also provides a mechanism to create phase delays in the activation of circadian
genes to suit the gene expression requirement according to the local physiology. These
TTFLs organise the molecular clocks in individual cells, but within the SCN, the cells
are synchronised through intercellular coupling regulated by neuropeptides such as
vasoactive intestinal peptide (Vip) (Aton et al., 2005) and gastrin-releasing peptide
(Grp) (Brown et al., 2005). Furthermore, other peptides like neuromedin S (Nms) and
prokineticin 2 (Prok2) have been identified to be important for circadian signalling
between the SCN and other parts of the brain (Lee et al., 2015; Prosser et al., 2007).
In the recent years, circadian rhythms research has benefited from various gene
discovery approaches, including ENU mutagenesis screens to identify novel genes
involved in the regulation of mammalian circadian circuit. This approach involves
treating the mice with ENU, a chemical mutagen which causes random point mutations
in the genome, and then screening the offspring for phenotypes (Nolan et al., 2000).
From the ENU mutagenesis screen of circadian phenotypes at the MRCHI, the Nolan lab
identified a mouse model in the G1 animals displaying a dominant shortened circadian
period (TDD = 23.0± 0.05 hr; TDD: behavioural circadian period of the animals in
constant darkness) as compared to the population mean (TDD = 23.6±0.08 hr) (Fig.
152
5.1 Introduction
Fig. 5.1 A schematic illustration of the mammalian core circadian clock. A diagram dis-
playing the transcriptional-translational feedback loops (TTFLs) in the mammalian circadian
gene network. P: Per, Cr: Cry, B: Bmal1, C: Clock, Rα: Rev-erbα , LRE: light-responsive
elements in the Per promoters. Grey diamonds display phosphorylation. Figure taken from
Lowrey and Takahashi (2004).
5.2A-B). Using positional candidate analysis, the observed phenotype was associated
to the genomic location between 107.67 Mb and 110.57 Mb on mouse chromosome
8 comprising of 25 genes. The coding regions of all these genes were scanned for
mutations using Sanger sequencing, which detected a point mutation in zinc-finger
homeobox 3 (Zfhx3) gene. The mutation was identified in exon 9 of Zfhx3, substituting
a phenylalanine to valine in a highly conserved region. This mutation was named as
Short Circuit (Sci).
Zfhx3 (also known as Atbf1 because of its property to bind AT rich motif) is a
large TF comprising of multiple zinc finger and homeodomains, known to be involved
in multiple biological functions (Yasuda et al., 1994). Zfhx3 controls neuronal and
myogenic differentiation, acts as a tumour suppressor in some cancers, and its knockout
in mice leads to developmental defects (Berry et al., 2001; Jung et al., 2005; Kaspar et
al., 1999; Sun et al., 2012). Moreover, Zfhx3 expression is found to be highly enriched in
the adult SCN (Lein et al., 2007). The homozygous Sci mutation caused lethality during
embryonic development, hence only heterozygous adult animals (Zfhx3Sci/+) could be
further investigated. The Nolan lab performed qPCR to examine the mRNA expression
of the core circadian genes across the light-dark cycle in the SCN, which revealed no
significant differences between the Zfhx3Sci/+ and Zfhx3+/+ animals (Fig. 5.2C). This
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Fig. 5.2 Overview of the short circuit (Sci) phenotype. (A) Actograms displaying the wheel
running activity in Zfhx3Sci/+ and Zfhx3+/+ mice. The mice were kept on a light-dark (LD)
cycle for 7 days, followed by 2 weeks in constant darkness (DD). Yellow shaded area shows
the duration when lights were on. (B) Bar plot displaying the free running period length of
Zfhx3Sci/+ and Zfhx3+/+ mice in constant darkness (n = 6) (* denotes p = 0.0009). (C) mRNA
expression of the core circadian genes in the SCN of Zfhx3Sci/+ (grey lines) and Zfhx3+/+ (black
lines) at six time points (n = 4, p > 0.2, ANOVA). Figure taken from Parsons et al. (2015).
suggested that the Sci phenotype is potentially caused by an altered Zfhx3-dependent
pathway rather than a TTFL-dependent effect. To understand how the Sci mutation
in the Zfhx3 disrupts the SCN circadian period, the transcriptome was sequenced to
analyse the gene expression levels between the Zfhx3Sci/+ and Zfhx3+/+ mice at two
circadian time points: Zeitgeber Time (ZT) 3 and 15 (ZT is a standard 24 hour notation
of the circadian cycle in which ZT=0 represents start of the day or the light phase, and
ZT=12 represents start of the night or the dark phase). The Nolan lab further performed
a ChIP-seq of the TF Zfhx3 at ZT3 and ZT15, to study its genome-wide binding patterns
and determine its associated functional pathways in the SCN. In this study, I describe
the transcriptome analysis of the mice exhibiting abnormal circadian cycles to identify
the impact of the Zfhx3Sci mutation on the transcriptional targets of Zfhx3. I further
investigate the regulatory networks and the mechanism potentially contributing to the
Sci phenotype by predicting molecular complexes in the Zfhx3 transcriptional network.
Finally, I map the in vivo binding of Zfhx3 in the SCN to inspect its binding affinity
between two circadian time points and identify its DNA binding motif. The results from
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this study provide evidence of a novel role of Zfhx3 in maintaining circadian oscillations
via a network of neuropeptides in the SCN.
5.2 Results
5.2.1 Effect of Zfhx3Sci mutation on gene expression
In order to examine the expression changes in Zfhx3Sci/+ animals and identify the
transcriptional targets of Zfhx3, RNA from the SCN tissue of mutant (Zfhx3Sci/+) and
wild type (Zfhx3+/+) mice was sequenced at ZT3 and ZT15 (n = 3). For RNA-seq
analysis, I developed a pipeline integrating multiple statistical methods to identify
differential expression between wild type and mutant mice. In brief, the pipeline aligns
RNA-seq reads to the genome and identifies differentially expressed genes using three
methods namely EdgeR (Robinson et al., 2010), DESeq (Anders and Huber, 2010)
and Cufflinks (Trapnell et al., 2012). A further filtering criteria was employed (log2
fold change >±1, q < 0.05 in at least two methods) to capture highly significant gene
expression changes. This approach detected 28 genes to be differentially expressed at
least at one time point (Fig. 5.3A). Of these 28 genes, 19 were differentially expressed
at ZT3 and 13 at ZT15 (Fig. 5.3B), while 4 genes were altered at both time points. Most
of the differentially expressed genes (17/28) were down-regulated in the Zfhx3Sci/+ mice.
Interestingly, the down-regulated genes included a number of neuropeptides and their
receptors (such as Vip, Vipr2, Avp and Prokr2) previously known to be associated with
circadian rhythms (Reghunandanan and Reghunandanan, 2006) (Fig. 5.3C). However,
no significant difference in the expression of core clock genes (such as Per1, Per2, Cry1
and Cry2) was observed.
Previous work identified that Zfhx3 regulates genes via an AT rich motif (Yasuda
et al., 1994). Therefore, I examined whether genes affected by the Zfhx3Sci/+ mutation
contains the AT motif sequence in their promoter region. Other well known circadian
related motifs such as the E-box, D-box and RRE were also included in this analysis
(Fig. 5.4). The core promoter regions (450 bp upstream and 50 bp downstream of TSSs)
of all differentially expressed genes (q < 0.05 in at least one analysis method, n = 168)
were searched for the presence of these motif sequences using Pscan (Zambelli et al.,
2009). This approach identified 39% (66/168) of the differentially expressed genes to
contain a predicted AT motif (Pscan score > 0.88), while the circadian motifs E-box,
D-box and RRE were absent (Fig. 5.4).
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Fig. 5.3 SCN genes differentially expressed between Zfhx3Sci/+ and Zfhx3+/+. (A) Venn dia-
grams displaying the number of differentially expressed genes (q < 0.05, log2 fold change >±1)
detected by each method. (B) Heatmaps showing the expression change in genes identified
to be differentially expressed by at least two analysis methods. The columns in the heatmap
show gene expression in wild type (wt) and mutant mice (mut) across different replicates. (C)
Box plots displaying decreased expression of neuropeptides in the mutant mice (‘***’ denotes
q < 0.001, ‘**’ denotes q < 0.01, ‘*’ denotes q < 0.05; wt: Zfhx3+/+; mut: Zfhx3Sci/+).
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Fig. 5.4 Motif enrichment in differentially expressed genes associated with Zfhx3Sci/+ mu-
tation. Left panel: positional weight matrix (PWM) logos of motifs used in the analysis. Right
panel: box plot displaying the Pscan scores of each motif for the promoter regions of differen-
tially expressed genes. Pscan calculates a score for each predicted motif site which represents
the sequence similarity between the motif sequence and the genomic sequence at that site. Red
line represents the threshold for Pscan score used here.
5.2.2 Dissecting functionally distinct modules in Zfhx3Sci/+ network
In order to investigate the functional pathways affected in Zfhx3Sci/+ mice, I examined
the protein-protein interactions (PPIs) amongst differentially expressed genes (q < 0.05
in at least one analysis method, n = 168) associated with the Zfhx3Sci/+ mutation using
STRING. This revealed 69 (out of 168) genes to have at least one PPI (Fig. 5.5). To
identify any potential functional modules in this protein interaction map, I applied a
graphical clustering method called MCODE (Molecular Complex Detection) (Bader
and Hogue, 2003), which identifies densely linked regions in a network by clustering
the nodes on the basis of their interconnectivity. These clusters could correspond
to functional complexes in a network. MCODE characterised the network into four
modules, with module 1 (comprising of 21 genes) attaining the highest connectivity
score of 10.1, followed by module 2 (comprising of 10 genes) with a score of 5.5, and
module 3 (comprising of 6 genes) and 4 (comprising of 10 genes) with a score of < 2.
GO enrichment analysis revealed these modules to be involved in distinct biological
functions; module 1 comprised of genes associated with neuropeptide signalling ac-
tivity (corrected p = 1.4×10−13) (Fig. 5.6A), module 2 comprised of genes related to
ribosome function (corrected p = 8.6×10−7) (Fig. 5.6B), module 4 contained genes
associated with cholesterol homeostasis (corrected p = 5.7× 10−3) (Appendix B.6),
whereas no GO terms were identified to be significantly enriched in module 3.
Interestingly, the majority of genes (15/21) in module 1 had decreased expression in
Zfhx3Sci/+ mice, including that of neuropeptides and their receptors like Avp, Vip, Vipr2,
Prok2, Prokr2, Grp and Nms. The neuropeptides Vip and Grp have been previously
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AT motif
ZT3
ZT15
Both
Module 1
Module 2
Module 3
Module 4
Up regulated
Down regulated
Fig. 5.5 PPI map of differentially expressed genes in Zfhx3Sci/+ mice. A PPI network
amongst genes detected to be differentially expressed in Zfhx3Sci/+ compared to Zfhx3+/+.
The nodes in the network represent genes while edges represent PPIs. The shape of the node
depicts the time point at which the gene was identified to be differentially expressed, while the
node size represents the corresponding gene expression fold change. Genes predicted to have an
AT motif sequence in their promoters are coloured in orange. The clusters represent functional
modules in the network identified by MCODE.
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Fig. 5.6 GO enrichment analysis of functional modules in the Zfhx3Sci/+ network. Bar plots
displaying the over-represented GO terms amongst genes in (A) module 1 and (B) module 2.
Down-regulated and up-regulated represents genes with decreased and increased expression in
Zfhx3Sci/+ mice respectively.
demonstrated to be involved in the regulation of firing of the SCN neurons (Aton et al.,
2005; Brown et al., 2005). The decrease in the mRNA expression of Vip and Grp
in the Zfhx3Sci/+ SCN was experimentally confirmed by qPCR (Appendix A.11A).
Furthermore, 6 out of the 15 down-regulated genes in module 1 had a predicted AT
motif binding site in their promoter regions (Pscan score > 0.88, Fig. 5.5), while the
circadian related E-box, D-box and RRE motifs were absent. These genes included
the down-regulated neuropeptides Vip, Avp and Prok2. To experimentally validate the
binding of Zfhx3 to the promoters of Avp and Vip, the Nolan lab performed a quantitative
ChIP in the SCN tissue from Zfhx3+/+ mice. Both Avp and Vip showed significantly
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higher immunoprecipitated DNA compared to the Gapdh control promoter region
(Appendix A.11B). These results suggest that Zfhx3 directly regulates the circadian
related neuropeptide network via the AT motif. Contrary to module 1, all the genes
in module 2 had significantly increased expression in Zfhx3Sci/+ compared to Zfhx3+/+
(Fig. 5.5). The majority of genes in module 2 are linked to ribosomal function (Fig.
5.6B) indicating that Zfhx3 may also be involved in the regulation of ribosomal proteins.
Overall, the Zfhx3Sci/+ mutation appears to cause a decrease in the ability of Zfhx3 to
activate transcription of circadian related neuropeptides via the AT motif, leading to the
Sci phenotype. To test this hypothesis, the Nolan lab cloned the AT motif into the pGL3-
Enhancer Luciferase Reporter Vector and co-transfected it with an expression vector
containing recombinant Zfhx3, with or without the Sci mutation in HEK293 cells. The
Zfhx3+ was observed to exhibit higher activation compared to the empty vector, whereas
Zfhx3Sci activation was equal to the empty vector (Appendix A.11C). This suggests that
Zfhx3Sci has a diminished ability to activate transcription via the AT motif. Furthermore,
the Nolan lab also cloned module 1 gene promoters into the pGL3-Enhancer Luciferase
Reporter Vector. Three types of genes were selected from module 1 for this experiment:
(1) with strong predicted AT motif (Avp, Vip; Pscan score > 0.88); (2) with moderate
predicted AT motif (Grp, Prokr2; Pscan score > 0.80); and (3) without the AT motif
(Drd1a, Vipr2; Pscan score < 0.80). These reporters were then co-transfected with
Zfhx3Sci or Zfhx3+ expression vectors (Appendix A.11D). Reporters containing the
strong predicted AT motif exhibited increased activation compared to the empty vector
for both Zfhx3Sci or Zfhx3+ over-expression, but activation by Zfhx3+ was significantly
higher than that of Zfhx3Sci. For reporters containing the moderate predicted AT motif,
Zfhx3+ showed increased activation of Prokr2, but not with Grp, while reporters without
the predicted AT motif did not show any notable activation. Moreover, to investigate
whether Zfhx3 driven transcription is dependent on the AT motif, the Nolan lab mutated
three conserved residues (residues 6, 8, and 10) within Avp and Vip promoter constructs.
The reporters with mutated AT motif showed significantly lower ability of transcriptional
activation (Appendix A.11E). These findings further convey the important role of the
AT motif in Zfhx3+ activation.
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5.2.3 Investigating the Zfhx3 regulome in the SCN
TFs function by binding to DNA within regulatory regions such as enhancers and
invoking mechanisms to activate or repress their target gene expression. Identification
of genome-wide localisation of TFs can help to unveil the molecular mechanisms
underlying their regulatory function and identify specific TF interactions. Therefore,
in order to further study the regulatory network of Zfhx3 in the SCN, ChIP-seq was
used to identify in vivo genome-wide binding of Zfhx3. The ChIP-seq experiment was
performed using the SCN from Zfhx3+/+ mice at ZT3 and ZT15 time points (n = 1). The
ChIP-seq analysis (see methods 5.3.4) identified 27,438 and 27,178 significant peaks
at ZT3 and ZT15 respectively (q < 0.01). Genomic view of few of the Zfhx3 ChIP-seq
peaks identified in the SCN are shown in Fig. 5.7. The average ChIP-seq signal across
all the significant peaks shows that Zfhx3 have similar ChIP-seq intensity and binding
profile at ZT3 and ZT15 (Fig. 5.8A-B). Comparing the Zfhx3 peaks with genomic
features revealed that the majority (∼61%) of Zfhx3 binding in the SCN occurs at
promoters (within≤ 1 kb of TSSs), followed by ∼15% in distal intergenic regions and
∼9% within 1-3 kb upstream of TSSs (Fig. 5.8C). This shows that Zfhx3 preferentially
binds to promoter regions. Next, I examined what fraction of the Zfhx3 binding in
the SCN occurs within active promoters and strong enhancer annotations (identified
using ChromHMM in chapter three) in different brain regions; cerebellum, cortex and
whole brain. Overall, ∼59% of the total genome covered by Zfhx3 peaks in the SCN
overlaps with active promoters in the cerebellum, cortex or whole brain (permutation
test, p < 10−3). Whereas only 2.4%, 3.6% and 4.35% overlaps with strong enhancers in
the cerebellum, cortex and whole brain respectively. A detailed comparison between the
number of Zfhx3 peaks, and active promoters and strong enhancers in different tissues
is shown in Fig. 5.8D-E.
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Fig. 5.7 Genomic view of Zfhx3 ChIP-seq peaks in the SCN. Genome browser snapshots of
Zfhx3 ChIP-seq binding profile. The tracks displayed are input normalised ChIP-seq signal of
Zfhx3 peaks in the SCN at ZT3 and ZT15.
Next, I associated the top 1,000 Zfhx3 bound ChIP-seq peaks at ZT3 and ZT15
with their potential gene targets using GREAT (McLean et al., 2010). This resulted
in 977 and 986 potential Zfhx3 gene targets at ZT3 and ZT15 respectively. In order
to examine the functional roles of these genes in the SCN, GO enrichment analysis
was performed. For this purpose, the target genes identified at both time points were
combined resulting in 1,216 unique genes. The GO enrichment analysis show that
these genes are involved in biological processes such as cellular metabolic process
(corrected p = 10−53), intracellular receptor signalling pathway (corrected p = 10−2),
neuron fate commitment (corrected p = 10−2); and molecular functions such as nucleic
acid binding (corrected p = 10−55), transcription regulator activity (corrected p = 10−16)
and structural constituent of ribosome (corrected p = 10−2) (Fig. 5.9). Interestingly, GO
terms enriched amongst these genes such as receptor signalling pathway and structural
constituent of ribosome, were also enriched amongst differentially expressed genes
associated with the Zfhx3Sci mutation.
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Fig. 5.8 Overview of Zfhx3 binding profile in the SCN. (A) Heatmaps showing the binding
intensity of Zfhx3 over TSSs and the surrounding 3 kb region. (B) Comparison of average
ChIP-seq density profile of Zfhx3 between ZT3 and ZT15. (C) Distribution of Zfhx3 binding in
the SCN with respect to known genomic features. (D-E) Upset plots displaying the intersection
of Zfhx3 peaks in the SCN with active promoter and strong enhancer regions in the cerebellum,
cortex and whole brain.
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Fig. 5.9 GO enrichment analysis of genes associated with Zfhx3 ChIP-seq peaks. Bar plots
displaying the significantly over-represented GO terms amongst genes associated with the top
1,000 Zfhx3 ChIP-seq peaks at ZT3 and ZT15. The gradient colour of the bars show the log
transformed corrected p-values associated with the GO terms. BP: biological processes; MF:
molecular function.
5.2.4 Differential Zfhx3 binding between ZT3 and ZT15
TF binding patterns and their gene regulatory networks are dynamic. Interactions
between various TFs and their gene targets along with external signals causes the gene
expression landscape to change with respect to time (Swift and Coruzzi, 2017). Due to
this reason, it is important to study the binding and function of TFs across different time
points, specially in the SCN where many circadian regulators oscillate in 24 hour cycles.
Therefore, to identify any significant transient events in Zfhx3 binding, I analysed its
binding patterns between ZT3 and ZT15. Comparing the genomic coordinates of Zfhx3
binding peaks between ZT3 and ZT15 revealed that ∼85% (23,453) of the peaks (at
q < 0.01) are common (with at least 1 bp overlap), with ∼74% (20,319) of the ZT3
peaks covering at least 50% of the genomic area within ZT15 peaks. In order to identify
Zfhx3 binding sites with significantly different binding affinity between ZT3 and ZT15,
I compared the ChIP-seq signal at their respective peak regions. However, this analysis
identified no significant differentially bound regions between ZT3 and ZT15 (p < 0.05,
log2 fold change >±1) (Fig. 5.10). Despite no Zfhx3 peaks attaining a statistically
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significant p-value (p < 0.05), 82 peaks (associated with 74 genes) were detected to
be differentially bound with a log2 fold change >±1. Using GO enrichment analysis,
I examined whether these 74 genes associated with differentially bound peaks have
common biological processes in the SCN. However, no GO terms were significantly
enriched amongst these genes (q < 0.05). These results indicate that Zfhx3 binding
affinity is similar between ZT3 and ZT15 in the SCN.
Fig. 5.10 Differential binding analysis of Zfhx3 activity between ZT3 and ZT15. (A) Venn
diagram displaying the overlap between the genomic coordinates of Zfhx3 peaks (at q < 0.01)
at ZT3 and ZT15. (B) Volcano plot displaying the p-values and fold changes obtained from
differential binding analysis of Zfhx3 peaks between ZT3 and ZT15.
5.2.5 Identifying Zfhx3 binding motif in the SCN
TFs comprise of one or more DNA binding domains which recognise a small set of
specific DNA sequences (called a motif) and then bind to it. Motifs can aid in the
study of protein structure of the TF, and in the identification of co-expressed genes
and co-regulators involved in the same functional pathway. Most importantly, since
the majority of the functional binding sites of a TF should contain its consensus motif,
the motifs can help to accurately predict the true-positive binding peaks in a ChIP-seq
experiment (Maurano et al., 2012). To identify the DNA motif sequence recognised
and bound by Zfhx3 protein in the SCN, Zfhx3 binding peaks were analysed to detect
over-represented motif sequences within it. For this analysis, the top 1,000 peaks (based
on q-value) from each time point were used. Additionally, I sought to examine whether
Zfhx3 motif binding patterns are similar in promoter and enhancer regions. In order to
do this, Zfhx3 peaks were classified into two groups; peaks binding within 2 kb upstream
and 200 bp downstream of a known TSS were considered to be occurring in promoter
regions, whereas the remaining peaks were considered to be within enhancer regions.
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This resulted in∼64% of the peaks to be classified within promoter regions at both time
points. The top 1,000 peaks (based on q-value) within promoter and enhancer regions
were then analysed for motif enrichment (see methods 5.3.5).
The motif analysis identified three distinct motifs significantly enriched at both
time points (Table 5.1). The binding site of zinc finger protein ZBTB33 (also known
as Kaiso) was the most significantly enriched motif (M1: E-value ≤ 1.2×10−600) in
Zfhx3 bound peaks in the SCN, followed by Thap11 (M2: E-value ≤ 4.4×10−217) and
CTCF (M3: E-value ≤ 2.3×10−16). ZBTB33 and Thap11 motifs were only enriched
in peaks within promoters as opposed to CTCF, which was only enriched in peaks
within enhancers. Indeed, previous studies have identified ZBTB33 to bind highly active
promoters (Blattler et al., 2013), while CTCF and Thap11 motifs are commonly found
to be significantly enriched within ChIP-seq peaks of various TFs (Worsley Hunt and
Wasserman, 2014). However, the de novo motif enrichment analysis did not identify the
AT rich consensus binding site of Zfhx3 in the ChIP-seq peaks. The highly enriched
ZBTB33 motif is significantly different to the known Zfhx3 canonical motifs (Fig. 5.11).
This could be attributed to the following scenarios: first, Zfhx3 primarily functions
via indirect binding to the DNA (tethered binding); second, the motifs identified to be
enriched (M1, M2 and M3) may be involved in cooperative or competitive binding with
Zfhx3; or third, the ChIP experiment was unsuccessful to identify Zfhx3 bound regions
(Whitington et al., 2011). Therefore, I further investigated these possibilities and also
examined the quality of these motifs.
Fig. 5.11 Comparison of ZBTB33 motif with previously known Zfhx3 binding motif mod-
els. (A) Alignment of ZBTB33 motif with AT rich Zfhx3 binding site identified by Parsons et al.
(2015). (B) Alignment of ZBTB33 motif with AT rich Zfhx3 binding site from HOCOMOCO
database. P-value: probability of a same length random motif with equal or better alignment;
RC: reverse compliment.
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First, I examined the centrality of the enriched motifs with respect to Zfhx3 binding
peaks. Previous studies have shown that in a successful ChIP-seq experiment, the
canonical motif of the ChIP-ed TF is enriched near the centre of the defined TF binding
peaks (Bailey and Machanick, 2012). For this purpose, I analysed the distance of
the enriched motifs (M1, M2 and M3) with respect to the summit of the peaks using
CentriMo (Bailey and Machanick, 2012). In addition to the enriched motifs, the
consensus AT motif of Zfhx3 (from Parsons et al. (2015)) was also analysed. At both
time points, the AT motif showed low enrichment and was not centrally enriched
(CentriMo corrected p = 1) (Fig. 5.12). On the other hand, ZBTB33 was very centrally
enriched with its highest number of motif sites at the centre of the peaks (CentriMo
corrected p < 10−104). This could indicate two potential scenarios: (1) Zfhx3 binds
to ZBTB33, which in turn binds to the DNA (indirect binding); or (2) a non-specific
antibody pull down in ChIP-seq. Both possibilities could result in very few peaks with
the consensus AT motif. Binding between Zfhx3 and ZBTB33 could be a consequence
of PPI, however, no evidence of genetic or physical interactions between Zfhx3 and
ZBTB33 was detected in BioGRID (Stark et al., 2006) and STRING database. On
the other hand, Thap11 and CTCF motifs were enriched broadly across the peaks
with some enrichment around the peak centres (Thap11 CentriMo corrected p = 10−11;
CTCF CentriMo corrected p < 10−5), which could indicate co-binding activity with
Zfhx3. However, no evidence of known interactions between Zfhx3 and Thap11, or
Zfhx3 and CTCF, was identified in the literature or databases. Overall, these results
suggests that either Zfhx3 binds indirectly to DNA via ZBTB33, or the ChIP-seq data
also contains regions from potential non-specific interactions.
Fig. 5.12 Distribution of motif sites with respect to Zfhx3 binding peak summits. Distri-
bution plots displaying the number of best scoring motif sites as a function of their relative
distance from the summit of the peaks. The density curves were averaged over bins of 20 bp.
p: probability that any tested region would be as enriched for best matches to the motif as the
reported region; w: width of the most enriched central region; grey shaded area shows ±50 bp
region surrounding the peak summit.
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Second, I investigated the presence of co-binding between ZBTB33 (M1), Thap11
(M2) and CTCF (M3) motifs. The motifs occurring within the same ChIP-seq peaks
could potentially be indulged in co-binding. To examine this, I compared the bind-
ing sites of M1, M2 and M3 in the top 1,000 peaks at ZT3 and ZT15 (Fig. 5.13).
Overall, the majority (∼60%) of peaks across both the time points were specific to
individual motifs (M1: 28%; M2: 20%; M3:12%), while only ∼18% of the peaks
showed co-occurrence between the three motifs (M1+M2+M3: 1.4%; M1+M2: 6.5%;
M2+M3: 5.3%; M1+M3: 4.9%) (fraction of peaks were averaged between ZT3 and
ZT15). Interestingly, CTCF has been previously shown to co-localise and interact with
ZBTB33 (Defossez et al., 2005), which provides evidence for the co-localisation of
M1 and M2 motifs. However, no evidence of genetic or physical interactions between
Thap11 and ZBTB33, or Thap11 and CTCF were detected in BioGRID and STRING
database. Moreover, of the top 1,000 peaks, M1 was detected in only ∼41% of the
peaks, while ∼22% of the peaks did not contain any of the top enriched motifs. This
shows that the enriched motifs cover only a limited fraction of the top scoring peaks
and should be further validated for their prevalence in the remaining peaks.
Fig. 5.13 Analysing co-binding between motifs enriched in Zfhx3 binding peaks. Upper
panel: venn-diagrams comparing Zfhx3 binding peaks associated with different enriched motifs.
Lower panel: bar plot displaying the fraction of top 1,000 peaks that are specific and common
between the enriched motifs.
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Third, I performed a computational validation on the enriched motifs using in-
dependent positive control peak sets not used in the motif discovery (training). For
each motif, ROC curves were generated which display the motif recognition quality
in the positive control sequences compared to random sequences of similar nucleotide
composition (see methods 5.3.6). The motifs were validated in three different sets of
positive sequences independent from training: (1) top 1,000 peaks not used in training;
(2) top 1,000 promoter associated peaks (≤2 kb from a TSS) not used in training; and
(3) top 1,000 enhancer associated peaks (> 2 kb from a TSS) not used in training. Since
the enriched motifs were present in only a small fraction of the training peaks (as shown
earlier), the motifs were also examined in the training sequence set i.e. the top 1,000
peaks which were used for motif discovery.
Overall, all the motifs performed very poorly, even in the training dataset (Fig.
5.14). Thap11 (M2) was moderately enriched only in the top∼200 peaks of the training
dataset (AUC≤ 0.61) and showed poor enrichment in the independent control peaks
(AUC≤ 0.56). Likewise, CTCF (M3) was only enriched in enhancer control peaks
(AUC < 0.66), whereas AT motif did not show enrichment in any of the validation
peaks (AUC≤ 0.48). Surprisingly, ZBTB33 (M1), the most enriched motif identified in
the motif discovery analysis, was moderately enriched in the top ∼400 training peaks
(AUC≤ 0.60), but performed the worst in all the other independent positive control
sets (AUC < 0.39). Previous studies have shown ZBTB33 to bind unmethylated regions
associated with highly active promoters (Blattler et al., 2013), which may explain its
enrichment only in the top 500 peaks. Indeed, highly active promoters are known to
produce false-positives peaks in ChIP-seq experiments (Jain et al., 2015). In order
to inspect if Zfhx3 peaks are associated with highly active promoters, I examined the
expression of Zfhx3 peaks associated genes in the SCN, which revealed that genes
associated with Zfhx3 peaks are likely to be highly expressed compared to genes not
associated with the peaks (Fig. 5.15). This suggests that ZBTB33 motif is likely to be an
artefact, perhaps arising from non-specific antibody interactions or poor input control
in the ChIP-seq experiment.
Collectively, these results indicate that the enriched motifs (ZBTB33, Thap11 and
CTCF) do not follow a common pattern of enrichment throughout the peaks and hence,
do not represent a ‘genuine’ set of binding sites for Zfhx3. The motif discovery tool
(MEME-ChIP) was sensitive enough to identify motifs enriched in only a fraction of
peaks, but these motifs did not validate when tested against independent positive control
peaks. Furthermore, the consensus Zfhx3 AT motif is not enriched in the peaks which
could indicate potential non-specific interaction pull-down, or the Zfhx3 is involved in
non-specific binding mediated by a repertoire of different TFs, though it is very hard to
distinguish between these scenarios without any additional data.
170
5.2 Results
Fig. 5.14 Computational validation assessing the recognition quality of enriched motifs.
ROC curves for significantly enriched motifs M1, M2 and M3, along with the AT motif. The
curves compare the performance of the motifs in the (A) training dataset and (B-D) different
positive control sequences independent of motif discovery. Larger area under the curve represents
better motif quality.
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Fig. 5.15 Expression of Zfhx3 ChIP-seq peaks associated genes in the SCN. Box plots
displaying the expression of genes associated with and without Zfhx3 binding peaks in the SCN.
Expression is represented as log2(RPKM+1).
5.2.6 Comparing Zfhx3 binding with Zfhx3Sci/+ transcriptional tar-
gets
Finally, I sought to examine the Zfhx3 ChIP-seq peaks within the differentially expressed
genes associated with the Zfhx3Sci/+ mutation. For this purpose, all the significant ChIP-
seq peaks (q < 0.01) at ZT3 and ZT15 were associated to potential target genes and
combined together into one list, which resulted in 14,222 unique genes. These genes
were then compared to the differentially expressed genes associated with the Zfhx3Sci/+
mutation (q < 0.05), which revealed that 72% (121/168) of Zfhx3Sci/+ transcriptional
targets are associated with Zfhx3 ChIP-seq peaks (Fisher’s exact test, p = 0.012, OR
= 1.54, CI = [1.09, 2.20]) (Fig. 5.16). Of these genes, 54 were identified to be
down-regulated and 67 to be up-regulated in the Zfhx3Sci/+ mice. Furthermore, half
of the differentially expressed genes identified in module 1 (11/21) of the Zfhx3Sci/+
transcriptional network are associated with Zfhx3 binding peaks (Fisher’s exact test,
p = 0.37, OR = 0.67, CI = [0.25, 1.73]). These genes include neuropeptide Prok2 and
its receptor Prokr2, which are involved in circadian intercellular signalling. However,
no Zfhx3 peaks are associated with the neuropeptides Vip and Avp. Additionally, all
the genes defined in module 2 of the Zfhx3Sci/+ transcriptional network (10/10) are
associated with Zfhx3 binding peaks (Fisher’s exact test, p = 0.016, OR = Inf, CI = [1.34,
Inf]).
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Fig. 5.16 Comparison of Zfhx3 ChIP-seq associated genes with Zfhx3Sci/+ transcriptional
targets. Venn diagram displaying the unique and shared genes associated with Zfhx3 ChIP-seq
peaks and differentially expressed genes in the Zfhx3Sci/+ mice.
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5.3 Methods
5.3.1 Analysis of RNA-seq data
A workflow of the RNA-seq data processing is displayed in Fig. 5.17. The RNA-seq
reads were aligned to the mouse genome (mm10) using TopHat (Trapnell et al., 2012).
The read counts aligning over each gene were quantified using HTSeq (Anders et al.,
2015). The raw read counts in each sample were used to calculate RPKM for each
gene. The differentially expressed genes between the Zfhx3+/+ and Zfhx3Sci/+ mice
were identified using three softwares: EdgeR (Robinson et al., 2010), DESeq (Anders
and Huber, 2010) and Cufflinks (Trapnell et al., 2012), default parameters were used for
all of them. Genes with a q-value (p-value after multiple testing correction) > 0.05 and
log2 fold change <±1 were filtered out. Genes identified to be differentially expressed
by at least two methods were used for populating the heatmap in Fig. 5.3.
Replicate	1 Replicate	2Replicate	1Replicate	2
Wild	Type Mutant
Align	reads	to	the	genome
Count	Reads	/	Calculate	expression	for	each	gene
Raw	Reads
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Tophat
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DESeq Cufflinks EdgeR
Fig. 5.17 Overview of the RNA-seq pipeline. A schematic representation displaying the
processing of RNA-seq data.
5.3.2 PPI and GO enrichment analysis of RNA-seq data
Genes identified to be significantly differentially expressed (q < 0.05) between Zfhx3+/+
and Zfhx3Sci/+ in at least 1 analysis tool were used for network analysis (n = 168). PPIs
were obtained from the STRING database (Franceschini et al., 2013) and visualised in
Cytoscape (Shannon et al., 2003). The MCODE algorithm (Bader and Hogue, 2003)
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was used to identify densely connected clusters in the PPI network. The MCODE
algorithm is implemented as a Cytoscape plugin. The GO enrichment of genes in each
module was performed using g:Profiler (Reimand et al., 2007). The over-represented
GO terms were corrected for multiple testing by g:Profiler and terms with q-value < 0.05
were considered significant.
5.3.3 Analysis of AT and other circadian related motifs
Previous studies have identified multiple genes which are directly regulated by Zfhx3,
such as Afp, Mrf4, Muc5ac, Pit1 (Berry et al., 2001; Mori et al., 2007; Qi et al., 2008).
Parsons et al. (2015) analysed the promoter sequences of these genes to construct a
consensus Zfhx3 binding AT motif using a phylogenetic shadowing based approach.
The promoter sequences of these genes were aligned and searched for conserved regions.
Using the multiple sequence alignments from UCSC, the AT motif was identified to be
conserved across both primates and mammals. The consensus AT motif sequence was
built using a mixture model by expectation maximisation (Bailey and Elkan, 1994b).
This consensus AT motif was searched in the promoter sequences (450 bp upstream and
50 bp downstream of TSSs) of differentially expressed genes using Pscan (Zambelli
et al., 2009) (threshold used: Pscan score > 0.88). Likewise, Pscan was used to identify
potential occurrences of the circadian related E-box, D-box and RRE motifs.
5.3.4 Processing of Zfhx3 ChIP-seq data
The ChIP-seq tags for ZT3 and ZT15, along with that of input control were aligned
to the mouse genome version mm10. The ChIP-seq peaks were called using MACS
(Model-based Analysis of ChIP-Seq) (Zhang et al., 2008) at a threshold of q < 0.01. This
identified 27,438 and 27,178 significant peaks at ZT3 and ZT15 respectively. In order to
examine what fraction of Zfhx3 binding in the SCN occurs within active promoters and
strong enhancer annotations, the genomic coordinates of these functional segments were
compared using BEDTools. The overlap fraction was calculated as: number of base
pairs in Zfhx3 peaks intersecting active promoter or strong enhancer regions, divided by
the total genomic coverage of Zfhx3 peaks in base pairs. The resulting fraction value was
then converted into a percentage. To examine if this overlap was significant compared to
what one would expect from independent datasets, a permutation test was performed. In
each permutation, the genomic coordinates of active promoter/strong enhancer elements
(reference data set) were shuffled to random locations (n = 1,000) preserving the length,
chromosome information and the number of elements. The empirical p-value was
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calculated as the number of permutations with the overlap fraction greater than the
observed overlap fraction, divided by the total number of permutations.
In order to investigate the functional role of Zfhx3 in the SCN, the top 1,000 ChIP-
seq peaks at ZT3 and ZT15 were associated to potential target genes using GREAT. In
cases where GREAT predicted multiple target genes for a particular Zfhx3 binding peak,
the gene nearer to the peak was selected as the primary predicted target. GREAT was
run using default parameters on mm10 assembly and the whole genome was selected
for control background regions. This approach identified 977 and 986 potential Zfhx3
gene targets at ZT3 and ZT15 respectively. These gene lists were combined together
resulting in 1,216 unique genes. To examine the functional associations of these genes,
GO enrichment analysis was performed using g:Profiler. Moderate filtering within
g:Profiler was applied on significant GO terms (corrected p-value < 0.05) to obtain the
best GO term per parent.
In order to detect changes in the binding affinity of Zfhx3 binding between ZT3 and
ZT15, differential binding analysis was performed using DiffBind (Ross-Innes et al.,
2012). A threshold of p < 0.05 and fold change >±2 was applied to the results, which
detected no significant differentially bound peaks between ZT3 and ZT15.
5.3.5 Motif analysis of Zfhx3 ChIP-seq peaks
To identify the Zfhx3 binding motif and other enriched motifs within the ChIP-seq
peaks, MEME-ChIP (Machanick and Bailey, 2011) was used to conduct a de novo motif
analysis. Only the top 1,000 peaks (based on q-value) were used for this analysis, as
the top scoring peaks tend to have the highest binding affinity and the least background
noise. For each peak, genomic sequence within ±250 bp from the summit of the
peak was extracted. MEME-ChIP first detects the enriched motif sequences amongst
the set of ChIP-seq peaks and then matches them to previously known motif models.
Additionally, I examined the pattern of enriched motifs in peaks within promoter regions
and enhancer (distal) regions. For this purpose, the Zfhx3 peaks were classified into
either promoter or enhancer associated on the basis of the following rule: peaks binding
within 2 kb upstream and 200 bp downstream of a known TSS were considered to be
promoter associated, while the remaining peaks (> 2 kb upstream, > 200 bp downstream)
were considered to be enhancer associated. This resulted in 17,673 and 17,505 promoter
associated peaks at ZT3 and ZT15 respectively (∼64% at both time points). The
top 1,000 peaks (based on q-value) within promoter and enhancer regions were then
analysed for motif enrichment.
Next, the PWM models of the top enriched motifs were used as input for FIMO
(Grant et al., 2011) to identify the potential motif sites in the top 1,000 peaks at ZT3
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and ZT15. Only the motif matches attaining a FIMO p-value< 10−4 were considered,
where the p-value represents the probability of a random sequence of the same length
as the motif matching that position of the sequence with as good as or a better score.
To examine the co-binding between the enriched motifs, the genomic locations of each
motif derived from FIMO were mapped to the peaks. The peak IDs were then compared
between the enriched motifs to identify potential motif sites occurring within the same
peaks. The location of the motifs were further analysed with respect to the summit
of the peaks using CentriMo (Bailey and Machanick, 2012). The consensus AT motif
identified by Parsons et al. (2015) was also analysed in a similar way.
5.3.6 Assessing the recognition quality of the enriched motifs
To examine the authenticity of the enriched motifs, a computational validation of the
motif models (PWMs) was performed using the strategy described in (Kulakovskiy
et al., 2013). In addition to the enriched motifs, the AT motif was also analysed to
examine whether it is enriched in the validation sequence set. Each PWM was first
validated on the training set (sequences/peaks used for motif discovery) itself, and then
using independent positive control sequences not used in the motif discovery process.
For true-positive cases, peaks from the positive set with at least one PWM match scoring
equal or better than the threshold were used.
For each PWM, the positive control sequences were sorted based on their decreasing
PWM match scores. This decreasing set of PWM scores were considered as PWM
threshold values, where each threshold corresponded to a true-positive rate value. Next,
for each PWM threshold, the likelihood Ps of identifying at least one PWM match with
an equal or better score than threshold, in a random double-stranded DNA segment of
length L. The length of the sequences in the positive control set was used as L (i.e. 500).
For a motif of length l, Ps was calculated as:
Ps = 1− (1−P)2(L−l+1) (5.1)
where P is the probability of getting a given score for a random word at the particular
position of a random double-strand DNA sequence (as computed in Touzet and Varré
(2007)), expecting the matches (including overlapping matches) are independent and
their number abide by compound poisson distribution.
To evaluate and visualise the recognition quality of the PWMs, ROC curves were
plotted displaying the true-positive rate as a function of Ps (which is considered as an
estimation of the false-positive rate) for a set of PWM thresholds based on the positive
177
Assessing the role of Zfhx3 as a circadian regulator in the SCN
control sequences. To quantify and compare the PWM quality, AUC was computed. A
higher AUC value corresponds to better motif recognition quality.
5.4 Discussion
The core circadian TTFL circuitry in mammals comprises of a network of TFs, reg-
ulatory co-factors and genes that regulate the intrinsic molecular clocks. During the
last decade, studies have been mostly focused on the characterisation of core circadian
genes which have uncovered their significance in maintaining the 24 hour cycles of
internal molecular clocks. Here, we provide evidence of Zfhx3 as a novel gene beyond
the core TTFL network that operates a clock-regulated transcriptional axis, possibly by
controlling a complex of neuropeptides responsible for molecular clock synchrony in
individual SCN cells. This study extends the catalogue of regulatory proteins engaged
in sustaining stable circadian rhythms in mammals.
With the increasing popularity of RNA-seq, multiple computational approaches
and software packages have been developed to analyse and interpret RNA-seq data.
However, none of the methods are optimal for all types of experimental data and can
produce results with large variation (Seyednasrollah et al., 2015). In order to overcome
such problems, I developed an analysis pipeline integrating multiple approaches to
identify differential expression, which could reduce false positives and capture a wide
range of genes potentially contributing to the phenotype. This approach detected that
the majority of differentially expressed genes in Zfhx3Sci/+ mice were down-regulated,
including expression of circadian related neuropeptides and receptors. Moreover,
scanning the promoters of differentially expressed genes predicted 39% of them to
contain the consensus AT motif. These genes may be directly regulated by Zfhx3, while
the remaining differentially expressed genes may have altered expression possibly as a
result of indirect regulation by Zfhx3 in the SCN. This indicates that other unknown
factors are also involved in the maintenance of stable circadian oscillations in SCN.
Although not explored yet, identification of these Zfhx3 binding partners would further
aid in understanding its function in the SCN. Another aspect which requires further
investigation is the complex of ribosomal proteins (module 2) up-regulated in Zfhx3Sci/+
mice. This observation indicates that Zfhx3 may indirectly contribute to the structural
integrity of ribosomal subunits via regulating ribosomal proteins, a Zfhx3 function not
known yet.
Previous studies have shown that Zfhx3 has the ability to both activate (Qi et al.,
2008) and suppress (Mori et al., 2007; Yasuda et al., 1994) the expression of its target
genes via the AT motif. Our data shows that Zfhx3 can activate the expression of a
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network of neuropeptides via AT motif binding, and that this function is distorted in
Zfhx3Sci/+ mice. Some Zfhx3Sci/+ phenotypes are common with features observed in
previous studies involving mouse models associated with neuropeptides. For instance,
mice not producing the Vip protein show arrhythmic or reduced circadian period relative
to wild type mice (Aton et al., 2005; Brown et al., 2007). Likewise, mouse models
lacking Prok2 and Prokr2 display a reduction in the amplitude of locomotor activity (Li
et al., 2006; Prosser et al., 2007). Overall, these observations suggest that the reduced
ability of Zfhx3 to transcriptionally activate the neuropeptide hub in Zfhx3Sci/+ mice
contributes to the observed circadian phenotype. The findings from this study further
propose the involvement of AT motif in synchronous cellular rhythms which has not
been previously found. This AT motif recognised and bound by the TF Zfhx3 now
expands the group of DNA motifs involved in the regulation of circadian function.
ChIP-seq has been widely used to identify the in vivo binding sites of TFs, which
can further help to investigate the regulatory network of the TF of interest. Using
ChIP-seq, the Zfhx3 binding peaks were mapped in the SCN at ZT3 and ZT15, revealing
Zfhx3 preferentially binds to promoter regions. The ChIP-seq analysis identified no
significant difference in binding affinity of Zfhx3 between ZT3 and ZT15. The Zfhx3
binding peaks were detected to be enriched in ZBTB33, Thap11 and CTCF motifs,
however, these motifs were present in only a small fraction of the peaks and showed
very little enrichment in positive control peaks independent of motif discovery. This
suggests that the enriched ZBTB33, Thap11 and CTCF motifs may not represent the
‘real’ motif sequence bound by Zfhx3. Prior research has also reported CTCF and
Thap11 motifs to be frequently over-represented within ChIP-seq peaks of various TFs
(Worsley Hunt and Wasserman, 2014). Surprisingly, the Zfhx3 bound peaks showed no
evidence for the enrichment of the consensus AT motif. This could suggest that Zfhx3
does not directly bind to the DNA and instead rides on other co-regulators, however,
almost all the inspected peaks were completely devoid of AT motif which is doubtful. It
remains unclear whether these ChIP-seq regions are associated to immunoprecipitated
Zfhx3, or if the majority of these regions are a result of some other cause such as
non-specific interactions or poor quality of the standard input control, and hence should
be considered as false-positives until further validated.
Further inspection of the ChIP-seq peaks showed the possibility of a common false
positive signal in this data, which occurs in many ChIP-seq profiles. Previous studies
have shown that despite using an antibody validated for its specificity, highly open
chromatin regions with high TF and co-factor occupancy can provide interaction-prone
surfaces which could result in non-specific interactions of the antibody (Jain et al., 2015).
These false-positive ChIP-seq regions, referred to as ‘Phantom Peaks’, are significantly
associated with highly active promoters and regions bound by large number of TFs.
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In the case of Zfhx3 ChIP-seq data, the majority (∼70%) of binding is identified in
promoter regions (within 3 kb of TSSs). Indeed, ∼59% of the genomic regions covered
by Zfhx3 peaks overlap with active promoters in the cerebellum, cortex or whole brain.
Furthermore, previous research has shown that ZBTB33 binds to promoters of highly
expressed genes which correlates with the high expression levels of genes associated
with the top 1,000 Zfhx3 ChIP-seq peaks in the SCN (Fig. 5.15). These observations
indicate the possible presence of ‘Phantom Peaks’ in this dataset. However, it is difficult
to confirm this without any additional data. Ideally, the ChIP-seq peaks in this data
could be validated by performing another ChIP-seq experiment in the SCN cells lacking
Zfhx3 protein. If the majority of the binding peaks are retained, that would prove the
observed peaks are false-positives or vice versa.
180
Chapter 6
Summary and future directions
The data presented in this thesis has helped us to understand the relationship between
enhancers and gene function in the mouse genome. However, there are several questions
which remain unanswered. A significant portion of the thesis focussed on identifying
potential enhancers in the mouse genome and investigating their functional properties.
Whereas, the second and the last chapter of the thesis focussed on MRCHI specific
mouse models where the aim was to decipher the regulatory networks associated with
the altered TFs in the mutant mouse. The overall purpose of this thesis was to gain
more understanding about the enhancer regulatory networks in the mouse genome, and
investigate how their presence may affect gene expression and phenotypes.
Initially, I analysed the Klf14 associated transcriptional targets in a Klf14 knockout
mouse model, with the aim to compare them with the KLF14 trans-network in human.
The results show that despite a conserved KLF14 regulatory motif between the human
and mouse genomes, KLF14 transcriptional targets are mostly species specific. However,
there are significant protein-protein interactions between the transcriptional targets in
the two species, which show their potential involvement in the same functional pathway.
A further ChIP-seq experiment in the mouse to identify Klf14 binding would be useful
to accurately reveal its regulatory targets across the mouse genome and its associated
regulatory pathways. The KLF14 associated adipose-specific enhancer in humans which
harbours binding sites for adipogenesis TFs and T2D risk variants, is likely to have no
regulatory activity in the mouse. I suggest that the loss of this enhancer in the mouse
genome may have shifted the function of Klf14 largely towards other areas such as
cholesterol metabolism, and therefore we observe no T2D associated phenotypes in the
Klf14 knockout mouse model. This study is a good example depicting the usefulness of
such enhancer annotations for comparing regulatory mechanisms across species and
also in translating biological knowledge between mouse models and humans.
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What T2D associated SNPs in the KLF14 locus are cis-regulatory variants and
what TFBS they disrupt are interesting but unanswered questions. Genetic variants
associated with diseases are being identified at a rapid pace through GWASs. The
variants occurring in enhancers, especially within the TFBSs, may disrupt the regulatory
networks of their associated TFs, leading to the loss of a normal healthy state. Based on
the density of conserved TFBSs near the T2D associated SNPs in the KLF14 locus, I
identified 16 SNPs which could be potential cis-regulatory variants, but could not detect
any common TFBS they disrupt. Future work should focus on developing improved
computational methods like PMCA, to more accurately detect the TF binding network
being altered by the cis-regulatory variants. Integrating methods like PMCA with ChIP-
seq profiles, DHSs and histone modification data would help in detecting functionally
active TFBSs with greater accuracy. Such methods would be immensely useful to
functionally characterise these genetic variants occurring within the regulatory regions.
The advancement in sequencing technologies has made it possible to capture a
detailed snapshot of enhancer profiles at a genome-wide scale. In this thesis, I have
produced a catalogue of multiple enhancer types in a diverse range of mouse tissues
and cell-types. This catalogue includes well defined tissue-specific enhancers, super-
enhancers (SEs), typical-enhancers (TEs) and weak-enhancers in previously unexplored
tissues. To produce these enhancer annotations, I used ChIP-seq data from only three
histone marks, primarily because they were the most investigated histone marks at the
time of producing this dataset, and hence, their ChIP-seq data was available for all the
22 mouse tissues analysed here. Future work would involve improving these annotations
by using more histone marks and additional datasets such as DHSs. The tissue-specific
enhancers in this catalogue were identified using the Tau metric which performed better
than the previously applied clustering methods. However, I used previously defined
thresholds for the Tau score. Future studies should optimise the thresholds for the
Tau score in such a way that it enables us to capture the maximum number of tissue-
specific elements with minimum amount of noise. Furthermore, adding more tissues
and cell-types to this catalogue in the future would further refine the quantification of
tissue-specific enhancers.
Which regions in the mouse genome should be targeted to functionally characterise
disease-associated SNPs (DA-SNPs) from GWASs is an important question. In this
thesis, I have shown that non-coding DA-SNPs from some GWAS traits were enriched
in mouse enhancers of disease-relevant tissues. However, this analysis was performed
using a small curated set of non-coding DA-SNPs from only 26 GWAS traits. A
similar, but more comprehensive study incorporating all the DA-SNPs and disease
traits in GWAS catalogue (Welter et al., 2014) should be conducted as this may help in
predicting the disease traits that can be better replicated in mouse models.
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I explored how enhancers influence the expression and phenotypes of their target
genes in order to understand gene regulation in cells. By comparing SEs and TEs, I
investigated their distinctive roles in gene function, as many researchers remain dubious
about such sub-categorisation of strong enhancers. SEs were identified to drive high
total-expression and tissue-specific expression of their associated genes compared to
TEs. However, a major finding in this thesis was that SE and TE associated genes
share common phenotypic outcomes even though their expression profiles and overall
numbers in the genome differ. The evidence described in this thesis show that there
is no significant difference in severity and breadth of phenotypes produced from the
knockouts of SE and TE associated genes. Following on from this, another interesting
finding was the high number of genes identified to be associated with TEs, which
highlights their importance in the genome - an observation consistent with a recent
report (Hamdan and Johnsen, 2018). While the majority of the previous studies have
focussed on SEs mainly because of their association with key cell identity genes, other
strong enhancers in the genome also appear to have a notable influence on the gene
function.
Irrespective of enhancer classes, the results described in this thesis increases our
understanding about the correlation between enhancers and gene function, which could
help in predicting the effect of enhancer disruption. However, it is important to note that
the enhancers were indirectly associated to phenotypes via the phenotype outcomes of
their potential target genes. An assessment of direct association between enhancers and
phenotypes would be difficult to perform in silico, and would require in vivo enhancer-
loss of function studies to accurately identify its phenotypic associations. Similar
studies involving deletion of enhancers using CRISPR-Cas9 have been performed in
the past (Groschel et al., 2014; Hay et al., 2016; Li et al., 2014; Moorthy et al., 2017;
Shin et al., 2016). However, such in vivo functional characterisation of enhancers rely
on comprehensive and well defined enhancer catalogues, such as the one produced in
this thesis. The wide range of tissues and cell-types analysed in this thesis provides a
platform to further characterise enhancer regulatory mechanisms in the mouse genome.
These studies would be helpful in developing novel approaches to manipulate gene
expression in research experiments and in drug development, for example BET inhibitors
are being used to disrupt SE activity which causes a reduction in the expression of
oncogenes (Drier et al., 2016; Loven et al., 2013; Peeters et al., 2015; Pelish et al., 2015;
Wyce et al., 2013).
Another important question which this thesis addressed is whether the constituent
enhancers within SEs or TEs exert an additive or a more complex cooperative effect
on target gene expression. The analysis described in this thesis predicts that total- and
tissue-specific expression levels are weakly correlated with the number of constituent
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enhancers at a genome-wide scale. Therefore, all constituent enhancers do not appear
to contribute to the transcriptional output with the same strength suggesting a non-
additive relationship between them. However, there is a possibility that some constituent
enhancers are redundant and do not contribute to the transcriptional output in normal
conditions (Cannavo et al., 2016; Frankel et al., 2010; Hong et al., 2008; Moorthy et al.,
2017). It is a difficult task to distinguish redundant enhancers from active enhancers in
silico, especially with the dataset collected and the computational nature of analysis
conducted in this thesis. Further in vivo experiments involving single and combinatorial
deletions of such constituent enhancers would be required to accurately detect their
function in gene expression. Though similar studies have been performed to decipher
the function of individual SE constituents towards expression of a single or a group
of genes (Hay et al., 2016; Hnisz et al., 2015; Moorthy et al., 2017; Shin et al., 2016;
Suzuki et al., 2017), their findings are highly variable. Furthermore, only a few genomic
loci have been investigated by such experiments and we cannot extrapolate the findings
from a few loci to the whole genome. Clearly, more studies are required as the question
still remains unanswered about the relationship between individual enhancer elements
at the genome-wide scale. Do these enhancers function independently? Do they interact
with each other and influence each other’s activity? The answers to these questions will
be important to understand whether SEs represent a new class of regulatory elements
and function as a single unit, or they are simply a cluster of traditional enhancers.
Since I used histone modification ChIP-seq data to predict genome-wide enhancers,
I could only predict a coarse level of enhancer annotations due to the limitations
associated with it. Histone modification data is good for predicting enhancers because
it allows us to effectively distinguish enhancers from other regulatory activity in the
genome. However, histone modifications occur at the regions flanking regulatory
elements, hence producing a broad ChIP-seq signal around regulatory regions like
enhancers. These extended signals can often introduce noise in the process of chromatin
state segmentation resulting in: (1) false enhancer regions; or (2) enhancer regions with
inaccurate boundaries and overestimated length. Therefore, future studies should focus
on using open chromatin signals captured by technologies such as DNase-seq or ATAC-
seq, which have been observed to predict enhancer regions at a finer resolution. These
datasets if applied here would generate enhancer annotations with increased genomic
location accuracy and fewer false-positives, which in turn would refine the classes of
enhancer associated genes and produce more significant enrichment results. As most
of the downstream analysis conducted in this thesis to investigate enhancer associated
functions were based on enrichment whilst seeking common patterns, implementing
DNase-seq/ATAC-seq data would produce similar enrichment outcomes and hence
not affect the conclusions made in this thesis. However, as a result of less noise and
fewer false-positives in the data, analysis which was not based on enrichment could be
184
benefited, in particular: (1) the correlation between the number of constituent enhancers
and target gene expression may improve; (2) the machine learning features associated
with tissue-specific enhancers/promoters in the random forest classifier may have a
cleaner signal, which in turn may improve the predictive capacity of tissue-specific
regulatory elements to infer gene-phenotype associations.
Tremendous progress has been made in the last five years in the field of enhancer
discovery. As studies similar to this thesis produce more characterised enhancer anno-
tations, the next step in the future is to functionally characterise them, either through
massively parallel reporter assays (Kwasnieski et al., 2012; Melnikov et al., 2012), or
through high-throughput CRISPR-Cas9 based functional screening (Canver et al., 2015;
Diao et al., 2016; Korkmaz et al., 2016; Peeters et al., 2015). It would be essential to test
these elements in their natural chromatin environment, however, it would be challenging
as the enhancers detected to have no activity in their natural chromatin context may have
a subtle effect, which may be difficult to capture using the current phenotypic tests, or
enhancers may have a critical role at a different stage of development. These functional
studies could play a key role in testing enhancer malfunction in diseases by generating
custom alleles and evaluating their chromatin interactions. It would also be important
to understand how the presence or absence of genetic variants within enhancer regions
affect drug responses. However, several questions remain outstanding: which elements
are critical to maintain the function of enhancers? Whether the distance between the
individual constituent enhancers have any effect on their function? How is the regulatory
information encoded in the DNA sequence? What controls the mechanisms that pair
enhancer with their target genes?
Lastly, I investigated the regulatory network altered by the Zfhx3Sci/+ mutation in a
MRCHI circadian mouse model. The evidence provided in this thesis showed that the
Zfhx3Sci/+ mutation disrupts the ability of Zfhx3 to activate transcription of a circadian
related neuropeptide network which contributed to the Sci phenotype. This study
identified Zfhx3 as a novel gene beyond the TTFL network to be involved in controlling
the circadian oscillations. However, not all the genes affected by the Zfhx3Sci/+ mutation
were identified to be directly regulated by Zfhx3 via an AT motif, which suggests the
involvement of other unknown factors or motifs in the functional pathway contributing
to the circadian phenotype. Future analysis would involve the identification of potential
co-factors or Zfhx3 binding partners in this network. This could be primarily achieved
by performing a de novo motif analysis amongst the Zfhx3Sci/+ transcriptional targets
to identify other TF binding motifs enriched within these genes, and inspecting if the
location of these motifs is near the AT motif. I characterised the genes altered by the
Zfhx3Sci/+ mutation into different functional modules. The first module consisted of a
network of neuropeptides known to be involved in circadian rhythms, while another
185
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module consisted of ribosomal proteins (module 2). The second module was not
explored, therefore, future analysis should also focus on investigating the function of
Zfhx3 in regulating ribosomal proteins.
Overall, in this thesis I have shown how the presence of enhancers affect the gene
function in the mouse genome. All this evidence goes to prove that they are important
contributors in disease causation, and understanding the mechanisms behind their
function could lead to clues on disease pathogenesis and possible therapies.
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Appendix A
Supplementary figures
Fig. A.1 ChromHMM models with different number of chromatin states. Heatmaps display
the ChromHMM models with different number of chromatin states used to segment the mouse
genome.
225
Supplementary figures
Fig. A.2 SEs and TEs identified in 22 mouse tissues. Bar plot displaying the number of SEs
and TEs identified in each tissue.
226
Fig. A.3 H3K27ac enrichment within SEs and TEs in 22 mouse tissues. Metagene profiles
displaying mean H3K27ac ChIP-seq signal across all the SEs and TEs in each tissue. The
profiles are centred on the enhancer region and the width represents the median length of the
enhancers. An additional 2 kb region flanking each enhancer is also shown.
227
Supplementary figures
Fig. A.4 Comparison of H3K4me1, H3K27ac and DNaseI signal across stitched cohesive
units. Distribution of H3K4me1, H3K27ac and DNaseI signal across stitched enhancers. The
plot was normalised by dividing the input-subtracted ChIP-seq signal for each enhancer by the
maximum ChIP-seq signal detected in each feature. The stitched enhancers for each feature on
the x-axis are ranked according to the H3K27ac ChIP-seq signal. Please note that DNase-seq
data was not available for all tissues.
228
Fig. A.5 Chromatin activity within SE and TE constituent enhancers. Comparison of (A)
H3K27ac, (B) H3K4me1 and (C) pol II ChIP-seq signal between SE and TE constituent
enhancers in every tissue. Please note that pol II ChIP-seq data was not available for all tissues.
p: p-values from Wilcoxon Rank Sum Test; ES: effect size.
229
Supplementary figures
Fig. A.6 Enrichment of DA-SNPs from GWASs in SE and TE domains of human and
mouse genomes. Heatmaps displaying the density of DA-SNPs occurring within SEs and TEs.
The SNP density is represented as number of DA-SNPs occurring per Mb of enhancer.
230
Fig. A.7 Effect of enhancer activity on target gene expression. (A) Box plot displaying the
expression of genes in each enhancer class. (B) Bar plots showing the proportion of genes
with high tissue-specific expression (τexp− f rac ≥ 0.85), intermediate tissue-specific expression
(0.20 < τexp− f rac < 0.85) and low tissue-specific expression (τexp− f rac ≤ 0.20) in each enhancer
class. The dotted lines show the mean across all the tissues.
231
Supplementary figures
Fig. A.8 PPI maps of enhancer associated genes. Nodes in each network represents enhancer
associated genes and edges represent a potential PPI between them. Genes associated with
tissue-type relevant phenotypes are highlighted in pink and the shape of the node displays SE
and TE associated genes (squares: SEC, circles: TEC).
232
Fig. A.9 PPI network simulations. Histograms showing the PPI simulations performed for
every tissue. The PPI networks were simulated 1,000 times by adding randomly selected
protein-coding genes (equal to the number of phenotype associated genes in each tissue) to
the network and counting their edges with the genes labelled as ‘novel’. The red vertical line
shows the observed number of edges between novel and phenotype associated genes and the
grey distribution (obtained from permutation) shows the number of edges between novel and
randomly added genes. The p-value shown was calculated by dividing the number of permuted
values larger than the observed value by the total number of items in the permutation distribution.
233
Supplementary figures
Fig. A.10 Feature importance of random forest classifiers used to predict gene-
phenotype associations. Feature importance chart of the best performing model
(Exp+PPI+TSRE+TSRE_PPI+TF) showing the top 20 predictor variables with the greatest
contribution towards predicting gene-phenotype associations. Exp: expression; Enh: enhancer;
Prom: promoter; TF: transcription factor.
234
Fig. A.11 Experimental data related to the Zfhx3Sci mutation. (A) Comparison of Vip and
Grp mRNA expression in the SCN of Zfhx3Sci/+ (grey lines) and Zfhx3+/+ (black lines) across
multiple time points (for both Vip and Grp: n = 4, p < 0.05, ANOVA). (B) Left panel shows a
schematic representation of the regions used to design the primers spanning the AT motif and its
adjacent regions. Right panel shows the results from quantitative ChIP in the SCN (time point:
ZT3, n = 3). The bars display fold change with respect to the input (corresponding coding region
of the gene). (C) Bar plot displaying the ability of Zfhx3 to activate the AT motif in vitro (n = 7,
p < 0.05, t-test). Zfhx3Sci: Zfhx3 with the Sci mutation ; Zfhx3+: Zfhx3 without the Sci mutation.
(D) In vitro transcriptional activation of module 1 gene promoters by Zfhx3 via the AT motif (‘*’
denotes p < 0.05, t-test). (E) Comparison of transcriptional activation by Zfhx3 via the intact AT
motif (+) and the disrupted AT motif (-). The three most conserved residues of the AT motif
were mutated to disrupt the motif (p < 0.05, t-test). (Error bars show SEM)
235

Appendix B
Supplementary tables
237
Supplementary tables
Table B.1 GO enrichment analysis of SE associated genes.
Category ID Name FDR B&H # Genes 
GO: MF GO:0000981 RNA polymerase II transcription factor 
activity, sequence-specific DNA binding 
6.64E-10 195 
GO: MF GO:0000982 transcription factor activity, RNA 
polymerase II proximal promoter 
sequence-specific DNA binding 
4.01E-09 119 
GO: MF GO:0001228 transcriptional activator activity, RNA 
polymerase II transcription regulatory 
region sequence-specific DNA binding 
3.35E-08 114 
GO: MF GO:0019904 protein domain specific binding 4.99E-08 198 
GO: MF GO:0022857 transmembrane transporter activity 2.10E-06 250 
GO: MF GO:0001227 transcriptional repressor activity 8.06E-06 63 
GO: MF GO:0098772 molecular function regulator 9.28E-06 330 
GO: MF GO:0044212 transcription regulatory region DNA 
binding 
1.11E-05 213 
GO: MF GO:0003705 transcription factor activity, RNA 
polymerase II distal enhancer sequence-
specific binding 
1.87E-05 41 
GO: MF GO:0001012 RNA polymerase II regulatory region 
DNA binding 
2.87E-05 163 
GO: BP GO:2000026 regulation of multicellular organismal 
development 
9.95E-26 524 
GO: BP GO:0045595 regulation of cell differentiation 9.33E-23 470 
GO: BP GO:0022008 neurogenesis 8.17E-20 442 
GO: BP GO:0051094 positive regulation of developmental 
process 
2.29E-17 366 
GO: BP GO:0060284 regulation of cell development 1.92E-16 287 
GO: BP GO:0051960 regulation of nervous system development 2.33E-15 259 
GO: BP GO:0048646 anatomical structure formation involved in 
morphogenesis 
2.44E-15 352 
GO: BP GO:0006928 movement of cell or subcellular component 2.56E-15 476 
GO: BP GO:0009719 response to endogenous stimulus 2.67E-15 446 
GO: BP GO:0006811 ion transport 7.83E-15 420 
GO: BP GO:0072358 cardiovascular system development 1.11E-14 296 
GO: BP GO:0072359 circulatory system development 1.11E-14 296 
GO: BP GO:0009790 embryo development 1.75E-14 312 
GO: BP GO:0009891 positive regulation of biosynthetic process 1.97E-14 487 
GO: BP GO:0051049 regulation of transport 2.21E-14 490 
GO: BP GO:0010628 positive regulation of gene expression 2.56E-14 472 
GO: BP GO:0016477 cell migration 4.76E-14 346 
 
Listed are the most enriched GO terms (MF: molecular function, BP: biological process) amongst SE
associated genes. The GO enrichment analysis was performed using ToppGene. The associated FDR
values were calculated using Benjamini-Hochberg method.
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Table B.2 GO enrichment analysis of TE associated genes.
Category ID Name FDR B&H # Genes 
GO: MF GO:0017076 purine nucleotide binding 3.33E-06 1122 
GO: MF GO:0019899 enzyme binding 3.33E-06 1149 
GO: MF GO:0032549 ribonucleoside binding 3.33E-06 1093 
GO: MF GO:0001882 nucleoside binding 3.33E-06 1096 
GO: MF GO:0044877 protein-containing complex binding 3.33E-06 976 
GO: MF GO:0005524 ATP binding 6.63E-06 888 
GO: MF GO:0004672 protein kinase activity 2.01E-05 412 
GO: MF GO:0098772 molecular function regulator 8.07E-03 835 
GO: MF GO:0003713 transcription coactivator activity 3.67E-02 196 
GO: BP GO:0007010 cytoskeleton organization 9.32E-09 740 
GO: BP GO:0034613 cellular protein localization 9.45E-07 1013 
GO: BP GO:0010256 endomembrane system organization 1.78E-06 381 
GO: BP GO:0032989 cellular component morphogenesis 4.15E-06 873 
GO: BP GO:0015031 protein transport 1.03E-05 1162 
GO: BP GO:0051640 organelle localization 1.54E-05 335 
GO: BP GO:0044248 cellular catabolic process 1.55E-05 1092 
GO: BP GO:0000902 cell morphogenesis 3.36E-05 811 
GO: BP GO:1902531 regulation of intracellular signal 
transduction 
3.36E-05 1062 
GO: BP GO:0044093 positive regulation of molecular function 7.02E-05 1122 
GO: BP GO:0022008 neurogenesis 1.29E-04 970 
GO: BP GO:0065003 protein-containing complex assembly 1.47E-04 1080 
GO: BP GO:0007049 cell cycle 2.74E-04 1044 
GO: BP GO:0070925 organelle assembly 3.30E-04 410 
GO: BP GO:0006629 lipid metabolic process 4.30E-04 823 
GO: BP GO:0048858 cell projection morphogenesis 4.65E-04 554 
GO: BP GO:0022402 cell cycle process 7.79E-04 825 
GO: BP GO:0016050 vesicle organization 7.95E-04 232 
GO: BP GO:0048699 generation of neurons 7.95E-04 905 
GO: BP GO:0006928 movement of cell or subcellular component 8.00E-04 1103 
GO: BP GO:0009894 regulation of catabolic process 8.04E-04 479 
 
Listed are the most enriched GO terms (MF: molecular function, BP: biological process) amongst TE
associated genes. The GO enrichment analysis was performed using ToppGene. The associated FDR
values were calculated using Benjamini-Hochberg method.
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Table B.4 Mammalian phenotype and human disease annotations enriched in the WEC.
 WEC 
Tissue N Mouse Phenotypes Disease 
BAT 214 o - o Otofaciocervical Syndrome, 10-3 
BmarrowDm 939 o - o Autism Spectrum Disorders, 10-3 
o Mental Retardation, X-Linked, 10-3 
Bmarrow 368 o - o - 
Cerebellum 1202 o abnormal innervation, 10-5  
o abnormal synaptic transmission, 10-4 
o Autistic Disorder, 10-10 
o Schizophrenia,10-6 
CH12 1117 o abnormal cartilage morphology, 10-2 
o perinatal lethality, 10-2 
o Mental Depression, 10-4 
o Alcoholic Intoxication, Chronic, 10-4 
Cortex 1006 o abnormal synaptic transmission, 10-14 
o abnormal nervous system physiology, 10-13 
o Bipolar Depression, 10-12 
o Schizophrenia, 10-11 
Esb4 391 o increased neurotransmitter release, 10-3 o Autistic Disorder, 10-2 
Es-E14 687 o perinatal lethality, 10-6 
o neonatal lethality, 10-5 
o Autism Spectrum Disorders, 10-3 
o Craniofacial Abnormalities, 10-2 
Heart 335 o abnormal muscle contractility, 10-4 
o increased heart ventricle size, 10-3 
o - 
Kidney 449 o - o Alcoholic Intoxication, Chronic, 10-2 
o Autism Spectrum Disorders, 10-2 
Limb 87 o abnormal palatal shelf fusion at midline, 
10-3 
o cleft hard palate, 10-2 
o - 
Liver 922 o - o Attention deficit hyperactivity, 10-5 
o Autistic Disorder, 10-5 
Lung 286 o abnormal olfactory lobe morphology, 10-3 
o abnormal nervous system physiology, 10-2 
o - 
MEF 601 o muscle phenotype, 10-3 
o abnormal limb bone morphology, 10-3 
o Ventricular Septal Defects, 10-2 
o Alcoholic Intoxication, Chronic, 10-2 
MEL 621 o - o Autistic Disorder, 10-4 
o Mental Retardation, X-Linked, 10-4 
OlfactoryBulb 360 o abnormal motor coordination/balance, 10-4 
o abnormal nervous system physiology, 10-3 
o Autistic Disorder, 10-4 
o Fragile X Syndrome, 10-3 
Placenta 975 o abnormal neuron differentiation, 10-3 
o abnormal respiratory system physiology, 
10-3 
o Central neuroblastoma, 10-7 
o Alzheimer's Disease, 10-7 
SmallIntestine 310 o abnormal gallbladder physiology, 10-3 
o postnatal lethality, 10-2 
o Obesity, 10-2 
Spleen 170 o abnormal semicircular canal morphology, 
10-3 
o abnormal otolith organ morphology, 10-2 
o Hypoplastic cochlea, 10-2 
o Congenital Abnormality, 10-2 
Testis 864 o abnormal neuron morphology, 10-3 
o abnormal synaptic transmission, 10-3 
o Autistic Disorder, 10-4 
o Craniofacial Abnormalities, 10-3 
Thymus 412 o - o - 
 
Wbrain 
776 o abnormal neuron differentiation, 10-10 
o abnormal nervous system development, 
10-8 
o Schizophrenia, 10-6 
o Autism Spectrum Disorders, 10-6 
 
Listed are the most enriched mammalian phenotypes and human disease annotation terms in the WEC.
The associated FDR values are reported next to the enriched terms and was calculated using
Benjamini-Hochberg method. N displays the number of weak-enhancer associated genes in each group.
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Table B.5 Disease annotation terms enriched amongst genes associated with nervous sys-
tem phenotype in the mouse.
Name Source P-value FDR 
B&H 
Genes 
from Input 
Genes in 
Annotation 
Schizophrenia DisGeNET Curated 1.06E-154 2.05E-150 750 1561 
Seizures DisGeNET Curated 1.22E-148 1.17E-144 551 982 
Alzheimer's Disease DisGeNET Curated 2.61E-138 1.67E-134 803 1825 
Epilepsy DisGeNET Curated 6.45E-135 3.10E-131 526 962 
Neuroblastoma DisGeNET Curated 1.04E-127 4.00E-124 745 1689 
Central neuroblastoma DisGeNET BeFree 5.04E-126 1.62E-122 725 1631 
Intellectual Disability DisGeNET Curated 1.42E-118 3.91E-115 559 1131 
Depressive disorder DisGeNET Curated 1.02E-112 2.45E-109 403 697 
Mental Retardation DisGeNET Curated 4.82E-107 1.03E-103 461 885 
Bipolar Disorder DisGeNET Curated 1.99E-104 3.83E-101 404 730 
Impaired cognition DisGeNET Curated 5.68E-95 9.93E-92 354 625 
Mental Depression DisGeNET Curated 3.48E-94 5.58E-91 327 554 
Low intelligence DisGeNET Curated 2.26E-89 2.90E-86 355 649 
Dull intelligence DisGeNET Curated 2.26E-89 2.90E-86 355 649 
Poor school performance DisGeNET Curated 2.26E-89 2.90E-86 355 649 
Mental deficiency DisGeNET Curated 7.28E-89 8.75E-86 355 651 
Autistic Disorder DisGeNET Curated 3.58E-84 4.05E-81 346 644 
Autosomal recessive predisposition DisGeNET Curated 5.64E-83 6.03E-80 592 1445 
Congenital Abnormality DisGeNET Curated 1.82E-82 1.84E-79 330 605 
Hyperactive behaviour DisGeNET Curated 1.03E-81 9.85E-79 416 866 
Neurodegenerative Disorders DisGeNET Curated 4.39E-81 4.02E-78 364 710 
Abnormal behaviour DisGeNET Curated 8.74E-81 7.64E-78 238 365 
Glioblastoma DisGeNET Curated 4.07E-79 3.40E-76 696 1851 
Malignant neoplasm of ovary DisGeNET Curated 5.12E-76 4.11E-73 705 1911 
nervous system disorder DisGeNET Curated 7.85E-72 6.04E-69 250 423 
Mammary Neoplasms DisGeNET Curated 7.20E-71 5.33E-68 704 1953 
Amyloidosis DisGeNET Curated 3.28E-70 2.33E-67 412 916 
Global developmental delay DisGeNET Curated 1.90E-69 1.30E-66 361 757 
Obesity DisGeNET Curated 2.03E-69 1.34E-66 661 1803 
Major Depressive Disorder DisGeNET Curated 5.63E-69 3.61E-66 276 505 
Malignant neoplasm of pancreas DisGeNET Curated 9.37E-69 5.81E-66 640 1730 
Parkinson Disease DisGeNET Curated 3.46E-68 2.08E-65 412 928 
Hypertensive disease DisGeNET Curated 8.35E-68 4.86E-65 466 1112 
Pancreatic carcinoma DisGeNET Curated 1.35E-67 7.66E-65 649 1774 
Autism Spectrum Disorders DisGeNET Curated 1.40E-66 7.72E-64 248 436 
Unipolar Depression DisGeNET Curated 2.87E-66 1.54E-63 241 418 
Malignant tumour of colon DisGeNET Curated 1.10E-64 5.69E-62 679 1915 
Adenoma DisGeNET Curated 1.78E-63 9.02E-61 414 964 
Anxiety DisGeNET Curated 3.42E-63 1.69E-60 242 432 
Squamous cell carcinoma DisGeNET Curated 3.77E-61 1.81E-58 602 1655 
Astrocytoma DisGeNET Curated 7.52E-61 3.53E-58 335 721 
Brain Neoplasms DisGeNET Curated 1.25E-60 5.73E-58 302 619 
Muscle hypotonia DisGeNET Curated 2.77E-60 1.24E-57 287 575 
leukaemia DisGeNET Curated 3.01E-60 1.32E-57 652 1854 
Anxiety Disorders DisGeNET Curated 1.35E-59 5.78E-57 219 382 
Medulloblastoma DisGeNET Curated 8.74E-59 3.65E-56 279 558 
Psychotic Disorders DisGeNET Curated 8.78E-58 3.59E-55 190 311 
Huntington Disease DisGeNET Curated 1.69E-57 6.75E-55 292 604 
Amyotrophic Lateral Sclerosis DisGeNET Curated 1.83E-57 7.18E-55 300 629 
Mental and motor retardation DisGeNET Curated 2.33E-57 8.78E-55 295 614 
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Table B.6 GO enrichment analysis of genes in module 4 of the Zfhx3Sci/+ network.
Category ID Name Corrected 
p-value 
Genes 
GO:BP GO:0034368 
protein-lipid complex 
remodelling 8.45E-05 
APOA2, PLA2G7, 
APOA1 
GO:BP GO:0034369 
plasma lipoprotein particle 
remodelling 8.45E-05 
APOA2, PLA2G7, 
APOA1 
GO:BP GO:0002740 
negative regulation of cytokine 
secretion involved in immune 
response 2.33E-03 APOA2, APOA1 
GO:BP GO:0002682 
regulation of immune system 
process 4.78E-03 
APOA2, PLA2G7, 
APOA1, RORA, 
LRRC17, H2-D1 
GO:BP GO:0042632 cholesterol homeostasis 5.79E-03 
APOA2, APOA1, 
RORA 
GO:BP GO:0030300 
regulation of intestinal cholesterol 
absorption 6.52E-03 APOA2, APOA1 
GO:BP GO:0018206 peptidyl-methionine modification 8.38E-03 APOA2, APOA1 
GO:BP GO:0010873 
positive regulation of cholesterol 
esterification 8.38E-03 APOA2, APOA1 
GO:BP GO:0070508 cholesterol import 1.28E-02 APOA2, APOA1 
GO:BP GO:0018158 protein oxidation 1.28E-02 APOA2, APOA1 
GO:BP GO:0060192 
negative regulation of lipase 
activity 1.81E-02 APOA2, APOA1 
GO:BP GO:0033700 phospholipid efflux 1.81E-02 APOA2, APOA1 
GO:BP GO:0043691 reverse cholesterol transport 2.44E-02 APOA2, APOA1 
GO:BP GO:0006656 
phosphatidylcholine biosynthetic 
process 3.56E-02 APOA2, APOA1 
GO:BP GO:0097164 ammonium ion metabolic process 4.56E-02 
APOA2, PLA2G7, 
APOA1 
GO:MF GO:0070653 
high-density lipoprotein particle 
receptor binding 2.33E-04 APOA2, APOA1 
GO:MF GO:0032934 sterol binding 7.86E-04 
APOA2, APOA1, 
RORA 
GO:MF GO:0060228 
phosphatidylcholine-sterol O-
acyltransferase activator activity 2.33E-03 APOA2, APOA1 
GO:MF GO:0034190 apolipoprotein receptor binding 4.89E-03 APOA2, APOA1 
GO:MF GO:0008035 
high-density lipoprotein particle 
binding 8.38E-03 APOA2, APOA1 
GO:MF GO:0055102 lipase inhibitor activity 1.54E-02 APOA2, APOA1 
GO:MF GO:0017127 cholesterol transporter activity 3.56E-02 APOA2, APOA1 
 
Listed are the most enriched GO terms (BP: biological process, MF: molecular function) amongst
differentially expressed genes in module 4 of the Zfhx3Sci/+ network. The GO enrichment analysis was
performed using g:Profiler.
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